PRELIMINARY OFFERING CIRCULAR
DATED DECEMBER 31, 2024
AN OFFERING STATEMENT PURSUANT
TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION CONTAINED IN THIS
PRELIMINARY OFFERING CIRCULAR IS SUBJECT TO COMPLETION OR AMENDMENT. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED
BEFORE THE OFFERING STATEMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IS QUALIFIED. THIS PRELIMINARY OFFERING CIRCULAR SHALL
NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR MAY THERE BE ANY SALES OF THESE SECURITIES IN ANY STATE IN
WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL BEFORE REGISTRATION OR QUALIFICATION UNDER THE LAWS OF ANY SUCH STATE. WE MAY
ELECT TO SATISFY OUR OBLIGATION TO DELIVER A FINAL OFFERING CIRCULAR BY SENDING YOU A NOTICE WITHIN TWO BUSINESS DAYS AFTER THE COMPLETION
OF OUR SALE TO YOU THAT CONTAINS THE URL WHERE THE FINAL OFFERING CIRCULAR OR THE OFFERING STATEMENT IN WHICH SUCH FINAL OFFERING CIRCULAR
WAS FILED MAY BE OBTAINED.
OFFERING CIRCULAR
Up to 15,000,000
Shares of Common Stock
Up to 15,000,000
Pre-Funded Warrants to Purchase up to 15,000,000 Shares of Common Stock
BioVie Inc.
By this offering circular (this “Offering Circular”),
BioVie Inc., a Nevada corporation (the “Company,” “us,” “we,” or “our”), is offering on
a “best-efforts” basis a maximum of 15,000,000 shares (the “Offered Shares”) of its Class A common stock, par
value $0.0001 per share (“Common Stock”), at a fixed price of $3.00 to $5.00 per share (to be fixed by post-qualification
supplement), pursuant to Tier 2 of Regulation A of the United States Securities and Exchange Commission (the “SEC”). There
is no minimum purchase requirement for investors in this offering.
We are also offering to certain purchasers, if any,
whose purchase of shares of Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain
related parties, beneficially owning more than 4.99% (or, at the election of such purchaser, 9.99%) of our outstanding Common Stock immediately
following the consummation of this offering, the opportunity to purchase, if the purchaser so chooses, pre-funded warrants (the “Pre-Funded
Warrants”) in lieu of Offered Shares that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% (or,
at the election of such purchaser, 9.99%) of our outstanding shares of Common Stock. Each Pre-Funded Warrant will be immediately exercisable
for one share of Common Stock and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The purchase
price of each Pre-Funded Warrants will equal the price per share at which the shares of Common Stock are being sold to the public in this
offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant will be $0.0001, per share. For each Pre-Funded Warrant we
sell, the number of Offered Shares we are offering will be decreased on a one-for-one basis. This offering also relates to the shares
of Common Stock issuable upon exercise of any Pre-Funded Warrants sold in this offering. We refer to the Offered Shares and Pre-Funded
Warrants to be sold in this offering collectively as the “Securities.”
This offering is being conducted on a “best-efforts”
basis, which means that there is no minimum number of Securities that must be sold by us for this offering to close; thus, we may receive
no or minimal proceeds from this offering. None of the proceeds received will be placed in an escrow or trust account. All proceeds from
this offering will become immediately available to us and may be used as they are accepted. Purchasers of the Securities will not be entitled
to a refund and could lose their entire investments. Please see the “Risk Factors” section, beginning on page 7, for
a discussion of the risks associated with a purchase of the Securities.
We estimate that this offering will commence
within two days of SEC qualification. This offering will terminate at the earliest of: (a) the date on which the maximum offering has
been sold; (b) one year from the date of SEC qualification; or (c) the date on which this offering is earlier terminated by us, in our
sole discretion. (See “Plan of Distribution”).
| | |
Number of Shares | | |
Price to Public(1) | | |
Broker-Dealer Discounts and Commissions(2) | | |
Proceeds to Company (3) | |
| Per Share: | |
| - | | |
$ | 4.00 | | |
$ | 0.28 | | |
$ | 3.72 | |
| Total Minimum: | |
| - | | |
$ | - | | |
$ | - | | |
$ | - | |
| Total Maximum: | |
| 15,000,000 | | |
$ | 60,000,000 | | |
$ | 4,200,000 | | |
$ | 55,800,000 | |
| (1) | Assumes a public offering price of $4.00, which represents the midpoint of the offering price range of
$3.00 to $5.00 per share. |
| (2) | We have engaged ThinkEquity LLC (“the “Placement Agent”) to act as our exclusive placement
agent for this offering, in exchange for a placement agent fee equal to 7% of the aggregate purchase price paid by each purchaser of Securities
that are placed in this offering (other than certain purchasers of Securities in this offering, which fee will be equal to 3% of the aggregate
purchase price paid by each such excluded purchaser). The table above assumes none of the Securities are sold to such excluded purchasers.
The Placement Agent and its affiliates will receive certain other compensation. See “Plan of Distribution” for more details. |
| (3) | Does not account for the payment of expenses
of this offering estimated at $400,000. See “Plan of Distribution.” |
Our Common Stock is listed on the Nasdaq Capital Market
under the symbol “BIVI.” On December 30, 2024, the last reported sale price of our Common Stock was $2.09 per share. In
addition, there is no established public trading market for the Pre-Funded Warrants and we do not expect a market to develop. Without
an active trading market, the liquidity of the Pre-Funded Warrants will be limited.
Investing in the Securities is speculative and
involves substantial risks. You should purchase Securities only if you can afford a complete loss of your investment. See “Risk
Factors”, beginning on page 7, for a discussion of certain risks that you should consider before purchasing any of the Securities.
THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION
DOES NOT PASS UPON THE MERITS OF, OR GIVE ITS APPROVAL TO, ANY SECURITIES OFFERED OR THE TERMS OF THIS OFFERING, NOR DOES IT PASS UPON
THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SOLICITATION MATERIALS. THESE SECURITIES ARE OFFERED PURSUANT TO AN EXEMPTION
FROM REGISTRATION WITH THE SEC; HOWEVER, THE SEC HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THE SECURITIES OFFERED ARE EXEMPT FROM
REGISTRATION.
The use of projections or forecasts in this offering
is prohibited. No person is permitted to make any oral or written predictions about the benefits you will receive from an investment in
the Securities.
No sale may be made to you in this offering, if
you do not satisfy the investor suitability standards described in this Offering Circular under “Plan of Distribution—State
Law Exemption and Offerings to “Qualified Purchasers” on page 27. Before making any representation that you satisfy
the established investor suitability standards, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information
on investing, we encourage you to refer to www.investor.gov.
This Offering Circular follows the disclosure format
of Form S-1, pursuant to the General Instructions of Part II(a)(1)(ii) of Form 1-A.
ThinkEquity
The date of this Offering Circular is _______________,
2025.
Table of
Contents
Neither we nor any of our officers, directors, agents,
or representatives make any representation to you about the legality of an investment in our securities. You should not interpret the
contents of this Offering Circular or any free writing Offering Circular to be legal, business, investment or tax advice. You should consult
with your own advisors for that type of advice and consult with them about the legal, tax, business, financial and other issues that you
should consider before investing in our securities. You should rely only on the information contained in this Offering Circular or in
any Offering Circular supplement that we may authorize to be delivered or made available to you. We have not authorized anyone to provide
you with different information. The information in this Offering Circular is accurate only as of the date hereof, regardless of the time
of its delivery or any sale of the Securities.
OFFERING
CIRCULAR Summary
This summary highlights certain information about
us and certain information contained elsewhere in this Offering Circular and in the documents incorporated by reference herein. This summary
is not complete and does not contain all of the information that you should consider before making an investment decision. For a more
complete understanding of the Company, you should read and consider carefully the more detailed information included in this Offering
Circular and in the documents incorporated by reference herein, including the factors described under the heading “Risk Factors,”
on page 7 of this Offering Circular, before making an investment decision.
Overview of the Company
We are a clinical-stage company developing innovative
drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders.
Neurodegenerative Disease Program
The Company acquired the biopharmaceutical assets
of NeurMedix, Inc. (“NeurMedix”) a privately held clinical-stage pharmaceutical company and a related party in June 2021.
The acquired assets included NE3107. In April 2024, the Company announced that the United States Adopted Names Council, and the World
Health Organization International Nonproprietary Names expert committee had approved “bezisterim” as the non-proprietary (generic)
name for NE3107. Bezisterim (NE3107) is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven
insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus
that both inflammation and insulin resistance may play fundamental roles in the development of AD and PD (each as defined below) and bezisterim
(NE3107) could, if approved by FDA, represent an entirely new medical approach to treating these devastating conditions affecting an estimated
6 million Americans suffering from AD and 1 million Americans suffering from PD.
In neurodegenerative disease, bezisterim (NE3107)
inhibits activation of inflammatory extracellular signal-regulated kinase (“ERK”) and nuclear factor kappa-light-chain-enhancer
of activated B cells (“NFκB”) (including interactions with tumor necrosis factor (“TNF”) signaling and other
relevant inflammatory pathways) that lead to neuroinflammation and insulin resistance. Bezisterim (NE3107) does not interfere with their
homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of
Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”).
A. Alzheimer’s Disease (NCT05083260)
On November 29, 2023, the Company announced topline
efficacy data from its Phase 3 clinical trial (NCT04669028) of bezisterim (NE3107) in the treatment of mild to moderate AD. The study
had co-primary endpoints looking at cognition using the Alzheimer’s Disease Assessment Scale-Cognitive Scale (ADAS-Cog 12) and function
using the Clinical Dementia Rating-Sum of Boxes. Patients were randomly assigned, 1:1 versus placebo, to receive sequentially 5 mg of
bezisterim (NE3107) orally twice a day for 14 days, then 10 mg orally twice a day for 14 days, followed by 26 weeks of 20 mg orally twice
daily.
Upon trial completion, as the Company began the process
of analyzing the trial data, the Company found significant deviation from protocol and current good clinical practices (“cGCPs”)
violations at 15 study sites (virtually all of which were from one geographic area). This highly unusual level of suspected improprieties
led the Company to exclude all patients from these sites and to refer the sites to the U.S. Food and Drug Administration (“FDA”)
Office of Scientific Investigations (“OSI”) for potential further action. After the patient exclusions, 81 patients remained
in the Modified Intent-to-Treat population, 57 of whom were in the Per-Protocol population which included those who completed the trial
and were verified to take study drug based on pharmacokinetic data.
The trial was originally designed to be 80% powered
with 125 patients in each of the treatment and placebo arms. The unplanned exclusion of so many patients left the trial underpowered for
its primary endpoints.
In the Per-Protocol population, which includes those
patients who completed the trial and who were further verified to have taken the study drug (based on pharmacokinetics data), an observed
but not statistically significant change from baseline appeared to suggest a slowing of cognitive loss; these same patients experienced
an advantage in age deceleration vs. placebo as measured by deoxyribonucleic acid (“DNA”) epigenetic change. Age deceleration
is used by longevity researchers to measure the difference between the patient’s biological age, in this case as measured by the
Horvath DNA methylation Skin Blood Clock, relative to the patient’s actual chronological age. This test was a non-primary/secondary
endpoint, other-outcome measure, done via blood test collected at week 30 (end of study).
Based on the efficacy signal seen in this trial, the
Company is exploring (1) a discussion with the FDA to potentially employ the adaptive trial feature of the protocol to continue enrolling
patients to achieve statistical significance; and/or (2) the design of a new Phase 3 study of bezisterim (NE3107) that leverages the most
recent data and understanding of the potential effects bezisterim (NE3107) may have in persons with AD.
B. Parkinson’s Disease (NCT05083260)
The Phase 2 study of bezisterim (NE3107) for the treatment
of PD (NCT05083260), completed in January 2023, was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study
in PD participants treated with carbidopa/levodopa and NE3107. Forty-five patients with a defined L-dopa “off state” were
randomized 1:1 to placebo or bezisterim (NE3107) 20 mg twice daily for 28 days. This trial was launched with two design objectives: (1)
the primary objective was safety and drug-drug interaction, as requested by the FDA, to assess the potential for adverse interactions
between bezisterim (NE3107) and carbidopa/ levodopa; and (2) the secondary objective was to determine if preclinical indications of promotoric
activity and apparent enhancement of levodopa activity could be seen in humans. Both objectives were met.
To extend this Phase 2 data in progressed patients,
the Company has designed a new Phase 2 study of bezisterim (NE3107) as a potential first line therapy to treat patients with new onset
PD. In July 2024, the Company submitted the protocol for this new study to the FDA for regulatory review.
C. Long COVID Program
In April 2024, the Company announced the grant of
a clinical trial award of up to $13.1 million from the U.S. Department of Defense (“DOD”), awarded through the Peer Reviewed
Medical Research Program of the Congressionally Directed Medical Research Programs. In August 2024, U.S. Army Medical Research and Development
Command, Office of Human Research Oversight (“OHRO”) approved the Company’s plan to evaluate bezisterim (NE3107) for
the treatment of neurological symptoms that are associated with long COVID. The FDA had previously reviewed and approved the study as
“Safe to Proceed” in August 2024. The approval from OHRO is the last scientific review milestone needed for the Company to
receive the additional $12.6 million of the aggregate $13.1 million in grant funding from the DOD. The award can provide up to 2 years
of non-dilutive funding for a Phase 2 clinical trial that will assess bezisterim (NE3107) for the treatment of neurological symptoms that
are associated with long COVID. The Company anticipates the trial to commence by early 2025. The study protocol was finalized and submitted
to the FDA for regulatory review in July 2024 and on August 22, 2024 the FDA authorized our Investigational New Drug (“IND”)
application for bezisterim (NE3107) allowing us to study a novel, anti-inflammatory approach or the treatment of the debilitating neurocognitive
symptoms associated with long covid.
Long COVID is a condition in which symptoms of COVID-19,
the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or more.
The Centers for Disease Control recently reported that 6.8% of adults in the United States (more than 17 million individuals) currently
or previously had long COVID. Symptoms, which include fatigue, cognitive dysfunction and sleep disturbances, are debilitating. The loss
in quality of life and earnings and increased medical costs has an enormous economic impact estimated to be 3.7 trillion dollars. To date
there are no therapies proven effective for treatment.
Chronic inflammation is one of the main hypotheses
that researchers have proposed to explain the persistence of symptoms in long COVID. Specifically in individuals with “brain fog,”
sustained systemic inflammation and persistent localized blood-brain-barrier (“BBB”) dysfunction are key physiological features.
Bezisterim (NE3107) permeates the BBB and has been shown to modulate inflammation via the inhibition of NF-kB activation, thus representing
a novel oral treatment targeting an underlying cause of long COVID symptoms.
Chronic neuroinflammation, insulin resistance, and
oxidative stress are common features in the major neurodegenerative diseases, including AD, PD, frontotemporal lobar dementia, and Amyotrophic
lateral sclerosis. Bezisterim (NE3107) is an investigational oral small molecule, blood-brain permeable, compound with potential anti-inflammatory,
insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation.
Bezisterim’s (NE3107) potential to inhibit neuroinflammation and insulin resistance forms the basis for the Company’s work
testing the molecule in AD, PD, and long COVID patients. Bezisterim (NE3107) is patented in the United States, Australia, Canada, Europe
and South Korea.
Liver Cirrhosis Program
In liver disease, our investigational drug candidate
BIV201 (continuous infusion terlipressin), which has been granted both FDA Fast Track designation status and FDA Orphan Drug status, is
being evaluated and discussed after receiving guidance from the FDA regarding the design of Phase 3 clinical testing for the treatment
of ascites due to chronic liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation.
In June 2021, the Company initiated a Phase 2 study
(NCT04112199) designed to evaluate the efficacy of BIV201 (terlipressin, administered by continuous infusion for two 28-day treatment
cycles) combined with standard-of-care (“SOC”), compared to SOC alone, for the treatment of refractory ascites. The primary
endpoints of the study are the incidence of ascites-related complications and change in ascites fluid accumulation during treatment compared
to a pre-treatment period.
In March 2023, the Company announced enrollment was
paused and that data from the first 15 patients treated with BIV201 plus SOC appeared to show at least a 30% reduction in ascites fluid
during the 28 days after treatment initiation compared to the 28 days prior to treatment. The change in ascites volume was significantly
different from those patients receiving SOC treatment. Patients who completed the treatment with BIV201 experienced a 53% reduction in
ascites fluid, which was sustained (43% reduction) during the three months after treatment initiation as compared to the three-month pre-treatment
period.
In June 2023, the Company requested and subsequently
received guidance from the FDA regarding the design and endpoints for definitive clinical testing of BIV201 for the treatment of ascites
due to chronic liver cirrhosis. The Company is currently finalizing protocol designs for the Phase 3 study of BIV201 for the treatment
of ascites due to chronic liver cirrhosis.
While the active agent, terlipressin, is approved
in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, treatment of ascites is not included in these
authorizations. Patients with refractory ascites suffer from frequent life-threatening complications, generate more than $5 billion in
annual treatment costs, and have an estimated 50% mortality rate within 6 to 12 months. The FDA has not approved any drug to treat refractory
ascites.
The BIV201 development program was initiated by LAT
Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently
owns all development and marketing rights to this drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11,
2016, between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty
on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett
Edge, Inc.
Recent Developments
On October 22, 2024, we closed an offering of 4,443,000
shares of our Common Stock at a price of $1.50 per share. In a concurrent private placement, we also issued and sold warrants to purchase
up to 4,443,000 shares of our Common Stock, with each warrant exercisable for one share of Common Stock at an exercise price of $1.37
per share. Each such warrant will be exercisable beginning six months following issuance and will expire five years following the initial
exercise date. The net proceeds received by us from this offering were approximately $5.8 million, after deducting the placement agent
fees and estimated offering expenses payable by us.
On October 24, 2024, we closed an offering of 2,667,000
shares of our Common Stock at a price of $2.25 per share. In a concurrent private placement, we also issued and sold warrants to purchase
up to 2,667,000 shares of our Common Stock, with each warrant exercisable for one share of Common Stock at an exercise price of $2.12
per share. Each such warrant will be exercisable beginning six months following issuance and will expire five years following the initial
exercise date. The net proceeds received by us from this offering were approximately $5.2 million, after deducting the placement agent
fees and estimated offering expenses payable by us.
On October 29, 2024, we closed an offering of 1,146,000
shares of our Common Stock at a price of $2.83 per share. The net proceeds received by us from this offering were approximately $2.7 million,
after deducting the placement agent fees and estimated offering expenses payable by us.
Corporate Information
Our principal executive office is located at 680 W. Nye Lane, Suite 201,
Carson City, Nevada 89703, and our phone number is (775) 888-3162. Our corporate website address is located at www.bioviepharma.com. The
information on or accessed through our website is not incorporated in this Offering Circular or the offering statement of which this Offering
Circular forms a part.
The
Offering
| Shares offered: |
|
15,000,000 shares of Common Stock are being offered by the Company on a “best-efforts” basis. |
| |
|
|
| Pre-Funded Warrants offered by us: |
|
We are also offering up to 15,000,000 Pre-Funded Warrants
to purchase up to 15,000,000 shares of Common Stock in lieu of Offered Shares to any purchaser whose purchase of shares of Common Stock
in this offering would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning
more than 4.99% (or, at the purchaser’s election, 9.99%) of our outstanding common stock immediately following the consummation
of this offering. Each Pre-Funded Warrant will be exercisable for one share of common stock, will have an exercise price of $0.0001 per
share, will be immediately exercisable, and will not expire prior to exercise. This Offering Circular also relates to the offering of
the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. For each Pre-Funded Warrant that we sell, the number of
Offered Shares we are offering will be decreased on a one-for-one basis.
|
| Common Stock outstanding before this offering: |
|
18,451,584 shares |
| |
|
|
| Common Stock to be outstanding after this offering (assuming no issuance of any Pre-Funded Warrants): |
|
33,451,584 shares |
| |
|
|
| Offering price per share: |
|
$3.00 to $5.00 per share |
| |
|
|
| Minimum number of shares to be sold in this offering: |
|
None |
| |
|
|
| Investor suitability standards: |
|
The Securities are being offered and sold to “qualified purchasers” (as defined in Regulation A under the Securities Act of 1933, as amended (the “Securities Act”)). “Qualified purchasers” include any person to whom securities are offered or sold in a Tier 2 offering pursuant to Regulation A under the Securities Act. |
| |
|
|
| Use of proceeds: |
|
We intend to use the net proceeds of this offering primarily for general corporate purposes, which may include, but is not limited to, working capital, capital expenditures, research and development expenditures and acquisitions of new technologies or businesses. |
| |
|
|
| Termination of this offering: |
|
This offering will terminate at the earliest of (a) the date on which all of the Securities have been sold, (b) the date which is one year from this offering being qualified by the SEC and (c) the date on which this offering is earlier terminated by us, in our sole discretion. (See “Plan of Distribution”). |
| |
|
|
| Risk factors: |
|
Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 7 and the similarly titled sections in the documents incorporated by reference into this Offering Circular for a discussion of the factors you should consider carefully before you decide to invest in our securities. |
| |
|
|
| Nasdaq Capital Market symbol: |
|
Our Common Stock is listed on the Nasdaq Capital Market under the symbol “BIVI.” There is no public market for the Pre-Funded Warrants, and none is expected to develop. We do not intend to apply for listing of the Pre-Funded Warrants on any national securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Pre-Funded Warrants will be limited. See “Risk Factors” on page 7. |
The number of shares of our Common Stock outstanding
before this offering and to be outstanding after this offering (assuming all of the Offered Shares are sold hereunder and assuming no
sale of the Pre-Funded Warrants in this offering) is based on 18,451,584 shares of our Common Stock issued and outstanding as of December
20, 2024, and excludes:
| |
· |
975,036 shares of our Common Stock issuable upon the exercise of outstanding stock options at a weighted average exercise price of $27.70 per share; |
| |
· |
9,600,835 shares of our Common Stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $3.50 per share; and |
| |
· |
|
96,672 shares of our Common Stock issuable upon vesting of restricted stock units issued under our equity incentive plan. |
Continuing Reporting Requirements Under Regulation
A
We are required to file periodic and other reports
with the SEC, pursuant to the requirements of Section 13(a) of the Exchange Act. Our continuing reporting obligations under Regulation
A are deemed to be satisfied as long as we comply with our Section 13(a) reporting requirements.
Risk Factors
Any investment in the Securities involves a high
degree of risk. You should carefully consider the risks described below, which we believe represent certain of the material risks to our
business, together with the information contained elsewhere in this Offering Circular, before purchasing any of the Securities. The occurrence
of any of the following risks might cause you to lose a significant part of your investment. Please note that the risks highlighted here
are not the only ones that we may face. For example, additional risks presently unknown to us or that we currently consider immaterial
or unlikely to occur could also impair our operations. If any of the following events occur or any additional risks presently unknown
to us actually occur, our business, financial condition and operating results may be materially adversely affected. In that event, the
trading price of our securities could decline and you could lose all or part of your investment.
Risks Relating to this Offering and Our Common
Stock
You may experience immediate and substantial
dilution in the net tangible book value per share of our Common Stock you purchase in this offering.
The offering price per share in this offering may
exceed the pro forma net tangible book value per share of our Common Stock outstanding prior to this offering. After giving effect to
the sale by us of the Securities at an assumed per share price of $4.00, which represents the midpoint of the offering price range herein,
and after placement agent fees and estimated offering expenses payable by us, you will experience immediate dilution of $1.02 per share,
representing the difference between our pro forma as adjusted net tangible book value per share as of September 30, 2024 after giving
effect to this offering and the assumed offering price. The exercise of outstanding warrants and stock options may also result in further
dilution of your investment. See the section entitled “Dilution” on page 16 below for a more detailed illustration of
the dilution you may incur if you participate in this offering.
This is a “best efforts” offering;
no minimum amount of Securities is required to be sold, and we may not raise the amount of capital we believe is required for our business.
There is no required minimum number of Securities
that must be sold as a condition to completion of this offering. Because there is no minimum offering amount required as a condition to
each closing of this offering, the actual offering amount, and proceeds to us are not presently determinable and may be substantially
less than the maximum amounts set forth in this Offering Circular. We may sell fewer than all of the Securities offered hereby, which
may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event
that we do not sell an amount of Securities sufficient to pursue the business goals outlined in this Offering Circular. Thus, we may not
raise the amount of capital we believe is required for our business and may need to raise additional funds, which may not be available
or available on terms acceptable to us. Despite this, any proceeds from the sale of the Securities offered by us will be available for
our immediate use, and because there is no escrow account and no minimum offering amount in this offering, investors could be in a position
where they have invested in us, but we are unable to fulfill our objectives due to a lack of interest in this offering.
Our management will have broad discretion over the use of the net
proceeds from this offering, may invest or spend the proceeds raised in this offering in ways with which you may not agree and the proceeds
may not yield a significant return.
Our management will have broad discretion over the
use of proceeds from this offering. We currently intend to use the net proceeds of this offering as described in the section entitled
“Use of Proceeds.” However, our management will have broad discretion in the application of the net proceeds from this offering
and could use them for purposes other than those contemplated at the time of this offering. Accordingly, you are relying on the judgment
of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision,
to assess whether the proceeds will be used appropriately. The failure by management to apply these funds effectively could result in
financial losses that could have a material adverse effect on our business, cause the price of our Common Stock to decline, and delay
the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in short-term, interest-bearing
instruments. These investments may not yield a favorable return, or any return, to us or our stockholders.
There is no public
market for the Pre-Funded Warrants being offered in this offering.
There is no established public
trading market for the Pre-Funded Warrants being offered in this offering, and we do not expect a market to develop. In addition, we do
not intend to apply to list the Pre-Funded Warrants on any national securities exchange or other nationally recognized trading system.
Without an active market, the liquidity of the Pre-Funded Warrants will be limited.
Except as provided
in the Pre-Funded Warrants, holders of the Pre-Funded Warrants offered hereby will have no rights as common stockholders with respect
to the shares our Common Stock underlying the Pre-Funded Warrants until such holders exercise their Pre-Funded Warrants and acquire our
Common Stock.
Until holders of the Pre-Funded
Warrants acquire shares of our Common Stock upon exercise thereof, such holders will have No rights with respect to the shares of our
Common Stock underlying such Pre-Funded Warrants, except to the extent that holders of such Pre-Funded Warrants will have certain rights
to participate in distributions or dividends paid on our Common Stock as set forth in the Pre-Funded Warrants. Upon exercise of the Pre-Funded
Warrants, the holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs
after the exercise date.
The Pre-Funded Warrants
are speculative in nature.
Holders of the Pre-Funded Warrants may acquire shares
of Common Stock issuable upon exercise of such Pre-Funded Warrants at an exercise price of $0.0001 per share of Common Stock. There can
be no assurance that the market value of the Pre-Funded Warrants will equal or exceed their public offering price.
Our stock price is and may continue to be volatile
and you may not be able to resell our Common Stock at or above the price you paid.
The market price for our Common Stock is volatile
and may fluctuate significantly in response to a number of factors, many of which we cannot control, such as quarterly fluctuations in
financial results, the timing and our ability to advance the development of our product candidates or changes in securities analysts’
recommendations could cause the price of our stock to fluctuate substantially. In addition, stock markets generally have recently experienced
volatility. Our stock price is likely to experience significant volatility in the future. The price of our Common Stock may decline and
the value of any investment in our Common Stock may be reduced regardless of our performance. Further, the daily trading volume of our
Common Stock has historically been relatively low. As a result of the historically low volume, our shareholders may be unable to sell
significant quantities of Common Stock in the public trading markets without a significant reduction in the price of our shares of Common
Stock. Each of these factors, among others, could harm your investment in our Common Stock and could result in your being unable to resell
the shares of our Common Stock that you purchase at a price equal to or above the price you paid.
In the past, when the market price of a stock has
been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders
were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would
be diverted from the operation of our business.
We do not intend to pay dividends on our Common
Stock, so any returns will be limited to the value of our Common Stock.
We currently anticipate that we will retain any future
earnings to finance the continued development, operation and expansion of our business. As a result, we do not anticipate declaring or
paying any cash dividends or other distributions in the foreseeable future. If we do not pay dividends, our Common Stock may be less valuable
because stockholders must rely on sales of their Common Stock after price appreciation, which may never occur, to realize any gains on
their investment.
You may experience future dilution as a result
of future equity offerings or if we issue shares subject to options, warrants, stock awards or other arrangements.
In order to raise additional capital, we may in the
future offer additional shares of our Common Stock or other securities convertible into or exchangeable for our Common Stock in any other
offering at a price per share that is less than the current market price of our securities, and investors purchasing shares or other securities
in the future could have rights superior to existing stockholders. The sale of additional shares of our Common Stock or other securities
convertible into or exchangeable for our Common Stock would dilute all of our stockholders, and if such sales of convertible securities
into or exchangeable into our Common Stock occur at a deemed issuance price that is lower than the current exercise price of our outstanding
warrants sold to Acuitas Group Holdings, LLC (“Acuitas”) in August 2022 (the “Acuitas Warrants”), the exercise
price for those warrants would adjust downward to the deemed issuance price pursuant to price adjustment protection contained within those
warrants.
As of December 20, 2024, there were warrants outstanding
to purchase an aggregate of 9,600,835 shares of our Common Stock at exercise prices ranging from $1.37 to $125.00 per share, 975,036 shares
issuable upon exercise of outstanding options at exercise prices ranging from $1.90 to $420.90 per share and restricted stock units totaling
96,672. We may also grant additional options, warrants or equity awards. To the extent such shares are issued, the interest of holders
of our Common Stock will be diluted.
Moreover, we are obligated to issue shares of our
Common Stock upon achievement of certain clinical, regulatory and commercial milestones with respect to certain of our drug candidates
(i.e., bezisterim (NE3107), NE3291, NE3413, and NE3789) pursuant to the asset purchase agreement, dated April 27, 2021, by and among the
Company, NeurMedix and Acuitas, as amended on May 9, 2021. The achievement of these milestones could result in the issuance of up to 1.8
million shares of our Common Stock, further diluting the interest of holders of our Common Stock.
We may, in the future, issue additional common
stock, which would reduce investors’ percent of ownership and may dilute our share value.
As of December 20, 2024, our Articles of Incorporation,
as amended, authorize the issuance of 800,000,000 shares of Common Stock, and we had 18,477,910 shares of our Common Stock issued and
18,451,584 issued and outstanding. Accordingly, we may issue up to an additional 781,522,090 shares of Common Stock. The future issuance
of Common Stock may result in substantial dilution in the percentage of our Common Stock held by our then existing stockholders. We may
value any Common Stock in the future on an arbitrary basis. The issuance of Common Stock for future services or acquisitions or other
corporate actions may have the effect of diluting the value of the shares held by our investors, might have an adverse effect on any trading
market for our Common Stock and could impair our ability to raise capital in the future through the sale of equity securities.
We effected a reverse stock split on August
6, 2024, and we cannot predict the effect that such reverse stock split will have on the market price for shares of our Common Stock.
Our board of directors approved a one-for-ten (1:10)
reverse stock split of our Common Stock, which became effective at 12:01 a.m. Eastern Time on August 6, 2024. We cannot predict the effect
that the reverse stock split will have on the market price for shares of our Common Stock, and the history of similar reverse stock splits
for companies in like circumstances has varied. Some investors may have a negative view of a reverse stock split. Even if the reverse
stock split has a positive effect on the market price for shares of our Common Stock, performance of our business and financial results,
general economic conditions and the market perception of our business, and other adverse factors which may not be in our control could
lead to a decrease in the price of our Common Stock following the reverse stock split.
Furthermore, even if the reverse stock split does
result in an increased market price per share of our Common Stock, the market price per share following the reverse stock split may not
increase in proportion to the reduction of the number of shares of our Common Stock outstanding before the implementation of the reverse
stock split. Accordingly, even with an increased market price per share, the total market capitalization of shares of our Common Stock
after a reverse stock split could be lower than the total market capitalization before the reverse stock split. Also, even if there is
an initial increase in the market price per share of our Common Stock after a reverse stock split, the market price many not remain at
that level.
If the market price of shares of our Common Stock
declines following the reverse stock split, the percentage decline as an absolute number and as a percentage of our overall market capitalization
may be greater than would occur in the absence of the reverse stock split due to decreased liquidity in the market for our Common Stock.
Accordingly, the total market capitalization of our Common Stock following the reverse stock split could be lower than the total market
capitalization before the reverse stock split.
Any failure to maintain effective internal control
over financial reporting could harm us.
Our management is responsible for establishing and
maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S.
generally accepted accounting principles (“GAAP”). Under standards established by the Public Company Accounting Oversight
Board (“PCAOB”), a deficiency in internal control over financial reporting exists when the design or operation of a control
does not allow management or personnel, in the normal course of performing their assigned functions, to prevent or detect misstatements
on a timely basis. The PCAOB defines a material weakness as a deficiency, or combination of deficiencies, in internal control over financial
reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not
be prevented, or detected and corrected, on a timely basis.
If we are unable to assert that our internal control
over financial reporting is effective, or when required in the future, if our independent registered public accounting firm is unable
to express an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence
in the accuracy and completeness of our financial reports, the market price of our Common Stock could be adversely affected and we could
become subject to litigation or investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities,
which could require additional financial and management resources.
There is a limited trading market for our
Common Stock, which could make it difficult to liquidate an investment in our Common Stock, in a timely manner.
Our Common Stock is currently traded on the Nasdaq
Capital Market. Because there is a limited public market for our Common Stock, investors may not be able to liquidate their investment
whenever desired. We cannot assure that there will be an active trading market for our Common Stock and the lack of an active public trading
market could mean that investors may be exposed to increased risk. In addition, if we failed to meet the criteria set forth in the regulations
of the SEC, various requirements would be imposed by law on broker dealers who sell our securities to persons other than established customers
and accredited investors. Consequently, such regulations may deter broker-dealers from recommending or selling our Common Stock, which
may further affect its liquidity.
The lack of public company experience of our
management team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have
a materially adverse effect on our business.
Our officers have limited public company experience,
which could impair our ability to comply with legal and regulatory requirements such as those imposed by Sarbanes-Oxley Act of 2002. Such
responsibilities include complying with federal securities laws and making required disclosures on a timely basis. Any such deficiencies,
weaknesses or lack of compliance could have a materially adverse effect on our ability to comply with the reporting requirements of the
Exchange Act, which is necessary to maintain our public company status. If we were to fail to fulfill those obligations, our ability to
continue as a U.S. public company would be in jeopardy in which event you could lose your entire investment in our Company.
We are considered a smaller reporting company
that is exempt from certain disclosure requirements, which could make our stock less attractive to potential investors.
Rule 12b-2 of the Exchange Act defines a “smaller
reporting company” as an issuer that is not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent
that is not a smaller reporting company and that:
| ● | Had a public float of less than $250 million as of the last business day of its most recently completed
fiscal quarter, computed by multiplying the aggregate number of worldwide number of shares of its voting and non-voting common equity
held by non-affiliates by the price at which the common equity was last sold, or the average of the bid and asked prices of common equity,
in the principle market for the common equity; or |
| ● | In the case of an initial registration statement under the Securities Act or the Exchange Act for shares
of its common equity, had a public float of less than $250 million as of a date within 30 days of the date of the filing of the registration
statement, computed by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus,
in the case of a Securities Act registration statement, the number of such shares included in the registration statement by the estimated
public offering price of the shares; or |
| ● | In the case of an issuer who had annual revenue of less than $100 million during the most recently completed
fiscal year for which audit financial statements are available, had a public float as calculated under paragraph (1) or (2) of this definition
that was either zero or less than $700 million. |
As a “smaller reporting company” we are
not required and may not include a Compensation Discussion and Analysis section in our proxy statements; we provide only 3 years of business
development information; and have other “scaled” disclosure requirements that are less comprehensive than issuers that are
not “smaller reporting companies” which could make our stock less attractive to potential investors, which could make it more
difficult for you to sell your shares.
We are subject to the periodic reporting requirements
of the Exchange Act, which require us to incur audit fees and legal fees in connection with the preparation of such reports. These additional
costs will negatively affect our ability to earn a profit.
We are required to file periodic reports with the
SEC pursuant to the Exchange Act and the rules and regulations thereunder. In order to comply with such requirements, our independent
registered auditors have to review our financial statements on a quarterly basis and audit our financial statements on an annual basis.
Moreover, our legal counsel has to review and assist in the preparation of such reports. Factors such as the number and type of transactions
that we engage in and the complexity of our reports cannot accurately be determined at this time and may have a major negative effect
on the cost and amount of time to be spent by our auditors and attorneys. However, the incurrence of such costs is an expense to our operations
and thus has a negative effect on our ability to meet our overhead requirements and earn a profit.
Because we do not intend to pay any cash dividends
on our Common Stock, our stockholders will not be able to receive a return on their shares unless they sell them.
We intend to retain any future earnings to finance
the development and expansion of our business. We do not anticipate paying any cash dividends on our Common Stock in the foreseeable future.
Unless we pay dividends, our stockholders will not be able to receive a return on their shares unless they sell them. There is no assurance
that stockholders will be able to sell shares when desired.
We are authorized to issue “blank check”
preferred stock without stockholder approval, which could adversely impact the rights of holders of our securities.
Our Articles of Incorporation authorize us to issue
up to 10,000,000 shares of blank check preferred stock. Any preferred stock that we issue in the future may rank ahead of our Common Stock
in terms of dividend priority or liquidation premiums and may have greater voting rights than our Common Stock. Any preferred stock issued
may contain provisions allowing those shares to be converted into shares of Common Stock, which could dilute the value of our Common Stock
to current stockholders and could adversely affect the market price, if any, of our Common Stock. The preferred stock could be utilized,
under certain circumstances, as a method of discouraging, delaying, or preventing a change in control of our company. Although we have
no present intention to issue any shares of our authorized preferred stock, there can be no assurance that we will not do so in the future.
Provisions in our Articles of Incorporation,
our Bylaws, and Nevada law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore,
depress the trading price of our Common Stock.
Provisions of our Articles of Incorporation, our Bylaws,
and Nevada law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in control of our company or
changes in our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then
current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem
to be in their best interests. These provisions include:
| ● | the inability of stockholders to call special meetings; |
| ● | the “business combinations” and “control share acquisitions” provisions of Nevada
law, to the extent applicable, could discourage attempts to acquire our stockholders stock even on terms above the prevailing market price;
and |
| ● | the ability of our board of directors to designate the terms of and issue new series of preferred stock
without stockholder approval, which could include the right to approve an acquisition or other change in our control or could be used
to institute a rights plan, also known as a poison pill, that would dilute the stock ownership of a potential hostile acquirer, likely
preventing acquisitions that have not been approved by our board of directors. |
The existence of the forgoing provisions and anti-takeover
measures could limit the price that investors might be willing to pay in the future for shares of our Common Stock. They could also deter
potential acquirers of our company, thereby reducing the likelihood that you could receive a premium for your Common Stock in an acquisition.
Risks Relating to Legal Proceedings
We are currently subject to securities class
action and shareholder derivative litigation and may be subject to similar or other litigation in the future, all of which will require
significant management time and attention, result in significant legal expenses and may result in unfavorable outcomes, which may have
a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our Common Stock.
We are, and may in the future become, subject to various
legal proceedings and claims that arise in or outside the ordinary course of business. For example, On January 19, 2024, a purported shareholder
class action complaint, captioned Eric Olmstead v. BioVie Inc. et al., No. 3:24-cv-00035, was filed in the U.S. District Court
for the District of Nevada, naming the Company and certain of its officers as defendants. On February 22, 2024, a second, related putative
securities class action was filed in the same court asserting similar claims against the same defendants, captioned Way v. BioVie
Inc. et al., No. 2:24-cv-00361. On April 15, 2024, the court consolidated these two actions under the caption In re BioVie
Inc. Securities Litigation, No. 3:24-cv-00035 (the “Securities Class Action”), appointed the lead plaintiff, and approved
selection of the lead counsel. On June 21, 2024, the lead plaintiff filed an amended complaint, alleging that the defendants made material
misrepresentations and/or omissions of material fact relating to the Company’s business, operations, compliance, and prospects,
including information related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to moderate probable Alzheimer’s
Disease, in violation of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder. The class
action is on behalf of purchasers of the Company’s securities during the period from December 7, 2022 through November 28, 2023
and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney’s
fees. The defendants filed a motion to dismiss the amended complaint on August 21, 2024; that motion was fully briefed as of December
5, 2024 and now awaits the court’s decision.
In addition, on December 30, 2024, a purported shareholder
derivative complaint was filed in the United States District Court for the District of Nevada by putative stockholder Andrew Hulm (No.
3:24-cv-00602; “Hulm Derivative Lawsuit”), allegedly on behalf of the Company, that piggy-backs on the Securities Class Action.
The derivative complaint names certain current officers and current and former directors as defendants, and generally alleges that they
breached their fiduciary duties by causing or failing to prevent the securities violations alleged in the Securities Class Action. The
derivative complaint also alleges claims for unjust enrichment, waste of corporate assets, gross mismanagement, and abuse of control as
against all defendants.
The defendants in the Securities Class Action and
the Hulm Derivative Lawsuit believe that the claims are without merit and intend to defend vigorously against them, but there can be no
assurances as to the outcome.
It is possible that additional lawsuits will be filed,
or allegations received from stockholders, with respect to these same or other matters and also naming us and/or our officers and directors
as defendants. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition
costs will depend upon many unknown factors. The outcome of such lawsuits is necessarily uncertain. We could be forced to expend significant
resources in the defense of the pending lawsuit and any additional lawsuits, and we may not prevail. In addition, we may incur substantial
legal fees and costs in connection with such lawsuits. We currently are not able to estimate the possible cost to us from these matters,
as the pending lawsuits are currently at an early stage, and we cannot be certain how long it may take to resolve the pending lawsuits
or the possible amounts of any damages that we may be required to pay. Monitoring, initiating and defending against legal actions is time-consuming
for our management, is likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities.
We could be forced to expend significant resources in the settlement or defense of the pending lawsuits and any potential future lawsuits,
and we may not prevail in such lawsuits.
Although we have insurance coverage that we believe
applies to these actions, the coverage is subject to a $2 million deductible. That means that we are responsible for the first $2 million
of loss arising from these actions, which includes both defense costs and damages, before any insurance coverage will apply. Furthermore,
our insurance coverage may be insufficient, and our assets may be insufficient to cover any amounts that exceed our insurance coverage,
and we may have to pay damage awards or otherwise may enter into settlement arrangements in connection with such claims. A decision adverse
to our interests in one or both of the pending lawsuits, or in similar or related litigation, could result in the payment of substantial
damages, or possibly fines, and could have a material adverse effect on our business, our stock price, cash flow, results of operations
and financial condition. We have not established any reserve for any potential liability relating to the pending lawsuits or any potential
future lawsuits. Any such payments or settlement arrangements in current or future litigation could have a material adverse effect on
our business, operating results or financial condition. In addition, such lawsuits may make it more difficult to finance our operations
and affect our ability to make payments for damages.
Cautionary
NOTE Regarding Forward-Looking Statements
This Offering Circular and the documents incorporated
by reference into this Offering Circular contain “forward-looking statements” within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that relate to future events or our future
financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of
activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed
or implied by these forward-looking statements. Such forward-looking statements concern our anticipated results and progress of our operations
in future periods, planned exploration and, if warranted, development of our properties, plans related to our business and other matters
that may occur in the future. These statements relate to analyses and other information that are based on forecasts of future results,
estimates of amounts not yet determinable and assumptions of management. All statements contained herein that are not clearly historical
in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,”
“may,” “will,” “could,” “leading,” “intend,” “contemplate,” “shall”
and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are subject to a variety
of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed
or implied by the forward-looking statements. The section in this Offering Circular entitled “Risk Factors” and the sections
in our periodic reports, including our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the “2024 Form 10-K”)
entitled “Business,” and in the 2024 Form 10-K and our Quarterly Report on Form 10-Q for the quarterly period ended September
30, 2024 entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results
of Operations,” as well as other sections in this Offering Circular and the documents or reports incorporated by reference into
this Offering Circular, discuss some of the factors that could contribute to these differences. Forward-looking statements in this Offering
Circular and the documents incorporated by reference herein include, but are not limited to, statements with respect to:
| |
- |
our limited operating history and experience in developing and manufacturing drugs; |
| |
- |
none of our products are approved for commercial sale; |
| |
- |
our substantial capital needs; |
| |
- |
product development risks; |
| |
- |
our lack of sales and marketing personnel; |
| |
- |
regulatory, competitive and contractual risks; |
| |
- |
no assurance that our product candidates will obtain regulatory approval or that the results of clinical studies will be favorable; |
| |
- |
risks related to our intellectual property rights; |
| |
- |
the volatility of the market price and trading volume in our Common Stock; |
| |
- |
the absence of liquidity in our Common Stock; |
| |
- |
the risk of substantial dilution from future issuances of our equity securities; and |
| |
- |
the other risks set forth herein and in the documents incorporated by reference herein under the caption “Risk Factors.” |
The foregoing does not represent an exhaustive list
of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with. The factors
set forth above under “Risk Factors” and other cautionary statements made in this Offering Circular should be read and understood
as being applicable to all related forward-looking statements wherever they appear in this Offering Circular. The forward-looking statements
contained in this Offering Circular represent our judgment as of the date of this Offering Circular. We caution readers not to place undue
reliance on such statements. You should read this Offering Circular and the documents that we have filed as exhibits to this Offering
Circular and incorporated by reference herein completely and with the understanding that our actual future results may be materially different
from the plans, intentions and expectations disclosed in the forward-looking statements we make. Except as required by law, we undertake
no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events
occur in the future. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are
expressly qualified in their entirety by the cautionary statements contained above and throughout this Offering Circular.
Use of Proceeds
The table below sets forth the estimated proceeds
we would derive from this offering, assuming the sale of 25%, 50%, 75% and 100% of the Offered Shares at an assumed per share price of
$4.00, which represents the midpoint of the offering price range herein. There is, of course, no guaranty that we will be successful in
selling any of the Offered Shares in this offering. The table below assumes no sale of the Pre-Funded Warrants in this Offering.
| | |
Assumed Percentage of Offered Shares Sold in this Offering | |
| | |
25% | | |
50% | | |
75% | | |
100% | |
| Offered Shares sold | |
| 3,750,000 | | |
| 7,500,000 | | |
| 11,250,000 | | |
| 15,000,000 | |
| Gross proceeds | |
$ | 15,000,000 | | |
$ | 30,000,000 | | |
$ | 45,000,000 | | |
$ | 60,000,000 | |
| Offering expenses (1) | |
| 1,450,000 | | |
| 2,500,000 | | |
| 3,550,000 | | |
| 4,600,000 | |
| Net proceeds | |
$ | 13,550,000 | | |
$ | 27,500,000 | | |
$ | 41,450,000 | | |
$ | 55,400,000 | |
| |
(1) |
Represents placement agent fees, legal and accounting fees and expenses and out-of-pocket costs (See “Plan of Distribution”). |
We intend to apply the net proceeds derived by us
in this offering for working capital and general corporate purposes.
We reserve the right to change the foregoing use of
proceeds, should our management believe it to be in the best interest of our company. The allocations of the proceeds of this offering
presented above constitute the current estimates of our management and are based on our current plans, assumptions made with respect to
the industry in which we currently or, in the future, expect to operate, general economic conditions and our future revenue and expenditure
estimates.
Investors are cautioned that expenditures may vary
substantially from the estimates presented above. Investors must rely on the judgment of our management, who will have broad discretion
regarding the application of the proceeds of this offering. The amounts and timing of our actual expenditures will depend upon numerous
factors, including market conditions, cash generated by our operations (if any), business developments and the rate of our growth. We
may find it necessary or advisable to use portions of the proceeds of this offering for other purposes.
In the event we do not obtain the entire offering
amount hereunder, we may attempt to obtain additional funds through private offerings of our securities or by borrowing funds. Currently,
we do not have any committed sources of financing.
Dividend
Policy
We have never declared or paid dividends on our Common
Stock and we do not anticipate paying any cash dividends on our Common Stock in the foreseeable future. Payment of cash dividends, if
any, in the future will be at the discretion of our board of directors and will depend on applicable law and then-existing conditions,
including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors
our board of directors may deem relevant. We currently intend to retain all available funds and any future earnings to fund the development
and growth of our business.
Dilution
If you invest in shares of our Common Stock in this
offering, your interest will be diluted to the extent of the difference between the assumed public offering price per share of Common
Stock and the net tangible book value per share of Common Stock immediately after this offering.
The net tangible book value of our Common Stock as
of September 30, 2024 was approximately $13.0 million, or approximately $1.63 per share. The net tangible book value per share of our
Common Stock represents our total tangible assets (total assets less intangible assets) less total liabilities divided by the number of
shares of Common Stock outstanding as of that date.
After giving effect to (i) the issuance of 4,443,000
shares of our Common Stock at an offering price of $1.50 per share, warrants to purchase up to 4,443,000 shares of our Common Stock in
a concurrent private placement, and placement agent warrants to purchase 222,150 shares of our Common Stock, pursuant to the Placement
Agent Agreement, dated as of October 21, 2024, by and between the Company and ThinkEquity LLC, (ii) the issuance of 2,667,000 shares of
our Common Stock at an offering price of $2.25 per share, warrants to purchase up to 2,667,000 shares of our Common Stock in a concurrent
private placement, and placement agent warrants to purchase 133,350 shares of Common Stock, pursuant to the Placement Agent Agreement,
dated as of October 23, 2024, by and between the Company and ThinkEquity LLC, and (iii) the issuance of 1,146,000 shares of our Common
Stock in a registered direct offering and placement agent warrants to purchase 57,300 shares of our Common Stock, pursuant to the Placement
Agent Agreement dated October 28, 2024 (clauses (i) through (iii) collectively, the “Prior Offerings”) our pro forma net tangible
book value as of September 30, 2024 would have been approximately $26.6 million, or approximately $1.64 per share.
After giving further effect to the sale by us in this
offering of 15,000,000 Offered Shares (assuming no sale of the Pre-Funded Warrants in this offering) at an assumed public offering price
of $4.00 per share (which represents the midpoint of the offering price range herein), after deducting estimated offering expenses, our
pro forma as adjusted net tangible book value as of September 30, 2024 would have been approximately $68.4 million, or approximately $2.98
per share. This represents an immediate increase in pro forma net tangible book value of approximately $1.35 per share to our existing
stockholders, and an immediate dilution in pro forma as adjusted net tangible book value of approximately $1.02 per share to new investors
participating in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book
value per share as of September 30, 2024 after this offering from the public offering price per share paid by new investors.
The following table illustrates this per share dilution:
| Assumed public offering price per share | |
| | | |
$ | 4.00 | |
| Historical net tangible book value per share as of September 30, 2024 | |
$ | 1.63 | | |
| | |
| Increase in historical net tangible book value per share after the Prior Offerings | |
$ | 0.01 | | |
| | |
| Pro forma net tangible book value per share as of September 30, 2024 after giving effect to the Prior Offerings | |
$ | 1.64 | | |
| | |
| Increase in pro forma net tangible book value per share after this offering | |
$ | 1.35 | | |
| | |
| Pro forma as adjusted net tangible book value per share as of September 30, 2024 after giving further effect to this offering | |
| | | |
$ | 2.98 | |
| Dilution per share to new investors in this offering | |
| | | |
$ | 1.02 | |
The number of shares of our Common Stock to be outstanding
after this offering (assuming all of the Offered Shares are sold hereunder and assuming no sale of the Pre-Funded Warrants in this offering)
is based on 7,956,660 shares of our Common Stock issued and outstanding as of September 30, 2024, and excludes:
| |
· |
517,996 shares of our Common Stock issuable upon the exercise of outstanding stock options at a weighted average exercise price of $54.10 per share; |
| |
· |
4,316,002 shares of our Common Stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $5.54 per share; and |
| |
· |
34,567 shares of our Common Stock issuable upon vesting of restricted stock units issued under our equity incentive plan. |
To the extent that outstanding exercisable options
or warrants are exercised, you may experience further dilution.
In addition, we may choose to raise additional capital
due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating
plans. To the extent that we raise additional capital by issuing equity securities or convertible debt, your ownership will be further
diluted.
Principal
Stockholders
Based solely upon information made available to us,
the following table sets forth information as of December 20, 2024 regarding the beneficial ownership of our Common Stock by:
| |
● |
each person known by us to be the beneficial owner of more than 5% of our outstanding shares of Common Stock; |
| |
|
|
| |
● |
each of our named executive officers and directors; and |
| |
|
|
| |
● |
all our executive officers and directors as a group. |
The percentage ownership information shown in the
table is based upon 18,451,584 shares of Common Stock outstanding as of December 20, 2024.
Beneficial ownership is determined in accordance with
the rules of the SEC and includes voting or investment power with respect to the securities. Except as otherwise indicated, each person
or entity named in the table has sole voting and investment power with respect to all shares of our capital shown as beneficially owned,
subject to applicable community property laws.
In computing the number and percentage of shares beneficially
owned by a person as of a particular date, shares that may be acquired by such person (for example, upon the exercise of options or warrants)
within 60 days of such date are counted as outstanding, while these shares are not counted as outstanding for computing the percentage
ownership of any other person.
The address of each holder listed below, except as
otherwise indicated, is c/o BioVie Inc., 680 W Nye Lane, Suite 201, Carson City, Nevada 89703.
| Name and Address of Beneficial Owner | |
Number of
Common
Shares of
Beneficial
Ownership | | |
Percentage
of
Beneficial
Ownership | |
| James Lang (1) | |
| 58,900 | | |
| * | |
| Richard Berman (2) | |
| 42,720 | | |
| * | |
| Robert Hariri (3) | |
| 46,130 | | |
| * | |
| Sigmund Rogich (4) | |
| 42,405 | | |
| * | |
| Michael Sherman (5) | |
| 60,695 | | |
| * | |
| Cuong Do (6) | |
| 156,780 | | |
| * | |
| Joanne Wendy Kim (7) | |
| 25,171 | | |
| * | |
| Joseph Palumbo (8) | |
| 26,692 | | |
| * | |
| Affiliate – Acuitas Group Holdings (9) | |
| 3,050,397 | | |
| 15.9 | % |
| All directors and executive officers as a group (8) | |
| 1,101,733 | | |
| 2.5 | % |
* Less than 1%
| (1) | Includes warrants to purchase 133 shares of Common Stock and 51,886 options to purchase shares of Common
Stock, all of which are exercisable within 60 days of December 20, 2024. |
| (2) | Includes options to purchase 27,727 shares of Common Stock and 8,550 Restricted Stock Units (RSU), all
of which are exercisable within 60 days of December 20, 2024. |
| (3) | Includes options to purchase 38,480 shares of Common Stock exercisable within 60 days of December 20,
2024. |
| (4) | Includes options to purchase 30,004 shares of Common Stock and 8,175 RSUs, all which are exercisable within
60 days of December 20, 2024. |
| (5) | Includes options to purchase 58,626 shares of Common Stock, which are exercisable within 60 days of December
20, 2024. Common stock held of record by Sherman Children’s Trust Brian Krisber, Trustee. All shares of common stock, warrants and
options are deemed to be beneficially owned or controlled by Michael Sherman. |
| (6) | Includes warrants to purchase 633 shares of Common Stock and options to purchase 109,730 shares of Common
Stock all of which are exercisable within 60 days of December 20, 2024 and 38,780 shares of Common Stock are held of record by Do &
Rickles Investments, LLC, a limited liability company 100% owned by Cuong Do and his wife, as such, Mr. Do may be deemed to beneficially
own or control. |
| (7) | Includes options to purchase shares 17,510 of Common Stock, all which are exercisable within 60 days of
December 20, 2024. |
| (8) | Includes options to purchase 16,506 shares of Common Stock, all which are exercisable within 60 days of
December 20, 2024. |
| (9) | Includes warrants to purchase 727,223 shares of Common Stock, and options to purchase 6,500 shares of
Common Stock, all of which are exercisable within 60 days of December 20, 2024. All shares held of record by Acuitas Group Holdings, LLC,
a limited liability company 100% owned by Terren Peizer, and as which Mr. Peizer may be deemed to beneficially own or control. Mr. Peizer
disclaims beneficial of any such securities. |
Description
of SECURITIES
The following
description is a summary of some of the terms of our securities, our organizational documents and Nevada law. The descriptions in this
Offering Circular of our securities and our organizational documents do not purport to be complete and are subject to, and qualified in
their entirety by reference to, our organizational documents, copies of which have been filed as exhibits to this Offering Circular.
General
As of December 20, 2024, our authorized capital stock
consists of 800,000,000 shares of Class A common stock, par value $0.0001 per share (the “Common Stock”), of which 18,451,584
shares were issued and outstanding; and 10,000,000 shares of preferred stock, par value $0.001 per share, none of which were issued and
outstanding. The authorized and unissued shares of Common Stock and preferred stock are available for issuance without further action
by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be
listed. Unless approval of our stockholders is so required, our board of directors will not seek stockholder approval for the issuance
and sale of our common stock.
Common Stock
Each holder of Common Stock is entitled to one vote
for each share of Common Stock held on all matters submitted to a vote of the stockholders, including the election of directors. Our Articles
of Incorporation and Bylaws do not provide for cumulative voting rights. Subject to preferences that may be applicable to any then outstanding
preferred stock, the holders of our outstanding shares of Common Stock are entitled to receive dividends, if any, as may be declared from
time to time by our board of directors out of legally available funds. In the event of our liquidation, dissolution or winding up, holders
of Common Stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment
of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding
shares of preferred stock. Holders of our Common Stock have no preemptive, conversion or subscription rights, and there are no redemption
or sinking fund provisions applicable to the Common Stock. The rights, preferences and privileges of the holders of Common Stock are subject
to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and
issue in the future. All of our outstanding shares of Common Stock are fully paid and nonassessable.
Our Common Stock is listed on the Nasdaq Capital Market
under the symbol “BIVI.” The transfer agent and registrar for our Common Stock is West Coast Stock Transfer, Inc., Encinitas,
California.
Pre-Funded Warrants
The following summary of certain terms and provisions of the Pre-Funded Warrants that are being offered
hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Pre-Funded Warrant, the form of which
is filed as an exhibit to this Offering Statement. Prospective investors should carefully review the terms and provisions of the form
of Pre-Funded Warrant for a complete description of the terms and conditions of the Pre-Funded Warrants.
Term
The Pre-Funded Warrants will not expire until they are fully exercised.
Exercisability
The Pre-Funded Warrants are exercisable at any time
until they are fully exercised. The Pre-Funded Warrants will be exercisable, at the option of each holder, in whole or in part by delivering
to us a duly executed exercise notice and payment of the exercise price. No fractional shares of Common Stock will be issued in connection
with the exercise of a Pre-Funded Warrant. The holder of the Pre-Funded Warrant may also satisfy its obligation to pay the exercise price
through a “cashless exercise,” in which the holder receives the net value of the Pre-Funded Warrants in shares of Common Stock
determined according to the formula set forth in the Pre-Funded Warrant.
Exercise Limitations
Under the terms of the Pre-Funded Warrants, the Company
may not effect the exercise of any such warrant, and a holder will not be entitled to exercise any portion of any such warrant, if, upon
giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder (together with its affiliates,
any other persons acting as a group together with the holder or any of the holder’s affiliates, and any other persons whose beneficial
ownership of Common Stock would or could be aggregated with the holder’s for purposes of Section 13(d) or Section 16 of the Securities
Exchange Act of 1934, as amended) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect
to the exercise, as such percentage ownership is determined in accordance with the terms of such warrant, which percentage may be increased
or decreased at the holder’s election upon 61 days’ notice to the Company subject to the terms of such warrants, provided
that such percentage may in no event exceed 9.99%.
Exercise Price
The exercise price of our shares of Common Stock purchasable
upon the exercise of the Pre-Funded Warrants is $0.0001 per share. The exercise price of the Pre-Funded Warrants and the number of shares
of Common Stock issuable upon exercise of the Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends
and distributions, stock splits, stock combinations, reclassifications or similar events affecting our shares of Common Stock, as well
as upon any distribution of assets, including cash, stock or other property, to our stockholders.
Transferability
Subject to applicable laws, the Pre-Funded Warrants
may be offered for sale, sold, transferred or assigned without our consent.
Exchange Listing
We do not intend to list the Pre-Funded Warrants on
the Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system.
Fundamental Transactions
Upon the consummation of a fundamental transaction
(as described in the Pre-Funded Warrants, and generally including any reorganization, recapitalization or reclassification of our shares
of Common Stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or
merger with or into another person, the acquisition of more than 50% of our outstanding shares of Common Stock, or any person or group
becoming the beneficial owner of 50% of the voting power of our outstanding shares of Common Stock), the holders of the Pre-Funded Warrants
will be entitled to receive, upon exercise of the Pre-Funded Warrants, the kind and amount of securities, cash or other property that
such holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction, without
regard to any limitations on exercise contained in the Pre-Funded Warrants. Notwithstanding the foregoing, in the event of a fundamental
transaction where the consideration consists solely of cash, solely of marketable securities or a combination of cash and marketable securities,
then each Pre-Funded Warrants shall automatically be deemed to be exercised in full in a cashless exercise effective immediately prior
to and contingent upon the consummation of such fundamental transaction.
No Rights as a Stockholder
Except by virtue of such holder’s ownership
of shares of Common Stock, the holder of a Pre-Funded Warrant does not have the rights or privileges of a holder of our shares of Common
Stock, including any voting rights, until such holder exercises the Pre-Funded Warrant.
Anti-Takeover Effects of Nevada Law
Business Combinations
The “business combination” provisions
of Sections 78.411 to 78.444, inclusive, of the Nevada Revised Statutes (“NRS”) generally prohibit a Nevada corporation with
at least 200 stockholders from engaging in various “combination” transactions with any interested stockholder for a period
of two years after the date of the transaction in which the person became an interested stockholder, unless the transaction is approved
by the board of directors prior to the date the interested stockholder obtained such status or the combination is approved by the board
of directors and thereafter is approved at a meeting of the stockholders by the affirmative vote of stockholders representing at least
60% of the outstanding voting power held by disinterested stockholders, such prohibition extends beyond the expiration of the two-year
period, unless:
| |
● |
the combination was approved by the board of directors prior to the person becoming an interested stockholder or the transaction by which the person first became an interested stockholder was approved by the board of directors before the person became an interested stockholder or the combination is later approved by a majority of the voting power held by disinterested stockholders; or |
| |
● |
the combination meets specified statutory requirements. |
A “combination” is generally defined to
include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in one transaction or
a series of transactions, with an “interested stockholder” having: (a) an aggregate market value equal to 5% or more of the
aggregate market value of the assets of the corporation, (b) an aggregate market value equal to 5% or more of the aggregate market value
of all outstanding shares of the corporation, (c) 10% or more of the earning power or net income of the corporation, and (d) certain other
transactions with an interested stockholder or an affiliate or associate of an interested stockholder.
In general, an “interested stockholder”
is a person who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation’s voting
stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts
to acquire our Company even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above
the prevailing market price.
Control Share Acquisitions
The “control share” provisions of Sections
78.378 to 78.3793, inclusive, of the NRS apply to “issuing corporations” that are Nevada corporations with at least 200 stockholders,
including at least 100 stockholders of record who are Nevada residents, and that conduct business directly or indirectly in Nevada. The
control share statute prohibits an acquirer, under certain circumstances, from voting its shares of a target corporation’s stock
after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the target corporation’s disinterested
stockholders. The statute specifies three thresholds: one-fifth or more but less than one-third, one-third but less than a majority, and
a majority or more, of the outstanding voting power. Generally, once an acquirer crosses one of the above thresholds, those shares in
an offer or acquisition and acquired within 90 days thereof become “control shares” and such control shares are deprived of
the right to vote until disinterested stockholders restore the right. These provisions also provide that if control shares are accorded
full voting rights and the acquiring person has acquired a majority or more of all voting power, all other stockholders who do not vote
in favor of authorizing voting rights to the control shares are entitled to demand payment for the fair value of their shares in accordance
with statutory procedures established for dissenters’ rights.
A corporation may elect to not be governed by, or
“opt out” of, the control share provisions by making an election in its articles of incorporation or bylaws, provided that
the opt-out election must be in place on the 10th day following the date an acquiring person has acquired a controlling interest,
that is, crossing any of the three thresholds described above. We have not opted out of the control share statutes, and will be subject
to these statutes if we are an “issuing corporation” as defined in such statutes.
The effect of the Nevada control share statutes is
that the acquiring person, and those acting in association with the acquiring person, will obtain only such voting rights in the control
shares as are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada control share law, if applicable,
could have the effect of discouraging takeovers of our Company.
Anti-Takeover Effects of Our Articles of Incorporation
and Bylaws
Our Articles of Incorporation and Bylaws contain certain
provisions that may have anti-takeover effects, making it more difficult for or preventing a third party from acquiring control of us
or changing our board of directors and management. According to our Articles of Incorporation and Bylaws, neither the holders of our Common
Stock nor the holders of any preferred stock we may issue in the future have cumulative voting rights in the election of our directors.
The combination of the present ownership by a few stockholders of a significant portion of our issued and outstanding Common Stock and
lack of cumulative voting makes it more difficult for other stockholders to replace our board of directors or for a third party to obtain
control of us by replacing our board of directors.
PLAN OF
DISTRIBUTION
In General
Our Company is offering a maximum of 15,000,000 Offered Shares on a
“best-efforts” basis, at a fixed price of $3.00 to $5.00 per Offered Share (to be fixed by post-qualification supplement).
We are also offering to certain purchasers, if any,
whose purchase of shares of Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain
related parties, beneficially owning more than 4.99% (or, at the election of such purchaser, 9.99%) of our outstanding Common Stock immediately
following the consummation of this offering, the opportunity to purchase, if the purchaser so chooses, Pre-Funded Warrants in lieu of
Offered Shares that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% (or, at the election of such
purchaser, 9.99%) of our outstanding shares of Common Stock. Each Pre-Funded Warrant will be immediately exercisable for one share of
Common Stock and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The purchase price of each Pre-Funded
Warrants will equal the price per share at which the shares of Common Stock are being sold to the public in this offering, minus $0.0001,
and the exercise price of each Pre-Funded Warrant will be $0.0001, per share. For each Pre-Funded Warrant we sell, the number of Offered
Shares we are offering will be decreased on a one-for-one basis. This offering also relates to the shares of Common Stock issuable upon
exercise of any Pre-Funded Warrants sold in this offering.
We have engaged ThinkEquity LLC (the “Placement
Agent”) to act as our exclusive placement agent to solicit offers to purchase the Securities offered by this Offering Circular.
The Placement Agent is not purchasing or selling any such Securities, nor is it required to arrange for the purchase and sale of any specific
number or dollar amount of such Securities, other than to use its “reasonable best efforts” to arrange for the sale of such
securities by us. Therefore, we may not sell all of the Securities being offered. The terms of this offering are subject to market conditions
and negotiations between us, the Placement Agent and prospective investors. The Placement Agent will have no authority to bind us by virtue
of their placement agency agreement with us (the “Placement Agency Agreement”). This is a “best efforts” offering
and there is no minimum offering amount required as a condition to each closing of this offering. All funds derived by us from this offering
will be immediately available for use by us, in accordance with the uses set forth in the section entitled “Use of Proceeds”
of this Offering Circular. No funds will be placed in an escrow account during the offering period and purchasers of the Securities will
not be entitled to a refund and could lose their entire investment.
This offering will terminate at the earliest of (a)
the date on which the maximum offering has been sold, (b) the date which is one year from this offering being qualified by the SEC, or
(c) the date on which this offering is earlier terminated by us, in our sole discretion.
Pursuant to the Placement Agency Agreement, we have paid the Placement
Agent an advance equal to $50,000, which will be creditable against the placement agent fees due and payable. Also pursuant to the Placement
Agency Agreement, we will pay the Placement Agent, concurrently with each closing of this offering, a placement agent fee equal to 7%
of the aggregate purchase price paid by each purchaser of Securities that are placed in this offering (other than certain purchasers of
Securities in this offering that are set forth on a schedule to the Placement Agency Agreement (the “Excluded Purchasers”),
which fee will be equal to 3% of the aggregate purchase price paid by each Excluded Purchaser). We have also agreed to pay a non-accountable
expense allowance to the Placement Agent equal to 1% of the gross proceeds received in this offering from purchasers other than the Excluded
Purchasers.
In addition, we will also pay the Placement Agent (a) all filing fees
and communication expenses relating to the Securities to be sold in this offering with the SEC; (b) all filing fees and expenses associated
with the review of this offering by FINRA; (c) all fees and expenses relating to the listing of the Offered Shares on the Nasdaq Capital
Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the NYSE or the NYSE American and on such other stock exchanges as
the Company and the Placement Agent together determine, including any fees charged by The Depository Trust Company (DTC) for new securities;
(d) all fees, expenses and disbursements relating to the registration or qualification of such Shares under the “blue sky”
securities laws of such states and other jurisdictions as the Placement Agent may reasonably designate; (e) all fees, expenses and disbursements
relating to the registration, qualification or exemption of such Securities under the securities laws of such foreign jurisdictions as
the Placement Agent may reasonably designate; (f) the costs of all mailing and printing of the offering documents; (g) the costs of preparing,
printing and delivering certificates representing the Offered Shares; (h) fees and expenses of the transfer agent for the Offered Shares;
(i) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the Placement Agent; (j) the
costs associated with bound volumes of the public offering materials as well as commemorative mementos and lucite tombstones, each of
which the Company or its designee will provide within a reasonable time after the initial closing of this offering in such quantities
as the Placement Agent may reasonably request; (k) the fees and expenses of the Company’s accountants; (l) the fees and expenses
of the Company’s legal counsel and other agents and representatives; (m) the fees and expenses of the Placement Agents’ legal
counsel not to exceed $125,000; (n) the $29,500 cost associated with the use of Ipreo’s book building, prospectus tracking and compliance
software for this offering; (o) up to $10,000 of the Placement Agent’s actual accountable “road show” expenses; and
(p) up to $30,000 of the Placement Agent’s market making and trading, and clearing firm settlement expenses for this offering. Such
reimbursement shall be paid at each closing (to the extent not paid at a prior closing) from the gross proceeds of the Securities. We
estimate our offering expenses to be approximately $400,000.
The Placement Agent may also ask other FINRA member
broker-dealers that are registered with the SEC to participate as soliciting dealers for this offering.
Placement Agent’s Warrants
Upon each closing of this offering, we have agreed
to issue the placement agent warrants (“Placement Agent’s Warrants”) to purchase up to 5% of the aggregate number of
Securities sold. The Placement Agent’s Warrants will be exercisable at an assumed per share exercise price equal $5.00, which is
equal to 125% of the assumed per share price of $4.00, which represents the midpoint of the offering price range herein. The Placement
Agent’s Warrants are exercisable at any time and from time to time, in whole or in part, during the five-year period commencing
180 days from the commencement of sales of the Securities in this offering.
The Placement Agent’s Warrants have been deemed
compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)(A) of FINRA. The placement agent (or
permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying
these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective
economic disposition of the warrants or the underlying securities for a period of 180 days following the commencement of sales of the
securities issued in this offering. In addition, the Placement Agent’s Warrants provide for registration rights upon request, in
certain cases. The sole demand registration right provided will not be greater than five years from the commencement of sales of the securities
issued in this offering in compliance with FINRA Rule 5110(g)(8)(C). The piggyback registration rights provided will not be greater than
seven years from the commencement of sales of the securities issued in this offering in compliance with FINRA Rule 5110(g)(8)(D). We will
bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants other than underwriting commissions
incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the Placement Agent’s Warrants
may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger or
consolidation. However, the Placement Agent’s Warrant exercise price or underlying shares will not be adjusted for issuances of
shares of our Common Stock at a price below the warrant exercise price.
Right of First Refusal
We have granted the placement agent an irrevocable right of first refusal
(the “Right of First Refusal”), for a period of 12 months after the date of the Placement Agency Agreement, provided that
the Securities are sold in this offering for aggregate net proceeds of not less than $5 million, to act, except as set forth below, as
sole financial advisor, sole investment banker, sole book-runner and/or sole placement agent, at the Placement Agent’s sole discretion,
for each and every (i) any disposition or acquisition of business units or acquisition of any outstanding securities or any exchange or
tender offer or merger, consolidation or other business combination or any recapitalization, reorganization, restructuring or other similar
transaction; (ii) any financing or refinancing of any indebtedness; or (iii) future public and private equity offering that is not an
“at-the-market” offering (an “ATM”) (an ATM executed through a broker dealer as sales agent), and sole investment
banker, sole book-runner and/or sole placement agent, at the Placement Agent’s sole discretion, for each and every future debt offering
(items (i), (ii) and (iii), a “Future Transaction”), including all equity linked financings, during such twelve (12) month
period for the Company, or any successor to or any subsidiary of the Company, on reasonable and customary terms, provided a Future Transaction
shall not be deemed to include, and no Right of First Refusal is granted to the Placement Agent in connection with, any of the following:
(a) any equity securities directly issued by the Company pursuant to acquisitions or strategic transactions, including as part of any
grant funding from a third party, or (b) any offer or sale of equity securities by the Company directly to non-U.S. persons domiciled
in the following jurisdictions: China, Korea, Latin America (e.g. the Caribbean and/or the Cayman Islands) and Middle East, in each case,
in a private placement not otherwise involving a public offering. Notwithstanding anything to the contrary set forth above, the Placement
Agent acknowledges that the Company is subject to a pre-existing agreement with a third party under which such third party has a right
of first refusal to act as the co-lead bookrunning underwriter, co-lead initial purchaser, co-lead placement agent or co-lead selling
agent, as the case may be, on any financing involving equity securities for the Company (the “Prior ROFR”). In case the Placement
Agent wishes to exercise its Right of First Refusal hereunder, the Company will use its commercially reasonable efforts to obtain a waiver
of the Prior ROFR, subject to certain conditions.
No Escrow Agent
None of the proceeds received will be placed in an
escrow or trust account. All proceeds from this offering will become immediately available to us and may be used as they are accepted.
Purchasers of the Securities will not be entitled to a refund and could lose their entire investment.
Procedures for Subscribing
If you are interested in subscribing for Securities
in this offering, please submit a request to your broker at the Placement Agent and all relevant information will be delivered to you
by return e-mail. Thereafter, should you decide to subscribe for Securities, you are required to follow the procedures included in the
delivered information and deliver funds directly by check or by wire or electronic funds transfer via ACH to our specified bank account.
Acceptance of Subscriptions
This Offering Circular will be furnished to prospective
investors upon their request via electronic PDF format and will be available for viewing and download 24 hours per day, 7 days per week
on our company’s page on the SEC’s website: www.sec.gov.
An investor will become a shareholder of the Company
and the Securities will be issued, as of the date of settlement. Settlement will not occur until a closing occurs under the Placement
Agency Agreement.
Issuance of Securities
Upon settlement, that is, at such time as a closing occurs under the Placement Agency Agreement, we
will either issue such investor’s purchased Offered Shares in book-entry form or issue a certificate or certificates representing
such investor’s purchased Offered Shares.
Transferability of the Offered Shares and Shares
of Common Stock underlying the Pre-Funded Warrants
The Offered Shares will be generally freely transferable,
subject to any restrictions imposed by applicable securities laws or regulations. The shares of Common Stock issuable upon the exercise
of the Pre-Funded Warrants, when issued pursuant to the terms of the Pre-Funded Warrants, will generally also be freely transferable,
subject to any restrictions imposed by applicable securities laws or regulations. Subject to applicable laws, a Pre-Funded Warrant may
be transferred at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the appropriate instruments of
transfer and exercise price.
Listing of Offered Shares
Our Common Stock is listed on the Nasdaq Capital Market
under the symbol “BIVI.” The Offered Shares will also be listed on the Nasdaq Capital Market. There is no public market for
the Pre-Funded Warrants and none is expected to develop. We do not intend to apply for the listing of the Pre-Funded Warrants offered
in this offering on any stock exchange. Without an active trading market, the liquidity of the Pre-Funded Warrants will be limited.
State Law Exemption and Offerings to “Qualified
Purchasers”
The Securities are being offered and sold to “qualified
purchasers” (as defined in Regulation A under the Securities Act). As a Tier 2 offering pursuant to Regulation A under the Securities
Act, this offering will be exempt from state “Blue Sky” law review, subject to certain state filing requirements and anti-fraud
provisions, to the extent that the Securities offered hereby are offered and sold only to “qualified purchasers.”
“Qualified purchasers” include any person
to whom securities are offered or sold in a Tier 2 offering pursuant to Regulation A under the Securities Act. We reserve the right to
reject any investor’s subscription in whole or in part for any reason, including if we determine, in our sole and absolute discretion,
that such investor is not a “qualified purchaser” for purposes of Regulation A. We intend to offer and sell the Securities
to qualified purchasers in every state of the United States and Canadian province.
Legal Matters
McGuireWoods LLP is acting as our counsel regarding securities law
matters. The validity of the shares of Common Stock offered hereby will be passed upon for us by Fennemore Craig, P.C. Certain legal matters
related to this offering will be passed upon for the Placement Agent by Sheppard, Mullin, Richter & Hampton LLP.
Experts
The balance sheets of BioVie Inc. as of June 30, 2024
and 2023, and the related statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for each
of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report
which is incorporated by reference, which report includes an explanatory paragraph about the existence of substantial doubt concerning
the Company’s ability to continue as a going concern. Such financial statements have been incorporated by reference in reliance
on the report of such firm given upon their authority as experts in accounting and auditing.
Where You
Can Find More Information
We have filed with the SEC an offering statement on
Form 1-A under the Securities Act with respect to the securities offered by this Offering Circular. This Offering Circular, which constitutes
a part of the offering statement, does not contain all of the information set forth in the offering statement, some of which is contained
in exhibits to the offering statement as permitted by the rules and regulations of the SEC. For further information with respect to us
and our securities, we refer you to the offering statement, including the exhibits filed as a part of the offering statement. Statements
contained in this Offering Circular concerning the contents of any contract or any other document is not necessarily complete. If a contract
or document has been filed as an exhibit to the offering statement, please see the copy of the contract or document that has been filed.
Each statement is this Offering Circular relating to a contract or document filed as an exhibit is qualified in all respects by the filed
exhibit. The SEC maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that
file electronically with the SEC. The address of that website is www.sec.gov.
We are subject to the information and reporting requirements
of the Securities Exchange Act of 1934, as amended, and, in accordance with this law, file periodic reports, proxy statements and other
information with the SEC. These periodic reports, proxy statements and other information are available on the website of the SEC referred
to above. We maintain a website at https://bioviepharma.com/. Information found on, or accessible through, our website is not a part of,
and is not incorporated into, this Offering Circular, and you should not consider it part of this Offering Circular.
INCORPORATION OF DOCUMENTS
BY REFERENCE
The SEC allows us to incorporate
by reference the information we file with it, which means that we can disclose important information to you by referring you to another
document that we have filed separately with the SEC. You should read the information incorporated by reference because it is an important
part of this Offering Circular. Information in this Offering Circular supersedes information incorporated by reference that we filed with
the SEC prior to the date of this Offering Circular, while information that we file later with the SEC will automatically update and supersede
the information in this Offering Circular. We incorporate by reference into this Offering Circular and the offering statement of which
this Offering Circular is a part the information or documents listed below that we have filed with the SEC (Commission File No. 001-39015):
| · | our Current Reports on Form 8-K, filed with the SEC on October
25, 2023, November
13, 2023, November
29, 2023, January
19, 2024, January
25, 2024, March
1, 2024, March
4, 2024 (as subsequently amended on March
4, 2024), March
6, 2024, March
11, 2024, April
19, 2024, July
30, 2024, August
1, 2024 (as subsequently amended on August
6, 2024), August
21, 2024, September
24, 2024 (as subsequently amended on September
24, 2024), September
25, 2024 (excluding Item 7.01 thereof), October
22, 2024 (with respect to Items 1.01 and 3.02 thereof only), October
22, 2024 (with respect to Item 8.01 thereof only), October
24, 2024 (with respect to Items 1.01 and 3.02 thereof only), October
24, 2024 (with respect to Item 8.01 thereof only), October
29, 2024 (with respect to Item 1.01 and Item 3.02 only), October
29, 2024 (with respect to Item 8.01 only) and November
8, 2024; and |
We also incorporate by reference
any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that
are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the offering statement of which this Offering
Circular is a part and prior to effectiveness of such offering statement, until we file a post-effective amendment that indicates the
termination of this offering and will become a part of this Offering Circular from the date that such documents are filed with the SEC.
Information in such future filings updates and supplements the information provided in this Offering Circular. Any statements in any such
future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that
is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace
such earlier statements.
We will furnish without charge
to each person, including any beneficial owner, to whom an Offering Circular is delivered, upon written or oral request, a copy of any
or all of the documents incorporated by reference into this Offering Circular but not delivered with this Offering Circular, including
exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to BioVie Inc.,
Attention: Corporate Secretary, 680 W Nye Lane, Suite 201, Carson City, Nevada 89703. Our phone number is (775) 888-3162.
You may also access these documents, free of charge
on the SEC’s website at www.sec.gov or on our website at https://bioviepharma.com. Information contained on our website is
not incorporated by reference into this Offering Circular, and you should not consider any information on, or that can be accessed from,
our website as part of this Offering Circular or any accompanying Offering Circular supplement.
You should rely only on information
contained in, or incorporated by reference into, this Offering Circular and any Offering Circular supplement. We have not authorized anyone
to provide you with information different from that contained in this Offering Circular or incorporated by reference into this Offering
Circular. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized
or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer
or solicitation.
PART III – EXHIBITS
| |
|
|
|
Incorporated by Reference |
|
|
Exhibit
No. |
|
Description |
|
Form |
|
File
No. |
|
Date
Filed |
|
Exhibit
No. |
|
Filed
Herewith |
|
| 1.1 |
|
Placement Agency Agreement |
|
|
|
|
|
|
|
|
|
X |
|
| 2.1 |
|
Articles of Incorporation of Company as filed with the Secretary of State of Nevada |
|
S-1 |
|
333-190635 |
|
August 15, 2013 |
|
3.1 |
|
|
|
| 2.2 |
|
Certificate of Amendment to Articles of Incorporation |
|
8-K |
|
000-55292 |
|
July 22, 2016 |
|
3.1 |
|
|
|
| 2.3 |
|
Certificate of Amendment to Articles of Incorporation |
|
Schedule 14C |
|
000-55292 |
|
July 13, 2018 |
|
Appendix A |
|
|
|
| 2.4 |
|
Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock |
|
8-K |
|
000-55292 |
|
July 3, 2018 |
|
3.1 |
|
|
|
| 2.5 |
|
Certificate of Amendment to Articles of Incorporation |
|
S-1 |
|
333-231136 |
|
November 22, 2019 |
|
3.6 |
|
|
|
| 2.6 |
|
Amended and Restated Bylaws of Company, dated June 16, 2020 |
|
10-Q |
|
001-39015 |
|
November 10, 2021 |
|
3.5 |
|
|
|
| 2.7 |
|
First Amendment to the Amended and Restated Bylaws of the Company, dated March 12, 2023 |
|
8-K |
|
001-39015 |
|
March 13, 2023 |
|
3.1 |
|
|
|
| 2.8 |
|
Certificate of Change |
|
8-K |
|
001-39015 |
|
August 1, 2024 |
|
3.1 |
|
|
|
| 2.9 |
|
Termination of Amendment/Certificate |
|
8-K/A |
|
001-39015 |
|
August 6, 2024 |
|
3.1 |
|
|
|
| 2.10 |
|
Certificate of Amendment |
|
8-K/A |
|
001-39015 |
|
August 6, 2024 |
|
3.1 |
|
|
|
| 3.1 |
|
Specimen Certificate representing shares of Class A Common Stock |
|
S-1 |
|
333-231136 |
|
April 26, 2019 |
|
4.1 |
|
|
|
| 3.2 |
|
Form of Warrant |
|
8-K |
|
001-39015 |
|
September 25, 2019 |
|
4.2 |
|
|
|
| 3.3 |
|
Form of 10% OID Convertible Delayed Draw Debenture |
|
8-K |
|
001-39015 |
|
September 25, 2019 |
|
4.1 |
|
|
|
| 3.4 |
|
Form of Common Stock Purchase Warrant |
|
8-K/A |
|
001-39015 |
|
July 18, 2022 |
|
4.1 |
|
|
|
| 3.5 |
|
Form of Warrant to Purchase Shares of Class A Common Stock of the Company |
|
8-K |
|
001-39015 |
|
December 1, 2021 |
|
10.3 |
|
|
|
| 3.6 |
|
Form of Pre-Funded Warrant |
|
8-K |
|
001-39015 |
|
March 4, 2024 |
|
4.1 |
|
|
|
| 3.7 |
|
Form of Common Stock Purchase Warrant |
|
8-K |
|
001-39015 |
|
March 4, 2024 |
|
4.2 |
|
|
|
| 3.8 |
|
Form of Placement Agent Warrant |
|
8-K |
|
001-39015 |
|
March 4, 2024 |
|
4.3 |
|
|
|
| 3.9 |
|
Form of Pre-Funded Warrant |
|
8-K |
|
001-39015 |
|
September 24, 2024 |
|
4.1 |
|
|
|
| 3.10 |
|
Form of Common Warrant |
|
8-K |
|
001-39015 |
|
September 24, 2024 |
|
4.2 |
|
|
|
| 3.11 |
|
Form of Placement Agent’s Warrant Agreement |
|
8-K |
|
001-39015 |
|
September 24, 2024 |
|
4.3 |
|
|
|
| 3.12 |
|
Form of Warrant |
|
8-K |
|
001-39015 |
|
October 22, 2024 |
|
4.1 |
|
|
|
| 3.13 |
|
Form of Placement Agent’s Warrant Agreement |
|
8-K |
|
001-39015 |
|
October 22, 2024 |
|
4.2 |
|
|
|
| 3.14 |
|
Form of Warrant |
|
8-K |
|
001-39015 |
|
October 24, 2024 |
|
4.1 |
|
|
|
| 3.15 |
|
Form of Placement Agent’s Warrant Agreement |
|
8-K |
|
001-39015 |
|
October 24, 2024 |
|
4.2 |
|
|
|
| 3.16 |
|
Form of Placement Agent’s Warrant Agreement |
|
8-K |
|
001-39015 |
|
October 29, 2024 |
|
4.1 |
|
|
|
| 3.17 |
|
Form of Pre-Funded Warrant |
|
|
|
|
|
|
|
|
|
X |
|
| 6.1 |
|
BioVie Inc. 2019 Omnibus Equity Incentive Plan |
|
Schedule 14C |
|
000-55292 |
|
May 8, 2019 |
|
Appendix D |
|
|
|
| 6.2 |
|
Asset Purchase Agreement, dated April 27, 2021, among the Company, NeurMedix, Inc. and Acuitas Group Holdings, LLC |
|
8-K |
|
001-39015 |
|
April 27, 2021 |
|
2.1 |
|
|
|
| 6.3 |
|
Amendment No. 1 of the Asset Purchase Agreement, dated May 9, 2021, among the Company, NeurMedix, Inc. and Acuitas Group Holdings, LLC |
|
8-K |
|
001-39015 |
|
May 10, 2021 |
|
2.2 |
|
|
|
| 6.4 |
|
Amendment No. 2 to the Asset Purchase Agreement, dated January 13, 2023, among the Company, Acuitas Group Holdings, LLC and Acuitas Group Holdings, LLC |
|
10-Q |
|
001-39015 |
|
May 12, 2023 |
|
10.1 |
|
|
|
| 6.5 |
|
Employment Offer & Agreement, between Chris Reading and the Company, dated June 18, 2021 |
|
10-Q |
|
001-39015 |
|
November 10, 2021 |
|
10.14 |
|
|
|
| 6.6 |
|
Employment Offer & Agreement, between Clarence Ahlem and the Company, dated June 18, 2021 |
|
10-Q |
|
001-39015 |
|
November 10, 2021 |
|
10.15 |
|
|
|
| 6.7 |
|
Employment Offer & Agreement, between Joanne Wendy Kim and the Company, dated June 26, 2021 |
|
10-Q |
|
001-39015 |
|
November 10, 2021 |
|
10.16 |
|
|
|
| 6.8 |
|
Employment Offer & Agreement, between Penelope Markham and the Company, dated September 7, 2021 |
|
10-Q |
|
001-39015 |
|
November 10, 2021 |
|
10.17 |
|
|
|
| 6.9 |
|
Employment Offer & Agreement, between Joseph Palumbo and the Company, dated September 3, 2021 |
|
10-Q |
|
001-39015 |
|
November 10, 2021 |
|
10.18 |
|
|
|
| 6.10 |
|
Loan and Security Agreement, dated November 30, 2021, among the Company, Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. |
|
8-K |
|
001-39015 |
|
December 1, 2021 |
|
10.1 |
|
|
|
| 6.11 |
|
Supplement to Loan and Security Agreement, dated November 30, 2021, among the Company, Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. |
|
8-K |
|
001-39015 |
|
December 1, 2021 |
|
10.2 |
|
|
|
| 6.12 |
|
Securities Purchase Agreement, dated July 15, 2022, by and between the Company and Acuitas Group Holdings, LLC |
|
8-K/A |
|
001-39015 |
|
July 18, 2022 |
|
10.1 |
|
|
|
| 6.13 |
|
Controlled Equity OfferingSM Sales Agreement, dated August 31, 2022, among the Company, Cantor Fitzgerald & Co. and B. Riley Securities, Inc. |
|
8-K |
|
001-39015 |
|
August 31, 2022 |
|
1.1 |
|
|
|
| 6.14 |
|
Amended and Restated Registration Rights Agreement, dated August 15, 2022, by and between BioVie Inc. and Acuitas Group Holdings, LLC |
|
10-Q |
|
001-39015 |
|
November 4, 2022 |
|
10.2 |
|
|
|
| 7.1 |
|
Agreement and Plan of Merger, dated April 11, 2016, among the Company, LAT Acquisition Corp and LAT Pharma, LLC |
|
8-K |
|
000-55292 |
|
April 15, 2016 |
|
2.1 |
|
|
|
| 10.1 |
|
Power of Attorney (included on the signature page hereto) |
|
|
|
|
|
|
|
|
|
X |
|
| 11.1 |
|
Consent of EisnerAmper LLP |
|
|
|
|
|
|
|
|
|
X |
|
| 11.2 |
|
Consent of Fennemore Craig, P.C. (included in Exhibit 12.1) |
|
|
|
|
|
|
|
|
|
X |
|
| 12.1 |
|
Opinion of Fennemore Craig, P.C. |
|
|
|
|
|
|
|
|
|
X |
|
SIGNATURES
Pursuant to the requirements of Regulation A,
the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A and has
duly caused this offering statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carson
City, State of Nevada, on December 31, 2024.
| |
BIOVIE INC. |
|
| |
|
|
|
| |
By: |
/s/ Cuong Do |
|
| |
|
Cuong Do |
|
| |
|
President and Chief Executive Officer
(Principal Executive Officer) |
|
POWER OF ATTORNEY
Each person whose signature appears below constitutes
and appoints each of Cuong Do and Joanne Wendy Kim as his or her true and lawful attorneys-in-fact and agents with full power of substitution
and resubstitution, for him and her in any and all capacities, to sign any or all amendments (including post-qualification amendments)
to this offering statement with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and
authority to do and perform each and every act and thing requisite and necessary to be done in and about the foregoing, as fully to all
intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents,
or their substitutes, may lawfully do or cause to be done by virtue hereof.
This offering statement has been signed by the following
persons in the capacities and on the dates indicated.
| Signature |
|
Title |
|
Date |
| |
|
|
|
|
| /s/ Cuong Do |
|
President and Chief Executive Officer, Director |
|
December 31, 2024 |
| Cuong Do |
|
(Principal Executive Officer) |
|
|
| |
|
|
|
|
| /s/ Joanne Wendy Kim |
|
Chief Financial Officer |
|
December 31, 2024 |
| Joanne Wendy Kim |
|
(Principal Financial Officer and Principal Accounting Officer) |
|
|
| |
|
|
|
|
| /s/ Jim Lang |
|
Chairman of the Board of Directors |
|
December 31, 2024 |
| Jim Lang |
|
|
|
|
| |
|
|
|
|
| /s/ Richard J. Berman |
|
Director |
|
December 31, 2024 |
| Richard J. Berman |
|
|
|
|
| |
|
|
|
|
| /s/ Robert Hariri |
|
Director |
|
December 31, 2024 |
| Robert Hariri |
|
|
|
|
| |
|
|
|
|
|
/s/ Sigmund Rogich |
|
Director |
|
December 31, 2024 |
| Sigmund Rogich |
|
|
|
|
| |
|
|
|
|
| /s/ Michael Sherman |
|
Director |
|
December 31, 2024 |
| Michael Sherman |
|
|
|
|
PLACEMENT AGENCY AGREEMENT
[*], 2025
ThinkEquity LLC
17 State Street, 41st Fl
New York, NY 10004
Ladies and Gentlemen:
Introductory. This
Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity”
or the “Placement Agent”) shall be engaged by BioVie Inc., a Nevada corporation (the “Company”),
to act as the exclusive Placement Agent in connection with the offering (hereinafter referred to as the “Offering”)
of up to [*] shares (the “Shares”) of the Company’s class A common stock, $0.0001 par value per share (the “Common
Stock”), and/or pre-funded common stock purchase warrants to purchase one share of Common Stock (the “Pre-Funded Warrants”
and together with the Shares, the “Securities”), directly to various investors (each, an “Investor”
and, collectively, the “Investors”). The purchase price to the Investors for each Share is $[*] (the “Share
Offering Price”), the purchase price to the Investors for each Pre-Funded Warrant is $[*] and the exercise price to the Investor
for each share of Common Stock issuable upon exercise of the Pre-Funded Warrants is $0.0001. The Placement Agent may retain other brokers
or dealers to act as sub-agents or selected- dealers on its behalf in connection with the Offering.
| 1. | Agreement to Act as Placement Agent; Closing; Placement Agent Compensation. |
1.1 On
the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the terms and conditions
of this Agreement between the Company and the Placement Agent, the Placement Agent is appointed as the Company’s exclusive placement
agent subject to the terms and conditions contained herein. On the basis of such representations and warranties and subject to such terms
and conditions, the Placement Agent hereby accepts such appointment and agrees to perform the services hereunder diligently and in good
faith and in a professional and businesslike manner and to use its commercially reasonable efforts to assist the Company in finding subscribers
of the Securities and to complete the Offering. The Placement Agent has no obligation to purchase any of the Securities. Unless sooner
terminated in accordance with this Agreement, the engagement of the Placement Agent hereunder shall continue until the date on which all
of the Securities have been sold. The Offering will be made on a “reasonable best efforts” basis. The Placement Agent may
retain other brokers or dealers to act as sub- placement agents on its behalf in connection with the Offering, with any fees they may
be entitled to being paid out of the fee paid to such Placement Agent pursuant to Section 1.6.
1.2 [Reserved].
1.3 Payment
of the aggregate purchase price paid by any and all Investors less the Cash Fee, the Non-Accountable Expenses and the other accountable
expenses payable in accordance with Section 3.10 of this Agreement (the “Purchase Price”) for, and delivery of, the
Securities (each, a “Closing”) shall be made at the offices of Sheppard, Mullin, Richter & Hampton LLP (“Placement
Agent Counsel”), 30 Rockefeller Plaza, New York, NY 10112, or at such other place as shall be agreed upon by the Placement Agent
and the Company, at such times and on such dates as shall be agreed upon by the Placement Agent and the Company (such time and date of
payment and delivery being herein called a “Closing Date”). The term “Business Day” means any day other
than a Saturday, a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by law to close in New
York, New York.
1.4 On
each Closing Date, the Purchase Price will be released to the Company either (a) by the Placement Agent on behalf of each Investor for
the Securities to be issued and sold to such Investor at such Closing, by wire transfer of immediately available funds in accordance with
the flow of funds letter regarding the Closing, or (b) by the Investor wiring the Purchase Price to the Company by wire transfer to an
account designated in writing by the Company, and (ii) the Company shall cause its transfer agent (together with any subsequent transfer
agent, the “Transfer Agent”) through the Depository Trust Company (“DTC”) Fast Automated Securities
Transfer Program, to credit such aggregate number of Shares that each Investor is purchasing as set forth in the flow of funds letter
regarding the applicable Closing to either (a) the Placement Agent’s balance account with DTC through its Deposit/Withdrawal at
Custodian system, or (b) directly to the account of each Investor or its respective nominee(s), at the designated account with DTC as
provided on the flow of funds letter (if applicable). All actions taken at any Closing shall be deemed to have occurred simultaneously
on the applicable Closing Date. Any Securities for which payment has not been received by the Company, to the extent they have been delivered
to the Placement Agent or any such Investor, shall be returned to the Company.
1.5 No
Securities which the Company has agreed to sell pursuant to this Agreement shall be deemed to have been purchased and paid for, or issued
and sold by the Company, until the appropriate corresponding number of Securities shall have been delivered to the Investors or the Placement
Agent against payment therefor. If the Company shall default in its obligations to deliver the Securities to the Investors or the Placement
Agent on behalf of such Investors as per such instructions, the Company shall indemnify and hold the Placement Agent harmless against
any loss, claim, damage or liability directly or indirectly arising from or as a result of such default by the Company.
1.6 As
compensation for services rendered, on each Closing Date, the Company shall pay to the Placement Agent the following:
1.6.1. A
cash fee (the “Cash Fee”) equal to either (a) 7.0% of the aggregate purchase price paid by the Investors in respect
of the Securities purchased at a Closing or (b) 3.0% of the aggregate purchase price paid by investors introduced to the Placement Agent
by the Company as set forth on Schedule 1 attached hereto (the “Company Introduced Investors”) (and in the case
of the initial Closing, less an advance equal to $50,000 previously paid by the Company to the Placement Agent), which fees shall be deducted
from the Purchase Price payable at each Closing.
1.6.2. A
non-accountable expense allowance (“Non-Accountable Expenses”) equal to one percent (1.0%) of the gross proceeds received
by the Company from the sale of the Securities to parties other than the Company Introduced Investors, which fees shall be deducted from
the Purchase Price payable at a Closing, provided, however, that in the event that the Offering is terminated, the Company agrees to reimburse
the Placement Agent pursuant to Section 7.3 hereof.
1.6.3. A
warrant (“Placement Agent’s Warrant”) for the purchase of up to [*] shares of Common Stock, representing 5% of
the Shares and Pre-Funded Warrants purchased at a Closing. The Placement Agent’s Warrant agreement, in the form attached hereto
as Exhibit A (the “Placement Agent’s Warrant Agreement”), shall be exercisable, in whole or in part, commencing
on a date which is one hundred eighty (180) days after the date hereof and expiring on the five-year anniversary of the date hereof at
an initial exercise price per share of Common Stock of $[*] which is equal to 125% of the Share Offering Price. The Placement Agent’s
Warrants shall not be transferable for six months from the date of the Offering except as permitted by Financial Industry Regulatory Authority
(“FINRA”) Rule 5110(e)(2). The Placement Agent’s Warrant Agreement and the shares of Common Stock issuable upon
exercise thereof are hereinafter referred to together as the “Placement Agent’s Securities”.
1.7 The
Company hereby acknowledges that (i) the Offering, including the determination of the offering price of the Common Stock and any related
discounts, commissions and fees, shall be an arm’s- length commercial transaction between the Company and the Investors, (ii) the
Placement Agent will be acting as an independent contractor and will not be the agent or fiduciary of the Company or its shareholders,
creditors, employees, the Investors, the Other Investors or any other party, (iii) the Placement Agent shall not assume an advisory or
fiduciary responsibility in favor of the Company (irrespective of whether the Placement Agent has advised or is currently advising the
Company on other matters) and the Placement Agent shall not have any obligation to the Company with respect to the Offering, except as
may be set forth expressly herein, (iv) the Placement Agent and its Affiliates may be engaged in a broad range of transactions that involve
interests that differ from those of the Company and (v) the Placement Agent will not provide any legal, accounting, regulatory or tax
advice with respect to the Offering, and the Company shall consult its own legal, accounting, regulatory and tax advisors to the extent
it deems appropriate.
1.8 The
Company is and will be solely responsible for the contents of any and all written or oral communications provided to the Investors regarding
the Offering or the Securities; and the Company recognizes that the Placement Agent, in acting pursuant to this Agreement, will be using
information provided by the Company and its agents and the Placement Agent assumes no responsibility for, and may rely, without independent
verification, on the accuracy and completeness of any such information.
1.9 The
Company agrees that any information or advice rendered by the Placement Agent in connection with this engagement is for the confidential
use of the Board of Directors of the Company (the “Board”) only and the Company will not, and will not permit any third
party to, disclose or otherwise refer to such advice or information, in any manner without the Placement Agent’s prior written consent.
2. Representations
and Warranties of the Company. The Company represents and warrants to the Placement Agent as of each Closing Date as follows:
| 2.1 | Filing of Offering Statement. |
2.1.1 Pursuant
to the Securities Act. The Company has prepared and filed with the U.S. Securities and Exchange Commission (the “Commission”)
an offering statement on Form 1-A, as amended (File No. 024-12458), and amendments thereto, for the offering under Regulation A, as amended
(“Regulation A”), promulgated by the Commission under the Securities Act of 1933, as amended (the “Securities
Act”), of the Securities, which offering statement, as so amended, was qualified by the Commission on [*],
2025. Such offering statement, including the exhibits thereto, as of the date of this Agreement, is hereinafter called the “Offering
Statement”. Any reference in this Agreement to the Offering Statement shall each be deemed to refer to and include the documents
incorporated by reference therein (the “Incorporated Documents”) on or before the date of this Agreement; and any reference
in this Agreement to the terms “amend,” “amendment” or “supplement” with respect to the Offering Statement
shall be deemed to refer to and include the filing of any document under the Securities Act and the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), after the date of this Agreement, deemed to be incorporated therein by reference. All
references in this Agreement to financial statements and schedules and other information which is “contained,” “included,”
“described,” “referenced,” “set forth” or “stated” in the Offering Statement (and all
other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information
which is or is deemed to be incorporated by reference in the Offering Statement. For purposes of this Agreement, “Preliminary
Offering Circular” means the preliminary offering circular contained in the Offering Statement at the time of Offering Statement
was qualified by the Commission and “Offering Circular” means the final offering circular filed with the Commission
pursuant to Rule 253(g) of Regulation A.
2.1.2 Pursuant
to the Exchange Act. The Company has filed with the Commission a Form 8-A12B (File Number 001-39015) providing for the registration
pursuant to Section 12(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), of the shares
of Common Stock. The registration of the shares of Common Stock under the Exchange Act has been declared effective by the Commission on
or prior to the date hereof. The Company has taken no action designed to, or likely to have the effect of, terminating the registration
of the shares of Common Stock under the Exchange Act, nor has the Company received any notification that the Commission is contemplating
terminating such registration.
2.1.3 [Reserved].
2.2 Stock
Exchange Listing. The shares of Common Stock have been approved for listing on the Nasdaq Capital Market (the “Exchange”)
and the Company has taken no action designed to, or likely to have the effect of, delisting the shares of Common Stock from the Exchange,
nor has the Company received any notification that the Exchange is contemplating terminating such listing except as described in the Offering
Statement, the Preliminary Offering Circular and the Offering Circular. The Company has submitted the Listing of Additional Shares Notification
Form with the Exchange with respect to the Offering of the Securities.
2.3 No
Stop Orders, etc. Neither the Commission nor, to the Company’s knowledge, any state regulatory authority has issued any order
preventing or suspending the use of the Offering Circular, any Preliminary Offering Circular or the Offering Statement or has instituted
or, to the Company’s knowledge, threatened to institute, any proceedings with respect to such an order. The Company has complied
with each request (if any) from the Commission for additional information.
2.4 Disclosures
in Offering Statement.
2.4.1. Compliance
with Securities Act and 10b-5 Representation.
(i) The
Offering Statement (and any further documents to be filed with the Commission) contains all exhibits and schedules as required by the
Securities Act. Each of the Offering Statement and any post-qualification amendment thereto, at the time the Offering Statement was qualified
by the Commission, complied in all material respects with the Securities Act and the Exchange Act and the rules and regulations (the “Rules
and Regulations”) of the Commission promulgated thereunder and did not and, as amended or supplemented, if applicable, will
not, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein not misleading.. Each Offering Circular delivered to the Placement Agent for use in connection with this Offering
was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation S-T promulgated under the Securities Act.
(ii) The
Preliminary Offering Circular and Offering Circular, at the time the Offering Statement was qualified by the Commission and as of each
Closing Date, did not, does not and will not include an untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; The Incorporated
Documents, when they were filed with the Commission, conformed in all material respects to the requirements of the Exchange Act and the
applicable Rules and Regulations, and none of such documents, when they were filed with the Commission, contained any untrue statement
of a material fact or omitted to state a material fact necessary to make the statements therein (with respect to Incorporated Documents
incorporated by reference in the Offering Statement), in the light of the circumstances under which they were made not misleading; and
any further documents so filed and incorporated by reference in the Offering Statement, when such documents are filed with the Commission,
will conform in all material respects to the requirements of the Exchange Act and the applicable Rules and Regulations, as applicable,
and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading.
(iii) No
post-qualification amendment to the Offering Statement reflecting any facts or events arising after the date thereof which represent,
individually or in the aggregate, a fundamental change in the information set forth therein is required to be filed with the Commission.
There are no documents required to be filed with the Commission in connection with the transaction contemplated hereby that (x) have not
been filed as required pursuant to the Securities Act or (y) will not be filed within the requisite time period.
(iv) The
Incorporated Documents, when they became effective or were filed with the Commission, as the case may be, conformed in all material respects
to the requirements of the Securities Act or the Exchange Act, as applicable, and the Rules and Regulations and none of such documents
contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to
make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so
filed and incorporated by reference in the Offering Statement, when such documents become effective or are filed with the Commission,
as the case may be, will conform in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable,
and the Rules and Regulations, and will not contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
2.4.2. Disclosure
of Agreements. The Incorporated Documents described in the Offering Statement, the Preliminary Offering Circular and the Offering
Circular, conform in all material respects to the descriptions thereof contained or incorporated by reference therein and there are no
agreements or other documents required by the Securities Act and the Rules and Regulations to be described in the Offering Statement,
the Preliminary Offering Circular and the Offering Circular or to be filed with the Commission as exhibits to the Offering Statement,
or to be incorporated by reference in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, that have not
been so described or filed or incorporated by reference. Each agreement or other instrument (however characterized or described) to which
the Company is a party or by which it is or may be bound or affected and (i) that is referred to or incorporated by reference in the Offering
Statement, the Preliminary Offering Circular and the Offering Circular, or (ii) is material to the Company’s business, has been
duly authorized and validly executed by the Company, is in full force and effect in all material respects and is enforceable against the
Company and, to the Company’s knowledge the other parties thereto, in accordance with its terms, except (x) as such enforceability
may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally, (y) as enforceability
of any indemnification or contribution provision may be limited under the federal and state securities laws, and (z) that the remedy of
specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion
of the court before which any proceeding therefor may be brought. None of such agreements or instruments has been assigned by the Company,
and neither the Company nor, to the Company’s knowledge, any other party is in default thereunder and, to the Company’s knowledge,
no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder. To the Company’s
knowledge, performance by the Company of the material provisions of such agreements or instruments will not result in a violation of any
existing applicable law, rule, regulation, ordinance, judgment, order or decree of any governmental or regulatory agency, body, authority
or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses (each, a “Governmental
Entity”), including, without limitation, those relating to environmental laws and regulations. Except as disclosed in the Offering
Statement, the Preliminary Offering Circular and the Offering Circular, the Company has no subsidiaries and has no other interest, nominal
or beneficial, direct or indirect, in any other corporation, joint venture or other business entity.
2.4.3. Prior
Securities Transactions. No securities of the Company have been sold by the Company or by or on behalf of, or for the benefit of,
any person or persons controlling, controlled by or under common control with the Company, except as disclosed in the Offering Statement,
the Preliminary Offering Circular and the Offering Circular.
2.4.4. Regulations.
The disclosures in the Offering Statement, the Preliminary Offering Circular and the Offering Circular concerning the effects of federal,
state, local and all foreign regulation on the Offering and the Company’s business as currently contemplated are accurate, correct
and complete in all material respects and no other such regulations are required to be disclosed in the Offering Statement, the Preliminary
Offering Circular and the Offering Circular which are not so disclosed.
2.4.5. No
Other Distribution of Offering Materials. The Company has not, directly or indirectly, distributed and will not distribute any offering
material in connection with the Offering other than any the Offering Statement, the Preliminary Offering Circular and the Offering Circular
and other materials, if any, permitted under the Securities Act and consistent with Section 3.2 below.
2.5 Changes
After Dates in Offering Statement.
2.5.1. No
Material Adverse Change. Since the respective dates as of which information is given in the Offering Statement, the Preliminary Offering
Circular and the Offering Circular, except as otherwise specifically stated therein: (i) there has been no material adverse change in
the financial position or results of operations of the Company, nor any change or development that, singularly or in the aggregate, would
involve a material adverse change or a prospective material adverse change in or affecting the business, general affairs, management,
condition (financial or otherwise), stockholders’ equity, results of operations, business, assets, properties or prospects of the
Company (a “Material Adverse Change”); (ii) there have been no material transactions entered into by the Company, other
than as contemplated pursuant to this Agreement; and (iii) no officer or director of the Company has resigned from any position with the
Company; and (iv) the Company has not sustained any material loss or interference with its business or properties from fire, explosion,
flood, earthquake, hurricane, accident or other calamity.
2.5.2. Recent
Securities Transactions, etc. Subsequent to the respective dates as of which information is given in the Offering Statement, the Preliminary
Offering Circular and the Offering Circular, and except as may otherwise be indicated or contemplated herein or disclosed in the Offering
Statement, the Preliminary Offering Circular and the Offering Circular, the Company has not: (i) issued any securities, other than securities
issued pursuant to the Company’s existing equity incentive or stock option plans for shares of Common Stock issuable upon the exercise
of then outstanding options, restricted stock units or convertible securities, or incurred any liability or obligation, direct or contingent,
for borrowed money; or (ii) declared or paid any dividend or made any other distribution on or in respect to its capital stock.
2.5.3. Disclosure
in Commission Filings. Since January 1, 2022, (i) none of the Company’s filings with the Commission contained any untrue statement
of a material fact or omitted to state any material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading, except to the extent such filings with the Commission were subsequently amended; and (ii)
the Company has made all filings with the Commission required under the Exchange Act and the Rules and Regulations.
2.6 Independent
Accountants. To the knowledge of the Company, EisnerAmper LLP (the “Auditor”), whose report is filed with the Commission
and included or incorporated by reference in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, is an
independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company
Accounting Oversight Board. The Auditor has not, during the periods covered by the financial statements included or incorporated by reference
in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, provided to the Company any non-audit services,
as such term is used in Section 10A(g) of the Exchange Act.
2.7 Financial
Statements, etc. The financial statements, including the notes thereto and supporting schedules included or incorporated by reference
in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, fairly present the financial position and the
results of operations of the Company at the dates and for the periods to which they apply; and such financial statements have been prepared
in conformity with U.S. generally accepted accounting principles (“GAAP”), consistently applied throughout the periods
involved (provided that unaudited interim financial statements are subject to year- end audit adjustments that are not expected to be
material in the aggregate and do not contain all footnotes required by GAAP); and the supporting schedules included or incorporated by
reference in the Offering Statement, the Preliminary Offering Circular and the Offering Circular present fairly the information required
to be stated therein. Except as included or incorporated by reference therein, no historical or pro forma financial statements or supporting
schedules are required to be included or incorporated by reference in the Offering Statement, the Preliminary Offering Circular and the
Offering Circular under the Securities Act or the Rules and Regulations. The pro forma and pro forma as adjusted financial information
and the related notes, if any, included or incorporated by reference in the Offering Statement, the Preliminary Offering Circular and
the Offering Circular have been properly compiled and prepared in accordance with the applicable requirements of the Securities Act, the
Exchange Act and the Rules and Regulations and present fairly the information shown therein, and the assumptions used in the preparation
thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred
to therein. All disclosures contained in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, or incorporated
or deemed incorporated by reference therein, regarding “non- GAAP financial measures” (as such term is defined by the rules
and regulations of the Commission), if any, comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities
Act, to the extent applicable. Each of the Offering Statement, the Preliminary Offering Circular and the Offering Circular discloses all
material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of the
Company with unconsolidated entities or other persons that may have a material current or future effect on the Company’s financial
condition, changes in financial condition, results of operations, liquidity, capital expenditures, capital resources, or significant components
of revenues or expenses. Except as disclosed in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, (a)
neither the Company nor any of its direct and indirect subsidiaries, including each entity disclosed or described in the Offering Statement,
the Preliminary Offering Circular and the Offering Circular as being a subsidiary of the Company (each, a “Subsidiary”
and, collectively, the “Subsidiaries”), has incurred any material liabilities or obligations, direct or contingent,
or entered into any material transactions other than in the ordinary course of business, (b) the Company has not declared or paid any
dividends or made any distribution of any kind with respect to its capital stock, (c) there has not been any change in the capital stock
of the Company or any of its Subsidiaries, or, other than in the course of business or any grants under any stock compensation plan, and
(d) there has not been any Material Adverse Change in the Company’s long-term or short-term debt.
2.8 Authorized
Capital; Options, etc. The Company had, at the date or dates indicated in the Offering Statement, the Preliminary Offering Circular
and the Offering Circular, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions stated
in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, the Company will have on each Closing Date the
adjusted stock capitalization set forth therein. Except as set forth in, or contemplated by, the Offering Statement, the Preliminary Offering
Circular and the Offering Circular, on the date hereof and on each Closing Date, there was, or will be, no stock options, warrants, or
other rights to purchase or otherwise acquire any authorized, but unissued shares of Common Stock of the Company or any security convertible
or exercisable into shares of Common Stock of the Company, or any contracts or commitments to issue or sell shares of Common Stock or
any such options, warrants, rights or convertible securities.
2.9 Valid
Issuance of Securities, etc.
2.9.1. Outstanding
Securities. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement have
been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights of rescission, rights
of first refusal, rights of participation or similar rights with respect thereto or put rights, and are not subject to personal liability
by reason of being such holders; and none of such securities were issued in violation of the preemptive rights, rights of first refusal
or rights of participation or similar rights of any holders of any security of the Company or similar contractual rights granted by the
Company. The authorized shares of Common Stock conform in all material respects to all statements relating thereto contained in the Offering
Statement, the Preliminary Offering Circular and the Offering Circular. The offers and sales of the outstanding shares of Common Stock
were at all relevant times either registered under the Securities Act and the applicable state securities or “blue sky” laws
or, based in part on the representations and warranties of the purchasers of such Shares, exempt from such registration requirements.
2.9.2. Securities
Sold Pursuant to this Agreement. The Securities, and Placement Agent’s Securities have been duly authorized for issuance and
sale and, when issued and paid for pursuant to the terms of this Agreement, will be validly issued, fully paid and non-assessable; the
holders thereof are not and will not be subject to personal liability by reason of being such holders; the Securities, and the Placement
Agent’s Securities are not and will not be subject to the preemptive rights of any holders of any security of the Company or similar
contractual rights granted by the Company; and all corporate action required to be taken for the authorization, issuance and sale of the
Securities and the Placement Agent’s Securities has been duly and validly taken. The Securities and the Placement Agent’s
Securities conform in all material respects to all statements with respect thereto contained in the Offering Statement, the Preliminary
Offering Circular and the Offering Circular. All corporate action required to be taken for the authorization, issuance and sale of the
Placement Agent’s Warrant Agreement has been duly and validly taken; the Placement Agent’s Securities have been duly authorized
and reserved for issuance by all necessary corporate action on the part of the Company and when paid for and issued in accordance with
the Placement Agent’s Warrant Agreement, such Placement Agent’s Securities will be validly issued, fully paid and non-assessable;
the holders thereof are not and will not be subject to personal liability by reason of being such holders; and such Placement Agent’s
Securities are not and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual
rights granted by the Company.
2.10 Registration
Rights of Third Parties. Except as set forth in the Offering Statement, the Preliminary Offering Circular and the Offering Circular,
no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities of the Company
have the right to require the Company to register any such securities of the Company under the Securities Act or to include any such securities
in a registration statement to be filed by the Company.
2.11 Validity
and Binding Effect of Agreements. This Agreement and the Placement Agent’s Warrant Agreement have been duly and validly authorized
by the Company, and, when executed and delivered, will constitute, the valid and binding agreements of the Company, enforceable against
the Company in accordance with their respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization
or similar laws affecting creditors’ rights generally; (ii) as enforceability of any indemnification or contribution provision may
be limited under the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive and other forms
of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may
be brought.
2.12 No
Conflicts, etc. The execution, delivery and performance by the Company of this Agreement, the Placement Agent’s Warrant Agreement,
and all ancillary documents, the consummation by the Company of the transactions herein and therein contemplated and the compliance by
the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both:
(i) result in a material breach of, or conflict with any of the terms and provisions of, or constitute a material default under, or result
in the creation, modification, termination or imposition of any lien, charge, mortgage, pledge, security interest, claim, equity, trust
or other encumbrance, preferential arrangement or restriction of any kind whatsoever upon any portion of any property or assets of the
Company pursuant to the terms of any indenture, mortgage, deed of trust, note, lease, loan agreement or any other agreement or instrument,
license or permit to which the Company is a party or as to which any property of the Company is a party or any of its assets are bound,
except as set forth in the Offering Statement, the Preliminary Offering Circular and the Offering Circular; (ii) result in any violation
of the provisions of the Company’s Articles of Incorporation, as amended (as the same may be amended or restated from time to time,
the “Charter”) or the amended and restated by-laws of the Company (as the same may be amended or restated from time
to time); or (iii) violate any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the
date hereof (including, without limitation, those promulgated by the Food and Drug Administration of the U.S. Department of Health and
Human Services (the “FDA”) or by any foreign, federal, state or local regulatory authority performing functions similar
to those performed by the FDA).
2.13 No
Defaults; Violations. No material default exists in the due performance and observance of any term, covenant or condition of any material
license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument evidencing
an obligation for borrowed money, or any other material agreement or instrument to which the Company is a party or by which the Company
may be bound or to which any of the properties or assets of the Company is subject; except for such defaults that would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Change. The Company is not in violation of any term or provision
of its Charter or by-laws, or, in violation of any franchise, license, permit, applicable law, rule, regulation, judgment, order or decree
of any Governmental Entity.
2.14 Corporate
Power; Licenses; Consents.
2.14.1. Conduct
of Business. Except as described in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, the Company
has all requisite corporate power and authority, and has all necessary consents, authorizations, approvals, registrations, orders, licenses,
certificates, qualifications, registrations and permits of and from all governmental regulatory officials and bodies that it needs as
of the date hereof to conduct its business purpose as described in the Offering Statement, the Preliminary Offering Circular and the Offering
Circular, except where such failure to have such consents, authorizations, approvals, registrations, orders, license, certificates, qualifications,
registrations and permit would not reasonably be expected to result in a Material Adverse Change.
2.14.2. Transactions
Contemplated Herein. The Company has all corporate power and authority to enter into this Agreement and the Placement Agent’s
Warrant Agreement, and to carry out the provisions and conditions hereof, and all consents, authorizations, approvals, registrations,
orders licenses, certificates, qualifications, registrations and permits required in connection therewith have been obtained. No consent,
authorization or order of, and no filing with, any court, government agency or other body is required for the valid issuance, sale and
delivery of the Securities, the Placement Agent’s Securities and the consummation of the transactions and agreements contemplated
by this Agreement and the Placement Agent’s Warrant Agreement and as contemplated by the Offering Statement, the Preliminary Offering
Circular and the Offering Circular, except with respect to applicable federal and state securities laws and the rules and regulations
of the Exchange and Financial Industry Regulatory Authority, Inc. (“FINRA”).
2.15 D&O
Questionnaires. To the Company’s knowledge, all information contained in the questionnaires (the “Questionnaires”)
completed by each of the Company’s directors and officers immediately prior to the Offering (the “Insiders”)
as supplemented by all information concerning the Company’s directors, officers and principal stockholders as described in the Offering
Statement, the Preliminary Offering Circular and the Offering Circular, provided to the Placement Agent, is true and correct in all material
respects and the Company has not become aware of any information which would cause the information disclosed in the Questionnaires to
become materially inaccurate and incorrect in any respect.
2.16 Litigation;
Governmental Proceedings. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding
pending or, to the Company’s knowledge, threatened against, or involving the Company, or, to the Company’s knowledge, any
executive officer or director which has not been disclosed in the Offering Statement, the Preliminary Offering Circular and the Offering
Circular or in connection with the Company’s listing application for the listing of the Securities on the Exchange and which is
required to be disclosed.
2.17 Good
Standing. The Company has been duly incorporated and is validly existing as a corporation and is in good standing under the laws of
the State of Nevada as of the date hereof, and is duly qualified to do business and is in good standing in each other jurisdiction in
which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to be so qualified
or in good standing, singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse Change.
2.18 Insurance.
The Company carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and covering such risks which
the Company believes are adequate, including, but not limited to, directors and officers insurance coverage at least equal to $5,000,000
and all such insurance is in full force and effect. The Company has no reason to believe that it will not be able (i) to renew its existing
insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary
or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Change.
2.19 Transactions
Affecting Disclosure to FINRA.
2.19.1. Finder’s
Fees. Except as described in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, there are no claims,
payments, arrangements, agreements or understandings relating to the payment of a finder’s, consulting or origination fee by the
Company or any Insider with respect to the sale of the Securities hereunder or any other arrangements, agreements or understandings of
the Company or, to the Company’s knowledge, any of its stockholders that may affect the Placement Agent’s compensation, as
determined by FINRA.
2.19.2. Payments
Within Twelve (12) Months. Except as described in the Offering Statement, the Preliminary Offering Circular and the Offering Circular,
the Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder’s fee,
consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who
raised or provided capital to the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct or indirect affiliation
or association with any FINRA member, within the twelve (12) months prior to the date of this Agreement, other than the payment to the
Placement Agent as provided hereunder in connection with the Offering.
2.19.3. Use
of Proceeds. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its affiliates,
except as specifically authorized herein.
2.19.4. FINRA
Affiliation. There is no (i) officer or director of the Company, (ii) beneficial owner of 10% or more of any class of the Company’s
securities or (iii) beneficial owner of the Company’s unregistered equity securities which were acquired during the 180-day period
immediately preceding the filing of the Offering Statement that is an affiliate or associated person of a FINRA member participating in
the Offering (as determined in accordance with the rules and regulations of FINRA). The Company (i) does not have any material lending
or other relationship with any bank or lending affiliate of any Placement Agent and (ii) does not intend to use any of the proceeds from
the sale of the Securities to repay any outstanding debt owed to any affiliate of any Placement Agent.
2.20 Foreign
Corrupt Practices Act. None of the Company and any of its Subsidiaries nor, to the Company’s knowledge, any director, officer,
agent, employee or affiliate of the Company and any of its Subsidiaries or any other person acting on behalf of the Company and any of
its Subsidiaries, has, directly or indirectly, (i) given or agreed to give any money, gift or similar benefit (other than legal price
concessions to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or
official or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate
for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company (or
assist it in connection with any actual or proposed transaction) that (a) might subject the Company to any damage or penalty in any civil,
criminal or governmental litigation or proceeding, (b) if not given in the past, might have had a Material Adverse Change; (c) if not
continued in the future, might adversely affect the assets, business, operations or prospects of the Company; or (d) violated or is in
violation of any provision of the Foreign Corrupt Practices Act (the “FCPA”) or any applicable non-U.S. anti-bribery
statute or regulation; (ii) made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment; or (iii) received notice
of any investigation, proceeding or inquiry by any Governmental Entity regarding any of the matters in clauses (i) or (ii) above; and
the Company has conducted its business in compliance with the FCPA in all material respects, and has instituted and maintains policies
and procedures designed to ensure, and which are reasonably expected to ensure, that the Company will continue to comply in all material
respects with the FCPA. The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to
cause the Company to comply in all material respects with the FCPA.
2.21 Compliance
with OFAC. None of the Company and any of its Subsidiaries or, to the Company’s knowledge, any director, officer, agent, employee
or affiliate of the Company and any of its Subsidiaries or any other person acting on behalf of the Company and any of its Subsidiaries,
is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury
(“OFAC”), and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing
the activities of any person currently subject to any U.S. sanctions administered by OFAC.
2.22 Forward-Looking
Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) contained in the Offering Statement, the Preliminary Offering Circular or the Offering Circular has been made or reaffirmed without
a reasonable basis or has been disclosed other than in good faith.
2.23 Money
Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action,
suit or proceeding by or before any Governmental Entity involving the Company with respect to the Money Laundering Laws is pending or,
to the best knowledge of the Company, threatened.
2.24 Regulatory.
(a) All preclinical studies and clinical trials conducted by or on behalf of the Company that are material to the Company and its Subsidiaries,
taken as a whole, are or have been adequately described in the Offering Statement, the Preliminary Offering Circular and the Offering
Circular in all material respects. Except as disclosed in the Offering Statement, the Preliminary Offering Circular and the Offering Circular,
the preclinical studies and clinical trials conducted by or on behalf of the Company and its Subsidiaries that are described in the Offering
Statement, the Preliminary Offering Circular and the Offering Circular or the results of which are referred to in the Offering Statement,
the Preliminary Offering Circular and the Offering Circular were and, if still ongoing, are being conducted in material compliance with
all laws and regulations applicable thereto in the jurisdictions in which they are being conducted and with all laws and regulations applicable
to preclinical studies and clinical trials from which data will be submitted to support marketing approval. The descriptions in the Offering
Statement, the Preliminary Offering Circular and the Offering Circular of the results of such studies are accurate and complete in all
material respects and fairly present the data derived from such studies, and the Company has no knowledge of, or reason to believe that,
any large well- controlled clinical study the aggregate results of which are inconsistent with or otherwise call into question the results
of any clinical study conducted by or on behalf of the Company that are described in the Offering Statement, the Preliminary Offering
Circular and the Offering Circular or the results of which are referred to in the Offering Statement, the Preliminary Offering Circular
and the Offering Circular. Except as disclosed in the Offering Statement, the Preliminary Offering Circular and the Offering Circular,
the Company has not received any written notices or statements from the FDA, the European Medicines Agency (“EMA”)
or any other governmental agency or authority imposing, requiring, requesting or suggesting a clinical hold, termination, suspension or
material modification for or of any preclinical studies and clinical trials that are described in the Offering Statement, the Preliminary
Offering Circular and the Offering Circular or the results of which are referred to in the Offering Statement, the Preliminary Offering
Circular and the Offering Circular. Except as disclosed in the Offering Statement, the Preliminary Offering Circular and the Offering
Circular, the Company has not received any written notices or statements from the FDA, the EMA or any other governmental agency, and otherwise
has no knowledge of, or reason to believe that, (i) any investigational new drug application for any potential product of the Company
is or has been rejected or placed on clinical hold; and (ii) any license, approval, permit or authorization to conduct any clinical trial
of any potential product of the Company has been, will be or may be suspended, revoked, modified or limited. Neither the Company nor any
of its subsidiaries has failed to file with the FDA or any foreign, federal, state or local governmental or regulatory authority performing
functions similar to those performed by the FDA, any filing, declaration, listing, registration, report or submission that is required
to be so filed. All such filings were in material compliance with applicable laws when filed and no deficiencies have been asserted by
any applicable regulatory authority (including, without limitation, the FDA or any foreign, federal, state or local governmental or regulatory
authority performing functions similar to those performed by the FDA) with respect to any such filings, declarations, listings, registrations,
reports or submissions. Except as disclosed in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, to
the knowledge of the Company, there are no facts that would be reasonably likely to result in any warning, untitled or notice of violation
letter or Form FDA- 483 from the FDA. The Company is not aware of any studies, tests or trials the results of which the Company believes
reasonably call into question (i) the study, test or trial results of any of its products, (ii) the efficacy or safety of any of its products
or (iii) any of the Company’s filings with any Governmental Entity.
(b) Regulatory
Filings and Permits. The Company and its Subsidiaries have such permits, licenses, clearances, registrations, exemptions, patents,
franchises, certificates of need and other approvals, consents and other authorizations (“Permits”) issued by the appropriate
domestic or foreign regional, federal, state, or local regulatory agencies or bodies necessary to conduct the business of the Company,
including, without limitation, any Investigational New Drug Application (an “IND”), Biologics License Application (“BLA”)
and/or New Drug Application (an “NDA”), as required by FDA, the Drug Enforcement Administration (the “DEA”),
or any other Permits issued by domestic or foreign regional, federal, state, or local agencies or bodies engaged in the regulation of
pharmaceuticals such as those being developed by the Company and its Subsidiaries (collectively, the “Regulatory Permits”),
except for any of the foregoing that would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Change;
the Company is in compliance in all material respects with the requirements of the Regulatory Permits, and all of such Regulatory Permits
are valid and in full force and effect; the Company has not received any notice of proceedings relating to the revocation, termination,
modification or impairment of rights of any of the Regulatory Permits that, individually or in the aggregate, if the subject of an unfavorable
decision, ruling or finding, would reasonably be expected to result in a Material Adverse Change; the Company has not failed to submit
to the FDA any IND, BLA or NDA necessary to conduct the business of the Company, any such filings that were required to be made were in
material compliance with applicable laws when filed, and no material deficiencies have been asserted by the FDA with respect to any such
filings or submissions that were made.
(c) Compliance
with Health Care Laws. Each of the Company and its Subsidiaries is, and at all times has been, in compliance in all material respects
with all applicable Health Care Laws, and has not engaged in activities which are, as applicable, cause for false claims liability, civil
penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal health care program. For purposes
of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301
et seq.), the Public Health Service Act (42 U.S.C. §§ 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable
federal, state, local and all applicable foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback
Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Physician Payment Sunshine Act (42 U.S.C. § 1320a-7h), the U.S. Civil False Claims
Act (31 U.S.C. Section 3729 et seq.), the criminal False Claims Law (42 U.S.C. § 1320a- 7b(a)), all criminal laws relating to health
care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under
the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the exclusion
laws (42 U.S.C. § 1320a-7), the civil monetary penalties law (42 U.S.C. § 1320a-7a), HIPAA, as amended by the Health Information
Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.), and the regulations promulgated pursuant to such statutes;
(iii) Medicare (Title XVIII of the Social Security Act); (iv) Medicaid (Title XIX of the Social Security Act); (v) the Controlled Substances
Act (21 U.S.C. §§ 801 et seq.) and the regulations promulgated thereunder; and (vi) any and all other applicable health care
laws and regulations. Neither the Company nor, to the knowledge of the Company, any subsidiary has received notice of any claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory
authority or third party alleging that any product operation or activity is in material violation of any Health Care Laws, and, to the
Company’s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is
threatened. Neither the Company nor, to the knowledge of the Company, any subsidiary is a party to or has any ongoing reporting obligations
pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders,
plans of correction or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company,
its Subsidiaries nor any of its respective employees, officers or directors has been excluded, suspended or debarred from participation
in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry,
investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.
2.25 Officers’
Certificate. Any certificate signed by any duly authorized officer of the Company and delivered to you or to Placement Agent Counsel
shall be deemed a representation and warranty by the Company to the Placement Agent as to the matters covered thereby.
2.26 [Reserved].
2.27 Subsidiaries.
All direct and indirect Subsidiaries of the Company are duly organized and in good standing under the laws of the place of organization
or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership or lease of property or the conduct
of business requires such qualification, except where the failure to qualify would not have a material adverse effect on the assets, business
or operations of the Company taken as a whole. The Company’s ownership and control of each Subsidiary is as described in the Offering
Statement, the Preliminary Offering Circular and the Offering Circular.
2.28 Related
Party Transactions. There are no business relationships or related party transactions involving the Company or any other person required
to be described in the Offering Statement, the Preliminary Offering Circular and the Offering Circular that have not been described as
required.
2.29 No
Relationships with Customers and Suppliers. No relationship, direct or indirect, exists between or among the Company on the one hand,
and the directors, officers, 5% or greater stockholders, customers or suppliers of the Company or any of the Company’s affiliates
on the other hand, which is required to be described in the Offering Statement, the Preliminary Offering Circular or the Offering Circular
or a document incorporated by reference therein and which is not so described.
2.30 No
Unconsolidated Entities. Except as disclosed in the Offering Statement, the Preliminary Offering Circular and the Offering Circular,
there are no transactions, arrangements or other relationships between and/or among the Company, any of its affiliates (as such term is
defined in Rule 405 of the Securities Act) and any unconsolidated entity, including, but not limited to, any structured finance, special
purpose or limited purpose entity that could reasonably be expected to materially affect the Company’s liquidity or the availability
of or requirements for its capital resources required to be described in the Offering Statement, the Preliminary Offering Circular or
the Offering Circular or a document incorporated by reference therein which have not been described as required.
2.31 Board
of Directors. The Board of Directors of the Company is comprised of the persons disclosed in the Offering Statement, the Preliminary
Offering Circular and the Offering Circular. The qualifications of the persons serving as board members and the overall composition of
the board comply with the Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder
(the “Sarbanes-Oxley Act”) applicable to the Company and the listing rules of the Exchange. At least one member of
the Audit Committee of the Board of Directors of the Company qualifies as an “audit committee financial expert,” as such term
is defined under Regulation S-K and the listing rules of the Exchange. In addition, at least a majority of the persons serving on the
Board of Directors qualify as “independent,” as defined under the listing rules of the Exchange.
2.32 Sarbanes-Oxley
Compliance.
2.32.1. Disclosure
Controls. The Company has developed and currently maintains disclosure controls and procedures that will comply with Rule 13a-15 or
15d-15 under the Exchange Act Regulations and such controls and procedures are effective to ensure that all material information concerning
the Company will be made known on a timely basis to the individuals responsible for the preparation of the Company’s Exchange Act
filings and other public disclosure documents.
2.32.2. Compliance.
The Company is, and on each Closing Date will be, in material compliance with the provisions of the Sarbanes-Oxley Act applicable to it,
and has implemented or will implement such programs and taken reasonable steps to ensure the Company’s future compliance (not later
than the relevant statutory and regulatory deadlines therefor) with all of the material provisions of the Sarbanes-Oxley Act.
2.32.3. Accounting
Controls. The Company and its Subsidiaries maintain systems of “internal control over financial reporting” (as defined
under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act and have been
designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing
similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability;
(iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. Except as disclosed in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, the Company
is not aware of any material weaknesses in its internal controls. The Company’s auditors and the Audit Committee of the Board of
Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of
internal controls over financial reporting which are known to the Company’s management and that have adversely affected or are reasonably
likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and (ii) any fraud
known to the Company’s management, whether or not material, that involves management or other employees who have a significant role
in the Company’s internal controls over financial reporting. Since the date of the latest audited financial statements included
in the Disclosure Package, there has been no change in the Company’s internal control over financial reporting that has materially
affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
2.33 No
Investment Company Status. The Company is not and, after giving effect to the Offering and the application of the proceeds thereof
as described in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, will not be, required to register
as an “investment company,” as defined in the Investment Company Act of 1940, as amended.
2.34 No
Labor Disputes. No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company,
is imminent.
2.35 Intellectual
Property Rights. The Company and each of its Subsidiaries owns or possesses or has valid rights to use all patents, patent applications,
trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets
and similar rights (“Intellectual Property Rights”) necessary for the conduct of the business of the Company and its
Subsidiaries as currently carried on and as described in the Offering Statement, the Preliminary Offering Circular and the Offering Circular.
To the knowledge of the Company, no action or use by the Company or any of its Subsidiaries necessary for the conduct of its business
as currently carried on and as described in the Offering Statement, the Preliminary Offering Circular and the Offering Circular will involve
or give rise to any infringement of, or license or similar fees for, any Intellectual Property Rights of others. Neither the Company nor
any of its Subsidiaries has received any notice alleging any such infringement of, license or similar fees for, or conflict with any asserted
Intellectual Property Rights of others. Except as would not reasonably be expected to result, individually or in the aggregate, in a Material
Adverse Change (A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any of
the Intellectual Property Rights owned by the Company; (B) there is no pending or, to the knowledge of the Company, threatened action,
suit, proceeding or claim by others challenging the rights of the Company in or to any such Intellectual Property Rights, and the Company
is unaware of any facts which would form a reasonable basis for any such claim, that would, individually or in the aggregate, together
with any other claims in this Section 2.35, reasonably be expected to result in a Material Adverse Change; (C) the Intellectual Property
Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company have not been
adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to the Company’s
knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property
Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim that would, individually or in
the aggregate, together with any other claims in this Section 2.35, reasonably be expected to result in a Material Adverse Change; (D)
there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others that the Company infringes,
misappropriates or otherwise violates any Intellectual Property Rights or other proprietary rights of others, the Company has not received
any written notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for any such claim
that would, individually or in the aggregate, together with any other claims in this Section 2.35, reasonably be expected to result in
a Material Adverse Change; and (E) to the Company’s knowledge, no employee of the Company is in or has ever been in violation in
any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition
agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis
of such violation relates to such employee’s employment with the Company, or actions undertaken by the employee while employed with
the Company and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change. To the Company’s
knowledge, all material technical information developed by and belonging to the Company which has not been patented or disclosed in a
patent application has been kept confidential. The Company is not a party to or bound by any options, licenses or agreements with respect
to the Intellectual Property Rights of any other person or entity that are required to be set forth in the Offering Statement, the Preliminary
Offering Circular and the Offering Circular and are not described therein. The Offering Statement, the Preliminary Offering Circular and
the Offering Circular contain in all material respects the same description of the matters set forth in the preceding sentence. None of
the technology employed by the Company has been obtained or is being used by the Company in violation of any contractual obligation binding
on the Company or any of its Subsidiaries or, to the Company’s knowledge, any of its officers, directors or employees, or otherwise
in violation of the rights of any persons.
To the Company’s knowledge,
all licenses for the use of the Intellectual Property described in the Offering Statement, the Preliminary Offering Circular and the Offering
Circular are in full force and effect in all material respects and are enforceable by the Company and, to the Company’s knowledge,
the other parties thereto, in accordance with their terms, except (x) as such enforceability may be limited by bankruptcy, insolvency,
reorganization or similar laws affecting creditors’ rights generally, (y) as enforceability of any indemnification or contribution
provision may be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive and
other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding
therefor may be brought. None of such agreements or instruments has been assigned by the Company, and the Company, has no knowledge, that
any other party is in default thereunder and no event has occurred that, with the lapse of time or the giving of notice, or both, would
constitute a default thereunder.
2.36 Clinical
Studies. All preclinical and clinical studies conducted by or on behalf of the Company Parties that are material to an understanding
of the Company’s business and an investment in the Company Parties, are or have been adequately described in the Offering Statement,
the Preliminary Offering Circular and the Offering Circular in all material respects. Except as disclosed in the Offering Statement, the
Preliminary Offering Circular and the Offering Circular, to the Company’s knowledge, after reasonable inquiry, the clinical and
preclinical studies conducted by or on behalf of the Company Parties that are described in the Offering Statement, the Preliminary Offering
Circular and the Offering Circular or the results of which are referred to in the Offering Statement, the Preliminary Offering Circular
and the Offering Circular were and, if still ongoing, are being conducted in material compliance with all laws and regulations applicable
thereto in the jurisdictions in which they are being conducted and with all laws and regulations applicable to preclinical and clinical
studies from which data will be submitted to support marketing approval. The descriptions in the Offering Statement, the Preliminary Offering
Circular and the Offering Circular of the results of such studies are accurate and complete in all material respects and fairly present
the data derived from such studies, and Company has no knowledge of any large well-controlled clinical study the aggregate results of
which are inconsistent with or otherwise call into question the results of any clinical study conducted by or on behalf of the Company
that are described in the Offering Statement, the Preliminary Offering Circular and the Offering Circular. Except as disclosed in the
Offering Statement, the Preliminary Offering Circular and the Offering Circular, the Company has not received any written notices or statements
from the FDA, the European Medicines Agency (“EMA”) or any other Governmental Entity imposing, requiring, requesting
or suggesting a clinical hold, termination, suspension or material modification for or of any clinical or preclinical studies that are
described in the Offering Statement, the Preliminary Offering Circular and the Offering Circular or the results of which are referred
to in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, the Company Parties have not received any written
notices or statements from the FDA, the EMA or any other Governmental Entity, and otherwise has no knowledge or reason to believe, that
(i) any investigational new drug application for potential product of the Company is or has been rejected or determined to be non-approvable
or conditionally approvable; and (ii) any license, approval, permit or authorization to conduct any clinical trial of any potential product
of the Company has been, will be or may be suspended, revoked, modified or limited.
2.37 Taxes.
Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with taxing authorities prior
to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company and its Subsidiaries has paid all
taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against the
Company or such respective Subsidiary. The provisions for taxes payable, if any, shown on the financial statements filed with or as part
of the Offering Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including
the dates of such consolidated financial statements. Except as disclosed in writing to the Placement Agent, (i) no issues have been raised
(and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company or
its Subsidiaries, and (ii) no waivers of statutes of limitation with respect to the returns or collection of taxes have been given by
or requested from the Company or its Subsidiaries. The term “taxes” means all federal, state, local, foreign and other net
income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding,
payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees,
assessments or charges of any kind whatever, together with any interest and any penalties, additions to tax or additional amounts with
respect thereto. The term “returns” means all United States returns, declarations, reports, statements and other documents
required to be filed in respect to taxes.
2.38 ERISA
Compliance. The Company and any “employee benefit plan” (as defined under the Employee Retirement Income Security Act
of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”)) established
or maintained by the Company or its “ERISA Affiliates” (as defined below) are in compliance in all material respects with
ERISA. “ERISA Affiliate” means, with respect to the Company, any member of any group of organizations described in Sections
414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the
“Code”) of which the Company is a member. No “reportable event” (as defined under ERISA) has occurred or is reasonably
expected to occur with respect to any “employee benefit plan” established or maintained by the Company or any of its ERISA
Affiliates. No “employee benefit plan” established or maintained by the Company or any of its ERISA Affiliates, if such “employee
benefit plan” were terminated, would have any “amount of unfunded benefit liabilities” (as defined under ERISA). Neither
the Company, nor any of its ERISA Affiliates has incurred or reasonably expects to incur any material liability under (i) Title IV of
ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or (ii) Sections 412, 4971, 4975 or
4980B of the Code. Each “employee benefit plan” established or maintained by the Company, or any of its ERISA Affiliates that
is intended to be qualified under Section 401(a) of the Code is so qualified and, to the knowledge of the Company, nothing has occurred,
whether by action or failure to act, which would cause the loss of such qualification.
2.39 Compliance
with Laws. The Company: (A) is and at all times has been in compliance with all statutes, rules, regulations, ordinances, judgments,
orders and decrees of all Governmental Entities applicable to the Company’s business (“Applicable Laws”), except
as could not, individually or in the aggregate, reasonably be expected to result in or have a Material Adverse Change; (B) has not received
any warning letter, untitled letter or other correspondence or notice from any other Governmental Entity alleging or asserting noncompliance
with any Applicable Laws or any licenses, consents, certificates, approvals, clearances, authorizations, permits, orders and supplements
or amendments thereto required by any such Applicable Laws (“Authorizations”); (C) possesses all material Authorizations
and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such Authorizations;
(D) has not received notice of any claim, action, suit, litigation, proceeding, hearing, enforcement, investigation, inquiry, arbitration
or other action from any Governmental Entity or third party alleging that any product operation or activity is in violation of any Applicable
Laws or Authorizations and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation,
arbitration, action, suit, litigation proceeding, hearing, enforcement, investigation, inquiry, arbitration or other action; (E) has not
received notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations
and has no knowledge that any such Governmental Entity considering such action; (F) has filed, obtained, maintained or submitted all material
reports, documents, forms, filings, notices, applications, records, claims, submissions and supplements or amendments as required by any
Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments were complete and correct on the date filed (or were corrected or supplemented by a subsequent submission);
and (G) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued,
any recall, market withdrawal or replacement, safety alert, post-sale warning, “dear doctor” letter, or other notice or action
relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company’s
knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.
2.40 Ineligible
Issuer. At the time of filing the Offering Statement and any post-effective amendment thereto, at the earliest time thereafter that
the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations)
of the Securities and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405, without
taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an
ineligible issuer.
2.41 Environmental
Laws. The Company and its Subsidiaries are in compliance with all foreign, federal, state and local rules, laws and regulations relating
to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or the environment
which are applicable to their businesses (“Environmental Laws”), except where the failure to comply would not, singularly
or in the aggregate, result in a Material Adverse Change. There has been no storage, generation, transportation, handling, treatment,
disposal, discharge, emission, or other release of any kind of toxic or other wastes or other hazardous substances by, due to, or caused
by the Company or any of its Subsidiaries (or, to the Company’s knowledge, any other entity for whose acts or omissions the Company
or any of its Subsidiaries is or may otherwise be liable) upon any of the property now or previously owned or leased by the Company or
any of its Subsidiaries , or upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment,
decree or permit or which would, under any law, statute, ordinance, rule (including rule of common law), regulation, order, judgment,
decree or permit, give rise to any liability; and there has been no disposal, discharge, emission or other release of any kind onto such
property or into the environment surrounding such property of any toxic or other wastes or other hazardous substances with respect to
which the Company has knowledge.
2.42 Real
Property. Except as set forth in the Offering Statement, the Preliminary Offering Circular and the Offering Circular, the Company
and each of its Subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items
of real or personal property which are material to the business of the Company and its Subsidiaries taken as a whole, in each case free
and clear of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate, materially affect
the value of such property and do not interfere with the use made and proposed to be made of such property by the Company or any of its
Subsidiaries; and all of the leases and subleases material to the business of the Company and its subsidiaries, considered as one enterprise,
and under which the Company or any of its Subsidiaries holds properties described in the Offering Statement, the Preliminary Offering
Circular and the Offering Circular, are in full force and effect, and neither the Company nor any Subsidiary has received any notice of
any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the
leases or subleases mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession
of the leased or subleased premises under any such lease or sublease.
2.43 Contracts
Affecting Capital. There are no transactions, arrangements or other relationships between and/or among the Company, any of its affiliates
(as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including, but not limited to,
any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially affect the Company’s
or any of its Subsidiaries’ liquidity or the availability of or requirements for their capital resources required to be described
or incorporated by reference in the Offering Statement, the Preliminary Offering Circular and the Offering Circular which have not been
described or incorporated by reference as required.
2.44 Loans
to Directors or Officers. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course
of business) or guarantees or indebtedness by the Company or its Subsidiaries to or for the benefit of any of the officers or directors
of the Company, its Subsidiaries or any of their respective family members, except as disclosed in the Offering Statement, the Preliminary
Offering Circular and the Offering Circular.
2.45 Smaller
Reporting Company. As of the time of filing of the Offering Statement, the Company was, and currently is, a “smaller reporting
company,” as defined in Rule 12b-2 of the Exchange Act Regulations.
2.46 Industry
Data. The statistical and market-related data included in each of the Offering Statement, the Preliminary Offering Circular and the
Offering Circular are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate
or represent the Company’s good faith estimates that are made on the basis of data derived from such sources.
2.47 Margin
Securities. The Company owns no “margin securities” as that term is defined in Regulation U of the Board of Governors
of the Federal Reserve System (the “Federal Reserve Board”), and none of the proceeds of Offering will be used, directly
or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness
which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any of the shares of
Common Stock to be considered a “purpose credit” within the meanings of Regulation T, U or X of the Federal Reserve Board.
2.48 Exchange
Act Reports. The Company has filed in a timely manner all reports required to be filed pursuant to Sections 13(a), 13(e), 14 and 15(d)
of the Exchange Act during the preceding 12 months (except to the extent that Section 15(d) requires reports to be filed pursuant to Sections
13(d) and 13(g) of the Exchange Act, which shall be governed by the next clause of this sentence); and the Company has filed in a timely
manner all reports required to be filed pursuant to Sections 13(d) and 13(g) of the Exchange Act since January 1, 2022, except where the
failure to timely file could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Change.
2.49 Minute
Books. The minute books of the Company and each Subsidiary have been made available to the Placement Agent and Placement Agent Counsel,
and such books (i) contain a complete summary of all meetings and actions of the board of directors (including each board committee) and
stockholders of the Company and each Subsidiary (or analogous governing bodies and interest holders, as applicable), and since January
2022 through the date of the latest meeting and action, and (ii) accurately in all material respects reflect all transactions referred
to in such minutes. There are no material transactions, agreements, dispositions or other actions of the Company and each Subsidiary that
are not properly approved and/or accurately and fairly recorded in the minute books of the Company or its Subsidiary, as applicable.
2.50 Integration.
Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering to be integrated
with prior offerings by the Company for purposes of the Securities Act that would require the registration of any such securities under
the Securities Act.
2.51 No
Stabilization. Neither the Company nor, to its knowledge, any of its employees, directors or stockholders (without the consent of
the Placement Agent) has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably
be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of
any security of the Company to facilitate the sale or resale of the Securities.
2.52 Confidentiality
and Non-Competition. To the Company’s knowledge, no director, officer, key employee or consultant of the Company is subject
to any confidentiality, non-disclosure, non- competition agreement or non-solicitation agreement with any employer or prior employer that
could reasonably be expected to materially affect his ability to be and act in his respective capacity of the Company or be expected to
result in a Material Adverse Change.
3. Covenants
of the Company. The Company covenants and agrees as follows:
3.1 Amendments
to Offering Statement. The Company shall deliver to the Placement Agent, prior to filing, any amendment or supplement to the Offering
Statement, the Preliminary Offering Circular and the Offering Circular proposed to be filed after the date hereof and not file any such
amendment or supplement to which the Placement Agent shall reasonably object in writing.
3.2 Federal
Securities Laws.
3.2.1. Compliance.
The Company, subject to Section 3.2.2, shall comply with the requirements of the Rules and Regulations, and will notify the Placement
Agent promptly, and confirm the notice in writing, (i) when any post-qualification amendment to the Offering Statement or any amendment
or supplement to the Preliminary Offering Circular and the Offering Circular shall have been filed and when any post-qualification amendment
to the Offering Statement shall become qualified; (ii) of the receipt of any comments from the Commission; (iii) of any request by the
Commission for any amendment to the Offering Statement or any amendment or supplement to any Preliminary Offering Circular and the Offering
Circular or for additional information; (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Offering
Statement or any post-qualification amendment thereto or of any order preventing or suspending the use of any Preliminary Offering Circular
and the Offering Circular, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of
the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the
Securities Act concerning the Offering Statement; and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities
Act in connection with the Offering of the Securities. Company shall effect all filings required under Rule 424(b) of the Securities Act
Regulations, in the manner and within the time period required by Regulation A and shall take such steps as it deems necessary to ascertain
promptly whether the form of offering statement transmitted for filing under Rule 253 was received for filing by the Commission and, in
the event that it was not, it will promptly file such offering circular. The Company shall use its reasonable best efforts to prevent
the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest
possible moment.
3.2.2. Continued
Compliance. The Company shall comply with the Securities Act, the Exchange Act and the Rules and Regulations so as to permit the completion
of the distribution of the Securities as contemplated in this Agreement and in the Offering Statement, the Preliminary Offering Circular
and the Offering Circular. If at any time when an offering circular relating to the Securities is (or, but for the exception afforded
by Rule 172 of the Securities Act Regulations (“Rule 172”), would be) required by the Securities Act to be delivered
in connection with sales of the Securities, any event shall occur or condition shall exist as a result of which it is necessary, in the
opinion of counsel for the Placement Agent or for the Company, to (i) amend the Offering Statement in order that the Offering Statement
will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading; (ii) amend or supplement the Preliminary Offering Circular and the Offering Circular in order
that the Preliminary Offering Circular and the Offering Circular, as the case may be, will not include any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances
existing at the time it is delivered to a purchaser or (iii) amend the Offering Statement or amend or supplement the Preliminary Offering
Circular and the Offering Circular, as the case may be, in order to comply with the requirements of the Securities Act or the Rules and
Regulations, the Company will promptly (A) give the Placement Agent notice of such event; (B) prepare any amendment or supplement as may
be necessary to correct such statement or omission or to make the Offering Statement, the Preliminary Offering Circular and the Offering
Circular comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Placement Agent
with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided, however,
that the Company shall not file or use any such amendment or supplement to which the Placement Agent or counsel for the Placement Agent
shall reasonably object. The Company will furnish to the Placement Agent such number of copies of such amendment or supplement as the
Placement Agent may reasonably request. The Company has given the Placement Agent notice of any filings made pursuant to the Exchange
Act or the Rules and Regulations within 48 hours prior to each Closing Date. The Company shall give the Placement Agent notice of its
intention to make any such filing until such Closing Date and will furnish the Placement Agent with copies of the related document(s)
a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the
Placement Agent or counsel for the Placement Agent shall reasonably object.
3.2.3. Exchange
Act Registration. For a period of three (3) years after the date of this Agreement, the Company shall use its best efforts to maintain
the registration of the shares of Common Stock under the Exchange Act. The Company shall not deregister the shares of Common Stock under
the Exchange Act without the prior written consent of the Placement Agent.
3.3 Delivery
to the Placement Agent of Offering Statements. The Company has delivered or made available or shall deliver or make available to the
Placement Agent and counsel for the Placement Agent, without charge, signed copies of the Offering Statement as originally filed and each
amendment thereto (including exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed to be
incorporated by reference therein) and signed copies of all consents and certificates of experts, and will also deliver to the Placement
Agent, without charge, a conformed copy of the Offering Statement as originally filed and each amendment thereto (without exhibits) for
the Placement Agent. The copies of the Offering Statement and each amendment thereto furnished to the Placement Agent will be identical
to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation
S-T.
3.4 Delivery
to the Placement Agent of Offering Circular. The Company has delivered or made available or will deliver or make available to the
Placement Agent, without charge, as many copies of each Prelminary Offering Circular as the Placement Agent reasonably requested, and
the Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to the Placement
Agent, without charge, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172,
would be) required to be delivered under the Securities Act, such number of copies of the Offering Circular (as amended or supplemented)
as the Placement Agent may reasonably request. The Offering Circular and any amendments or supplements thereto furnished to the Placement
Agent will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation S-T.
3.5 Qualification
and Events Requiring Notice to the Placement Agent. The Company shall use its best efforts to cause the Offering Statement to remain
qualified with a current offering circular until the termination of the Offering, and shall notify the Placement Agent immediately and
confirm the notice in writing: (i) of the qualification of the Offering Statement and any amendment thereto; (ii) of the issuance by the
Commission of any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii) of the issuance by any
state securities commission of any proceedings for the suspension of the qualification of the Securities for offering or sale in any jurisdiction
or of the initiation, or the threatening, of any proceeding for that purpose; (iv) of the mailing and delivery to the Commission for filing
of any amendment or supplement to the Offering Statement or Offering Circular; (v) of the receipt of any comments or request for any additional
information from the Commission; and (vi) of the happening of any event during the period described in this Section 3.5 that, in the judgment
of the Company, makes any statement of a material fact made in the Offering Statement, any Preliminary Offering Circular or the Offering
Circular untrue or that requires the making of any changes in (a) the Offering Statement in order to make the statements therein not misleading,
or (b) in any Preliminary Offering Circular or the Offering Circular in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend such
qualification at any time, the Company shall make every reasonable effort to obtain promptly the lifting of such order.
3.6 Review
of Financial Statements. For a period of five (5) years after the date of this Agreement, the Company, at its expense, shall cause
its regularly engaged independent registered public accounting firm to review (but not audit) the Company’s financial statements
for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.
3.7 Listing.
The Company shall use its commercially reasonable efforts to maintain the listing of the shares of Common Stock (including the Securities)
on the Exchange for at least three (3) years from the date of this Agreement.
3.8 Financial
Public Relations Firm. The Company has retained a financial public relations firm reasonably acceptable to the Placement Agent and
the Company, which firm shall be experienced in assisting issuers in public offerings of securities and in their relations with their
security holders, and shall retain such firm or another firm reasonably acceptable to the Placement Agent for a period of not less than
two (2) years after the date hereof.
3.9 Reports
to the Placement Agent.
3.9.1. Periodic
Reports, etc. For a period of three (3) years after the date of this Agreement, the Company shall furnish or make available to the
Placement Agent copies of such financial statements and other periodic and special reports as the Company from time to time furnishes
generally to holders of any class of its securities and also promptly furnish to the Placement Agent: (i) a copy of each periodic report
the Company shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every
press release and every news item and article with respect to the Company or its affairs which was released by the Company; (iii) a copy
of each Form 8-K prepared and filed by the Company; (iv) five copies of each registration statement filed by the Company under the Securities
Act; (v) a copy of each report or other communication furnished to stockholders; and (vi) such additional documents and information with
respect to the Company and the affairs of any future subsidiaries of the Company as the Placement Agent may from time to time reasonably
request; provided, however, the Placement Agent shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement
which is reasonably acceptable to the Placement Agent and Placement Agent Counsel in connection with the Placement Agent’s receipt
of such information. Documents filed with the Commission pursuant to its EDGAR system shall be deemed to have been delivered to the Placement
Agent pursuant to this Section 3.9.1.
3.9.2. Transfer
Agent; Transfer Sheets. For a period of three (3) years after the date of this Agreement, the Company shall retain a transfer agent,
and registrar acceptable to the Placement Agent (the “Transfer Agent”) and shall furnish to the Placement Agent at
the Company’s sole cost and expense such transfer sheets of the Company’s securities as the Placement Agent may reasonably
request, including the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. West Coast Stock Transfer, Inc. is
acceptable to the Placement Agent to act as Transfer Agent for the shares of Common Stock.
3.9.3. Trading
Reports. During such time as the Securities are listed on the Exchange, the Company shall provide to the Placement Agent, at the Company’s
expense, such reports published by Exchange relating to price trading of the Securities, as the Placement Agent shall reasonably request.
3.10 Payment
of Expenses. The Company hereby agrees to pay on each Closing Date, to the extent not paid on a prior Closing Date, all expenses incident
to the performance of the obligations of the Company under this Agreement, including, but not limited to: (a) all filing fees and communication
expenses relating to the Securities to be sold in the Offering with the Commission; (b) all filing fees and expenses associated with the
review of the Offering by FINRA; (c) all fees and expenses relating to the listing of such Shares on the Nasdaq Capital Market, the Nasdaq
Global Market, the Nasdaq Global Select Market, the NYSE or the NYSE American and on such other stock exchanges as the Company and the
Placement Agent together determine, including any fees charged by The Depository Trust Company (DTC) for new securities; (d) all fees,
expenses and disbursements relating to the registration or qualification of such Shares under the “blue sky” securities laws
of such states and other jurisdictions as the Placement Agent may reasonably designate; (e) all fees, expenses and disbursements relating
to the registration, qualification or exemption of such Securities under the securities laws of such foreign jurisdictions as the Placement
Agent may reasonably designate; (f) the costs of all mailing and printing of the Offering documents; (g) the costs of preparing, printing
and delivering certificates representing the Shares; (h) fees and expenses of the transfer agent for the Shares; (i) stock transfer and/or
stamp taxes, if any, payable upon the transfer of securities from the Company to the Placement Agent; (j) the costs associated with bound
volumes of the public offering materials as well as commemorative mementos and lucite tombstones, each of which the Company or its designee
will provide within a reasonable time after the initial Closing in such quantities as the Placement Agent may reasonably request; (k)
the fees and expenses of the Company’s accountants; (l) the fees and expenses of the Company’s legal counsel and other agents
and representatives; (m) the fees and expenses of the Placement Agent’s legal counsel not to exceed $125,000; (n) the $29,500 cost
associated with the use of Ipreo’s book building, prospectus tracking and compliance software for the Offering; (o) up to $10,000
of the Placement Agent’s actual accountable “road show” expenses; and (p) up to $30,000 of the Placement Agent’s
market making and trading, and clearing firm settlement expenses for the Offering. Such reimbursement shall be paid at each Closing from
the gross proceeds of the Securities. The Placement Agent may deduct from the net proceeds of the Offering payable to the Company on each
Closing Date (to the extent not paid on a prior Closing Date), the expenses set forth herein (less any amounts previously advanced against
such actual reimbursable expense) to be paid by the Company to the Placement Agent; provided however, that in the event that the Offering
is terminated, the Company agrees to reimburse the Placement Agent pursuant to Section 8.3.
3.11 Application
of Net Proceeds. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the application
thereof described under the caption “Use of Proceeds” in the Offering Statement, the Preliminary Offering Circular and the
Offering Circular.
3.12 Delivery
of Earnings Statements to Security Holders. The Company shall make generally available to its security holders as soon as practicable,
but not later than the first day of the fifteenth (15th) full calendar month following the date of this Agreement, an earnings
statement (which need not be certified by independent registered public accounting firm unless required by the Securities Act or the Securities
Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act) covering a period of
at least twelve (12) consecutive months beginning after the date of this Agreement.
3.13 Stabilization.
Neither the Company nor, to its knowledge, any of its employees, directors or stockholders (without the consent of the Placement Agent)
has taken or shall take directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to
cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Securities.
3.14 Internal
Controls. The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i)
transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary
in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii) access
to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
3.15 Accountants.
As of the date of this Agreement, the Company shall continue to retain a nationally recognized independent registered public accounting
firm for a period of at least three (3) years after the date of this Agreement. The Placement Agent acknowledges that the Auditor is acceptable
to the Placement Agent.
3.16 FINRA.
The Company shall advise the Placement Agent (who shall make an appropriate filing with FINRA) if it is or becomes aware that (i) any
officer or director of the Company, (ii) any beneficial owner of 5% or more of any class of the Company’s securities or (iii) any
beneficial owner of the Company’s unregistered equity securities which were acquired during the 180 days immediately preceding the
filing of the Offering Statement is or becomes an affiliate or associated person of a FINRA member participating in the Offering (as determined
in accordance with the rules and regulations of FINRA).
3.17 No
Fiduciary Duties. The Company acknowledges and agrees that the Placement Agent’s responsibility to the Company is solely contractual
in nature and that none of the Placement Agent or their affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity,
or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions
contemplated by this Agreement.
3.18 Restriction
on Continuous Offerings. Notwithstanding the restrictions contained in Section 3.19, the Company, on behalf of itself and any successor
entity, agrees that, without the prior written consent of the Placement Agent, it will not, for a period of ninety (90) days after the
date of this Agreement, directly or indirectly in any “at-the-market” or continuous equity transaction, offer to sell, sell,
contract to sell, grant any option to sell or otherwise dispose of shares of capital stock of the Company or any securities convertible
into or exercisable or exchangeable for shares of capital stock of the Company.
3.19 Company
Lock-Up Agreements. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of
the Placement Agent, it will not for a period of [*] ([*]) days after the date of this Agreement (the “Lock-Up Period”),
(i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock
of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file
or cause to be filed any registration statement with the Commission relating to the offering of any shares of capital stock of the Company
or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company other than a registration
statement on Form S- 4 or Form S-8; (iii) complete any offering of debt securities of the Company, other than entering into a line of
credit with a traditional bank or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii), (iii)
or (iv) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.
The restrictions contained in this Section 3.19 shall not apply to (i) the shares of Common Stock to be sold hereunder, (ii) the issuance
by the Company of shares of Common Stock upon the exercise of a stock option or warrant or the conversion of a security outstanding on
the date hereof, which is disclosed in the Registration Statement, Disclosure Package and Prospectus, provided that such options, warrants,
and securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise
price, exchange price or conversion price of such securities, (iii) the issuance by the Company of stock options, shares of capital stock
of the Company or other awards under any equity compensation plan of the Company, provided that in each of (ii) and (iii) above, the
underlying shares shall be restricted from sale during the entire Lock-Up Period, (iv) the issuance by the Company of restricted shares
of Common Stock in connection with mergers, acquisitions or joint ventures, provided that such securities are issued as “restricted
securities” (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement
in connection therewith during the Lock-Up Period, and provided that any such issuance shall only be to a Person (or to the equityholders
of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with
the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not
include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary
business is investing in securities, and (v) the issuance by the Company of restricted shares of Common Stock to consultants in the Company’s
ordinary course of business and not for capital raising transactions and carry no registration rights that require or permit the filing
of any registration statement in connection therewith during the Lock-Up Period.
3.20 [Reserved].
3.21 Blue
Sky Qualifications. The Company shall use its reasonable best efforts, in cooperation with the Placement Agent, if necessary, to qualify
the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign)
as the Placement Agent may designate and to maintain such qualifications in effect so long as required to complete the distribution of
the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify
as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation
in respect of doing business in any jurisdiction in which it is not otherwise so subject.
3.22 Reporting
Requirements. The Company, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by
Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed with the Commission
pursuant to the Exchange Act within the time periods required by the Exchange Act and Rules and Regulations. Additionally, the Company
shall report the use of proceeds from the issuance of the Securities as may be required under Rule 463 under the Rules and Regulations.
3.23 Press
Release. Prior to a Closing Date and for a period of thirty (30) days after such Closing Date,
the Company shall not issue any press release or other communication directly or indirectly or hold any press conference or engage in
any other publicity with respect to the Company, its condition, financial or otherwise, or earnings, business affairs or business prospects
(except for routine and customary releases and oral marketing communications in the ordinary course of business and consistent with the
past practices of the Company and of which the Placement Agent is notified), without the prior written consent of the Placement Agent,
which consent shall not be unreasonably withheld, unless in the judgment of the Company and its counsel, and after notification to the
Placement Agent, such press release or communication is required by law.
3.24 Sarbanes
Oxley. The Company shall at all times comply with all applicable provisions of the Sarbanes Oxley Act in effect from time to time.
3.25 [Reserved].
3.26 Board
Composition and Board Designations. The Company shall ensure that: (i) the qualifications of the persons serving as members of the
Board of Directors and the overall composition of the Board comply with the Sarbanes-Oxley Act, with the Exchange Act and with the listing
rules of the Exchange or any other national securities exchange, as the case may be, in the event the Company seeks to have its Securities
listed on another exchange or quoted on an automated quotation system, and (ii) if applicable, at least one member of the Audit Committee
of the Board of Directors qualifies as an “audit committee financial expert,” as such term is defined under Regulation S-K
and the listing rules of the Exchange.
4. Representations
and Warranties of the Placement Agent. The Placement Agent represents and warrants to the Company as of each Closing Date as follows:
4.1.1. Authority.
This Agreement has been duly authorized, executed and delivered by the Placement Agent, and upon due execution and delivery by the Company,
this Agreement will be a valid and binding agreement of the Placement Agent enforceable against it in accordance with its terms, except
as may be limited by principles of public policy and, as to enforceability, subject to applicable bankruptcy, insolvency, reorganization,
moratorium and similar laws relating to or affecting creditor's rights from time to time in effect and subject to general equity principles.
4.1.2. No
Conflict. None of the execution or delivery of or performance by the Placement Agent under this Agreement or any other agreement or
document entered into by the Placement Agent in connection herewith or the consummation of the transactions herein or therein contemplated
conflicts with or violates, any agreement or other instrument to which the Placement Agent is a party or by which its assets may be bound,
or its limited liability company agreement, or any license, permit, judgment, decree, order, statute, rule or regulation applicable to
the Placement Agent or any of its assets, except in each case as would not have a material adverse effect on the transactions contemplated
hereby.
4.1.3. Compliance
with FINRA. The Placement Agent is a member in good standing of FINRA and is registered as a broker-dealer under the Exchange Act,
and under the securities acts of each state into which it is making offers or sales of the Securities. The Placement Agent is in compliance
with all applicable rules and regulations of the Commission and FINRA, except to the extent that such noncompliance would not have a material
adverse effect on the transactions contemplated hereby. None of the Placement Agent or its affiliates, or any person acting on behalf
of the foregoing (other than the Company or its affiliates or any person acting on its or their behalf, in respect of which no representation
is made) has taken nor will take any action that conflicts with the conditions and requirements of, or that would make unavailable with
respect to the Offering, the exemption(s) from registration available pursuant to Section 4(a)(2) of the Securities Act or knows of any
reason why any such exemption would be otherwise unavailable to it.
4.1.4. No
Disqualification Event. Neither the Placement Agent nor any of the Placement Agents Related Persons (as defined below) are subject
to any Disqualification Event as of the date hereof. The Placement Agent has exercised reasonable care to determine whether any Placement
Agent Related Person is subject to such a Disqualification Event. As used herein, “Placement Agent Related Persons”
means any predecessor of the relevant Placement Agent, any affiliated issuer, any director, executive officer, other officer of the Placement
Agent participating in the Offering, any general partner or managing member of the Placement Agent, any beneficial owner of 20% or more
of the Placement Agent’s outstanding voting equity securities, calculated on the basis of voting power, and any “promoter”
(as defined in Rule 405 under the Securities Act) connected with the Placement Agent in any capacity. The Placement Agent agrees to promptly
notify the Company in writing of (i) any Disqualification Event relating to any Placement Agent Related Person and (ii) any event that
would, with the passage of time, become a Disqualification Event relating to any Placement Agent Related Person.
4.1.5. [Reserved].
4.1.6. FINRA
Affiliations. There are no affiliations with any FINRA member firm among the Company's officers, directors or, to the knowledge of
the Company, any five percent (5.0%) or greater stockholder of the Company, except as set forth in the Offering Statement.
5. Conditions
to Closing. The obligations of the Investors to purchase and pay for the Securities, shall be subject to (i) the continuing accuracy
of the representations and warranties of the Company and the Placement Agent as of the date hereof and as of each Closing Date; (ii) the
accuracy of the statements of officers of the Company made pursuant to the provisions hereof; (iii) the performance by the Company of
its obligations hereunder; and (iv) the following conditions:
5.1 Regulatory
Matters.
5.1.1. Commission
Actions; Required Filings. On each Closing Date, no stop order suspending the qualification of the Offering Statement or any post-qualification
amendment thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Offering Circular
or the Offering Circular has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company’s
knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information.
An Offering Circular shall have been filed with the Commission in the manner and within the time frame required by Rule 253 under the
Rules and Regulations or a post-qualification amendment providing such information shall have been filed with, and qualified by, the Commission
in accordance with the requirements under the Rules and Regulations.
5.1.2. Exchange
Clearance. On each Closing Date, the Company’s shares of Common Stock shall have been approved for listing on the Exchange,
subject only to official notice of issuance.
5.2 Company
Counsel Matters.
5.2.1. Closing
Date Opinion of U.S. Counsel for the Company. On the initial Closing Date, the Placement Agent shall have received the opinion of
McGuireWoods LLP, U.S. counsel to the Company, and a written statement providing certain “10b-5” negative assurances, dated
the initial Closing Date and addressed to the Placement Agent, in a form reasonably acceptable to the Placement Agent.
5.2.2. Closing
Date Opinion of Nevada Counsel for the Company. On the initial Closing Date, the Placement Agent shall have received the favorable
opinion of Fennemore Craig, P.C., Nevada counsel to the Company, dated the initial Closing Date and addressed to the Placement Agent,
in a form reasonably acceptable to the Placement Agent.
5.2.3. Opinion
of Special Intellectual Property Counsels for the Company. On the initial Closing Date, the Placement Agent shall have received the
opinions of Knobbe Martens and Mcdonnell Boehnen Hulbert & Berghoff LLP , as special intellectual property counsel for the Company,
and a written statement providing certain "10b-5" negative assurances, dated the initial Closing Date and addressed to the Placement
Agent, in a form reasonably acceptable to the Placement Agent.
5.2.4. Reliance.
In rendering such opinions, such counsel may rely: (i) as to matters involving the application of laws other than the laws of the United
States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified in such opinion,
if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Placement Agent) of other counsel reasonably
acceptable to the Placement Agent, familiar with the applicable laws; and (ii) as to matters of fact, to the extent they deem proper,
on certificates or other written statements of officers of the Company and officers of departments of various jurisdictions having custody
of documents respecting the corporate existence or good standing of the Company, provided that copies of any such statements or certificates
shall be delivered to Placement Agent Counsel if requested.
5.3 Comfort
Letters.
5.3.1. Cold
Comfort Letter. On the initial Closing Date, the Placement Agent shall have received a cold comfort letter containing statements and
information of the type customarily included in accountants’ comfort letters with respect to the financial statements and certain
financial information contained or incorporated by reference or deemed incorporated by reference in the Offering Statement, the Preliminary
Offering Circular and the Offering Circular, addressed to the Placement Agent and in form and substance satisfactory in all respects to
you and to the Auditor, dated as of the date of this Agreement.
5.3.2. Intentionally
Omitted.
5.4 Officers’
Certificates.
5.4.1. Officers’
Certificate. The Company shall have furnished to the Placement Agent a certificate, dated the initial Closing Date, of its Chief Executive
Officer and its Chief Financial Officer stating that (i) such officers have carefully examined the Offering Statement, the Preliminary
Offering Circular and the Offering Circular and, in their opinion, the Offering Statement, the Preliminary Offering Circular and the Offering
Circular, as of the respective dates thereof and each Closing Date, did not include any untrue statement of a material fact and did not
omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) since the
qualification date of the Offering Statement, no event has occurred which should have been set forth in a supplement or amendment to the
Offering Statement, the Preliminary Offering Circular or the Offering Circular, (iii) to the best of their knowledge after reasonable
investigation, as of the initial Closing Date, the representations and warranties of the Company in this Agreement are true and correct
in all material respects (except for those representations and warranties qualified as to materiality, which shall be true and correct
in all respects and except for those representations and warranties which refer to facts existing at a specific date, which shall be true
and correct as of such date) and the Company has complied with all agreements and satisfied all conditions on its part to be performed
or satisfied hereunder at or prior to the initial Closing Date, and (iv) there has not been, subsequent to the date of the most recent
audited financial statements included or incorporated by reference in the Disclosure Package, any material adverse change in the financial
position or results of operations of the Company, or any change or development that, singularly or in the aggregate, would involve a material
adverse change or a prospective material adverse change, in or affecting the condition (financial or otherwise), results of operations,
business, assets or prospects of the Company, except as set forth in the Offering Statement, the Preliminary Offering Circular and the
Offering Circular.
5.4.2. Secretary’s
Certificate. On the initial Closing Date, the Placement Agent shall have received a certificate of the Company signed by the Secretary
of the Company, dated the initial Closing Date, certifying: (i) that each of the Charter and Bylaws is true and complete, has not been
modified and is in full force and effect; (ii) that the resolutions of the Company’s Board of Directors relating to the Offering
are in full force and effect and have not been modified; (iii) as to the accuracy and completeness of all correspondence between the Company
or its counsel and the Commission; and (iv) as to the incumbency of the officers of the Company. The documents referred to in such certificate
shall be attached to such certificate.
5.4.3. Intentionally
Omitted.
5.5 No
Material Changes. Prior to and on each of the Closing Date: (i) there shall have been no Material Adverse Change or development involving
a prospective Material Adverse Change from the latest dates as of which such condition is set forth in the Offering Statement, the Preliminary
Offering Circular and the Offering Circular and no change in the capital stock or debt of the Company; (ii) no action, suit or proceeding,
at law or in equity, shall have been pending or threatened against the Company or any Insider before or by any court or federal or state
commission, board or other administrative agency wherein an unfavorable decision, ruling or finding may materially adversely affect the
business, operations, properties, assets, prospects or financial condition or income of the Company, except as set forth in the Offering
Statement, the Preliminary Offering Circular and the Offering Circular; (iii) no stop order shall have been issued under the Securities
Act and no proceedings therefor shall have been initiated or threatened by the Commission; (iv) no action shall have been taken and no
law, statute, rule, regulation or order shall have been enacted, adopted or issued by any Governmental Entity which would prevent the
issuance or sale of the Securities or materially and adversely affect or potentially materially and adversely affect the business or operations
of the Company; (v) no injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction
shall have been issued which would prevent the issuance or sale of the Securities or materially and adversely affect or potentially materially
and adversely affect the business or operations of the Company; and (vi) the Offering Statement, the Preliminary Offering Circular and
the Offering Circular and any amendments or supplements thereto shall contain all material statements which are required to be stated
therein in accordance with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements
of the Securities Act and the Securities Act Regulations, and neither the Offering Statement, the Preliminary Offering Circular and the
Offering Circular nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading.
5.6 Corporate
Proceedings. All corporate proceedings and other legal matters incident to the authorization, form and validity of each of this Agreement,
the Securities, the Offering Statement, the Preliminary Offering Circular and the Offering Circular and all other legal matters relating
to this Agreement and the transactions contemplated hereby and thereby shall be reasonably satisfactory in all material respects to counsel
for the Placement Agent, and the Company shall have furnished to such counsel all documents and information that they may reasonably request
to enable them to pass upon such matters.
5.7 Delivery
of Agreements.
5.7.1. [Reserved].
5.7.2. Placement
Agent’s Warrant Agreement. On each Closing Date, the Company shall have delivered to the Placement Agent executed copies of
the Placement Agent’s Warrant Agreement.
5.8 Additional
Documents. On each Closing Date, Placement Agent Counsel shall have been furnished with such documents and opinions as they may require
for the purpose of enabling Placement Agent Counsel to deliver an opinion to the Placement Agent, or in order to evidence the accuracy
of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken
by the Company in connection with the issuance and sale of the Securities and the as herein contemplated shall be satisfactory in form
and substance to the Placement Agent and Placement Agent Counsel.
6.1 General.
Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless the Placement Agent, its affiliates and each
of its and their respective directors, officers, members, employees, representatives, partners, stockholders, affiliates, counsel, and
agents and each person, if any, who controls any such Placement Agent within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act (collectively the “Placement Agent Indemnified Parties,” and each a “Placement Agent
Indemnified Party”), against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to
any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or
threatened, or any claim whatsoever, whether arising out of any action between any of the Placement Agent Indemnified Parties and the
Company or between any of the Placement Agent Indemnified Parties and any third party, or otherwise) to which they or any of them may
become subject under the Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws of foreign
countries (a “Claim”), (i) arising out of or based upon any untrue statement or alleged untrue statement of a material
fact contained in (A) the Offering Statement, the Preliminary Offering Circular and the Offering Circular(as from time to time each may
be amended and supplemented); (B) any materials or information provided to investors by, or with the approval of, the Company in connection
with the marketing of the Offering, including any “road show” or investor presentations made to investors by the Company (whether
in person or electronically); or (C) any application or other document or written communication (in this Section 5, collectively called
“application”) executed by the Company or based upon written information furnished by the Company in any jurisdiction in order
to qualify the Securities and Placement Agent’s Securities under the securities laws thereof or filed with the Commission, any state
securities commission or agency, the Exchange or any other national securities exchange; or the omission or alleged omission therefrom
of a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading, unless such statement or omission was made in reliance upon, and in conformity with, the Placement
Agents’ Information or (ii) otherwise arising in connection with or allegedly in connection with the Offering. The Company also
agrees that it will reimburse each Placement Agent Indemnified Party for all fees and expenses (including but not limited to any and all
legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened,
or any claim whatsoever, whether arising out of any action between any of the Placement Agent Indemnified Parties and the Company or between
any of the Placement Agent Indemnified Parties and any third party, or otherwise) (collectively, the “Expenses”), and
further agrees wherever and whenever possible to advance payment of Expenses as they are incurred by an Placement Agent Indemnified Party
in investigating, preparing, pursuing or defending any Claim.
6.1.1. Procedure.
If any action is brought against an Placement Agent Indemnified Party in respect of which indemnity may be sought against the Company
pursuant to Section 5.1.1, such Placement Agent Indemnified Party shall promptly notify the Company in writing of the institution of such
action and the Company shall assume the defense of such action, including the employment and fees of counsel (subject to the approval
of such Placement Agent Indemnified Party) and payment of actual expenses if an Placement Agent Indemnified Party requests that the Company
do so. Such Placement Agent Indemnified Party shall have the right to employ its or their own counsel in any such case, but the fees and
expenses of such counsel shall be at the expense of the Company, and shall be advanced by the Company; provider however, that the Company
shall not be obligated to bear the reasonable fees and expenses of more than one firm of attorneys selected by the Placement Agent Indemnified
Party (in addition to any local counsel). The Company shall not be liable for any settlement of any action effected without its consent
(which shall not be unreasonably withheld). In addition, the Company shall not, without the prior written consent of the Placement Agents,
settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate any pending or threatened action in respect
of which advancement, reimbursement, indemnification or contribution may be sought hereunder (whether or not such Placement Agent Indemnified
Party is a party thereto) unless such settlement, compromise, consent or termination (i) includes an unconditional release of each Placement
Agent Indemnified Party, acceptable to such Placement Agent Indemnified Party, from all liabilities, expenses and claims arising out of
such action for which indemnification or contribution may be sought and (ii) does not include a statement as to or an admission of fault,
culpability or a failure to act, by or on behalf of any Placement Agent Indemnified Party.
6.2 [Reserved].
6.3 Contribution.
6.3.1. Contribution
Rights. If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient to hold harmless
an indemnified party under Section 5.1 or 5.2 in respect of any loss, claim, damage or liability, or any action in respect thereof, referred
to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid or payable
by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof, (i) in such proportion as
shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and the Placement Agents, on the other,
from the Offering of the Securities, or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of
the Company, on the one hand, and the Placement Agents, on the other, with respect to the statements or omissions that resulted in such
loss, claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations. The relative benefits
received by the Company, on the one hand, and the Placement Agent, on the other, with respect to such Offering shall be deemed to be in
the same proportion as the total net proceeds from the Offering of the Securities purchased under this Agreement (before deducting expenses)
received by the Company, as set forth in the table on the cover page of the Offering Circular, on the one hand, and the total underwriting
discounts and commissions received by the Placement Agents with respect to the shares of the Common Stock purchased under this Agreement,
as set forth in the table on the cover page of the Offering Circular, on the other hand. The relative fault shall be determined by reference
to whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates
to information supplied by the Company or the Placement Agents, the intent of the parties and their relative knowledge, access to information
and opportunity to correct or prevent such statement or omission. The Company and the Placement Agents agree that it would not be just
and equitable if contributions pursuant to this Section 5.3.1 were to be determined by pro rata allocation (even if the Placement Agents
were treated as one entity for such purpose) or by any other method of allocation that does not take into account the equitable considerations
referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or action
in respect thereof, referred to above in this Section 5.3.1 shall be deemed to include, for purposes of this Section 5.3.1, any legal
or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this Section 5.3.1 in no event shall an Placement Agent be required to contribute any amount in excess
of the amount by which the total underwriting discounts and commissions received by such Placement Agent with respect to the Offering
of the Securities exceeds the amount of any damages that such Placement Agent has otherwise been required to pay by reason of such untrue
or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
6.3.2. Contribution
Procedure. Within fifteen (15) days after receipt by any party to this Agreement (or its Placement Agent) of notice of the commencement
of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party
(“contributing party”), notify the contributing party of the commencement thereof, but the failure to so notify the contributing
party will not relieve it from any liability which it may have to any other party other than for contribution hereunder. In case any such
action, suit or proceeding is brought against any party, and such party notifies a contributing party or its Placement Agent of the commencement
thereof within the aforesaid 15 days, the contributing party will be entitled to participate therein with the notifying party and any
other contributing party similarly notified. Any such contributing party shall not be liable to any party seeking contribution on account
of any settlement of any claim, action or proceeding affected by such party seeking contribution on account of any settlement of any claim,
action or proceeding affected by such party seeking contribution without the written consent of such contributing party. The contribution
provisions contained in this Section 5.3.2 are intended to supersede, to the extent permitted by law, any right to contribution under
the Securities Act, the Exchange Act or otherwise available.
7. Right
of First Refusal. Provided that the Securities are sold in accordance with the terms of this Agreement that results in not less than
$5 million in net proceeds to the Company, the Placement Agent shall have a right of first refusal (the "Right of First Refusal"),
for a period of twelve (12) months after the date hereof, to act, except as set forth below, as sole financial advisor, sole investment
banker, sole book- runner and/or sole placement agent, at the Placement Agent’s sole discretion, for each and every (i) disposition
or acquisition of business units or acquisition of any outstanding securities or any exchange or tender offer or merger, consolidation
or other business combination or any recapitalization, reorganization, restructuring or other similar transaction; (ii) financing or refinancing
of any indebtedness; or (iii) future public and private equity offering that is not an “at-the-market” offering (an ATM executed
through a broker dealer as sales agent), and sole investment banker, sole book-runner and/or sole placement agent, at the Placement Agent’s
sole discretion, for each and every future debt offering (items (i), (ii) and (iii), a “Future Transaction”), including
all equity linked financings, during such twelve (12) month period for the Company, or any successor to or any subsidiary of the Company,
on reasonable and customary terms. If the Company intends to enter into a definitive agreement with a third party for a Future Transaction,
the Company shall provide the Placement Agent with a written notice (the “ROFR Notice") describing in detail all the
material commercial terms and conditions of the proposed agreement, including the scope of the financial advisory, underwriting or placement
services, the pricing and payment terms, and the duration and termination rights. The Company shall provide the ROFR Notice to the Placement
Agent at least thirty (30) days before the anticipated execution date of the proposed agreement. Within ten (10) days after receiving
the ROFR Notice, the Placement Agent may elect, by written notice to the Company, to exercise the ROFR pursuant to which the Placement
Agent shall have the right to act as sole financial advisor, investment banker, sole book-runner and/or sole placement agent for such
Future Transaction on commercial terms that are substantially the same as those set forth in in ROFR Notice and on such other reasonable
and customary terms for such Future Transaction as the Company and the Placement Agent shall manually agree. If the Placement Agent exercises
the Right of First Refusal, the parties shall negotiate in good faith to execute a financial advisory, underwriting or placement agent
agreement for the Future Transaction within twenty (20) days after the Placement Agent's notice to the Company exercising the Right of
First Refusal, unless otherwise mutually agreed by the Company and the Placement Agent. If the Placement Agent does not exercise the Right
of First Refusal within the 10-day period set forth above, the Company shall be free to enter into the proposed agreement with the third
party for such Future Transaction. The Placement Agent shall have the sole right to determine whether or not any other broker dealer shall
have the right to participate in any such Future Transaction and the economic terms of any such participation; provided that the Placement
Agent shall consider in good faith any broker dealer(s) proposed by the Company. The parties also agree that a Future Transaction shall
not be deemed to include, and no Right of First Refusal is granted to the Placement Agent in connection with, any of the following: (a)
any equity securities directly issued by the Company pursuant to acquisitions or strategic transactions, including as part of any grant
funding from a third party, or (b) any offer or sale of equity securities by the Company directly to non-U.S. persons domiciled in the
following jurisdictions: China, Korea, Latin America (ex Caribbean and the Cayman Islands) and Middle East, in each case, in a private
placement not otherwise involving a public offering. Notwithstanding anything to the contrary set forth above in this Section 7, the Placement
Agent acknowledges that the Company is subject to a pre-existing agreement with a third party under which such third party has a right
of first refusal to act as the co-lead bookrunning underwriter, co-lead initial purchaser, co-lead placement agent or co-lead selling
agent, as the case may be, on any financing involving equity securities for the Company (the “Prior ROFR”). In the
case the Placement Agent wishes to exercise its Right of First Refusal hereunder, the Company will use its commercially reasonable efforts
to obtain a waiver of the Prior ROFR, but if such efforts are not successful, then the rights granted above to the Placement Agent for
any Future Transaction for Company equity securities shall be deemed to provide the Placement Agent the rights to be left lead bookrunner,
left lead placement agent or left lead selling agent, as applicable, with the Placement Agent retaining a minimum of 65% of the economics
for such equity financing. The Placement Agent may elect, in its sole and absolute discretion, not to exercise its Right of First Refusal
with respect to any Future Transaction; provided that any such election by the Placement Agent shall not adversely affect the Placement
Agent's Right of First Refusal with respect to any other Future Transaction during the twelve (12) month period agreed to above.
| 8. | Effective Date of this Agreement and Termination Thereof. |
8.1 Effective
Date. This Agreement shall become effective when both the Company and the Placement Agent have executed the same and delivered counterparts
of such signatures to the other party.
8.2 Termination.
The term of the Placement Agent’s exclusive engagement will be as set forth in the Engagement Agreement (as defined below). Notwithstanding
anything to the contrary contained herein, the provisions concerning confidentiality, indemnification and contribution contained herein
and the Company’s obligations contained in the indemnification provisions will survive any expiration or termination of this Agreement,
and the Company’s obligation to pay fees actually earned and payable and to reimburse expenses actually incurred and reimbursable
pursuant to Section 1 hereof and which are permitted to be reimbursed under FINRA Rule 5110(g)(4)(A), will survive any expiration or termination
of this Agreement. Nothing in this Agreement shall be construed to limit the ability of the Placement Agent or its Affiliates to pursue,
investigate, analyze, invest in, or engage in investment banking, financial advisory or any other business relationship with Persons (as
defined below) other than the Company. As used herein (i) “Persons” means an individual or corporation, partnership, trust,
incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or
subdivision thereof) or other entity of any kind and (ii) “Affiliate” means any Person that, directly or indirectly through
one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed
under Rule 405 under the Securities Act.
8.3 Expenses.
Notwithstanding anything to the contrary in this Agreement, in the event that this Agreement shall not be carried out for any reason whatsoever,
within the time specified herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the
Placement Agent their actual and accountable out-of-pocket expenses related to the transactions contemplated herein then due and payable
(including the fees and disbursements of Placement Agent Counsel) up to $125,000, and upon demand the Company shall pay the full amount
thereof to the Placement Agent; provided, however, that such expense cap in no way limits or impairs the indemnification and contribution
provisions of this Agreement. Notwithstanding the foregoing, any advance received by the Placement Agent will be reimbursed to the Company
to the extent not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).
8.4 Indemnification.
Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and whether
or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in full force and effect and shall not be in
any way affected by, such election or termination or failure to carry out the terms of this Agreement or any part hereof.
8.5 Representations,
Warranties, Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates of
officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation
made by or on behalf of the Placement Agent or its Affiliates or selling agents, any person controlling the Placement Agent, its officers
or directors or any person controlling the Company or (ii) delivery of and payment for the Securities.
9.1 Notices.
All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or
certified mail, return receipt requested), personally delivered or sent by electronic mail transmission and confirmed and shall be deemed
given when so delivered and confirmed or if mailed, two (2) days after such mailing.
If to the Representative:
ThinkEquity LLC
17 State Street, 41st
Floor
New York, New York 10004
Attn: Head of Investment Banking
Email: Notices@think-equity.com
with a copy (which shall not
constitute notice) to:
Sheppard, Mullin, Richter
& Hampton LLP
30 Rockefeller Plaza, 39th
Floor
New York, New York 10112
Attn: Jeffrey Fessler and
Stephen Cohen
e-mail: jfessler@sheppardmullin.com
and scohen@sheppardmullin.com
If to the Company:
BioVie Inc.
680 W Nye Lane, Suite 204
Carson City, Nevada 89703
Attention: Cuong Do, CEO
Email: cdo@bioviepharma.com
with a copy (which shall not
constitute notice) to:
McGuireWoods LLP
1251 6th Ave 20th Floor
New York, NY 10020
Attn: Stephen Older and Carly Ginley
e-mail: solder@mcguirewoods.com and
cginley@mcguirewoods.com
9.2 Research
Analyst Independence. The Company acknowledges that the Placement Agent’s research analysts and research departments are required
to be independent from its investment banking division and are subject to certain regulations and internal policies, and that the Placement
Agent’s research analysts may hold views and make statements or investment recommendations and/or publish research reports with
respect to the Company and/or the Offering that differ from the views of their investment banking division. The Company acknowledges that
the Placement Agent is a full service securities firm and as such from time to time, subject to applicable securities laws, rules and
regulations, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity
securities of the Company; provided, however, that nothing in this Section 8.2 shall relieve the Placement Agent of any responsibility
or liability it may otherwise bear in connection with activities in violation of applicable securities laws, rules or regulations.
9.3 Headings.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning
or interpretation of any of the terms or provisions of this Agreement.
9.4 Amendment.
This Agreement may only be amended by a written instrument executed by each of the parties hereto.
9.5 Entire
Agreement. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this
Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and supersedes
all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. Notwithstanding anything
herein to the contrary, the Engagement Agreement, dated December 18, 2024 (“Engagement Agreement”), between the Company
and the Placement Agent shall continue to be effective and the terms therein shall continue to survive and be enforceable by the Placement
Agent in accordance with its terms, provided that, in the event of a conflict between the terms of the Engagement Agreement and this Agreement,
the terms of this Agreement shall prevail.
9.6 Binding
Effect. This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Placement Agent, the
Company and the controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors, legal representatives,
heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect
of or by virtue of this Agreement or any provisions herein contained. The term “successors and assigns” shall not include
a purchaser, in its capacity as such, of securities from any of the Placement Agent.
9.7 Governing
Law; Consent to Jurisdiction; Trial by Jury. This Agreement shall be governed by and construed and enforced in accordance with the
laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action,
proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in the New York
Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits
to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and
that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting
a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in
Section 9.1 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding
or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies)
all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection with the
preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates)
and each of the Placement Agent hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
9.8 Execution
in Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts,
each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall
become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties
hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient
delivery thereof.
9.9 Waiver,
etc. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or
construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof or the
right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non- compliance
or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by
the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment
shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.
[Signature Page Follows]
If the foregoing correctly
sets forth the understanding between the Placement Agent and the Company, please so indicate in the space provided below for that purpose,
whereupon this letter shall constitute a binding agreement between us.
| |
Very truly yours, |
| |
|
| |
BIOVIE INC. |
| |
|
|
| |
By: |
|
| |
|
Name: |
| |
|
Title: |
Confirmed as of the date first written above mentioned
THINKEQUITY LLC
| By: |
|
|
| |
Name: |
Kevin Mangan |
|
| |
Title: |
Managing Director, Head of Equity Syndicate |
|
[Signature Page to the Placement Agency Agreement]
SCHEDULE 1
Company Introduced Investors
Tcgx
Perceptive
Soleus
Suvretta
Octagon
Braidwell
Deep
Track
Great
Point
Longitude
Nantahala
GordonMD
Ally
Bridge
Blackstone
Orbimed
Surveyor
Adar1
Dellora
Jasper
EXHIBIT A
Form of Placement Agent’s Warrant Agreement
THE REGISTERED HOLDER OF THIS PURCHASE WARRANT
BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED
HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD
OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE COMMENCEMENT DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) THINKEQUITY LLC OR A PLACEMENT AGENT
OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF THINKEQUITY LLC OR OF ANY SUCH PLACEMENT
AGENT OR SELECTED DEALER.
THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR
TO [*], 2025. VOID AFTER 5:00 P.M., EASTERN TIME, [*], 2030.
WARRANT TO PURCHASE COMMON STOCK
BIOVIE INC.
| Warrant Shares: [*] |
Initial Issuance Date: [*] |
THIS WARRANT TO PURCHASE COMMON
STOCK (“Warrant”) certifies that, for value received,
or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after [*], 2025 (the “Initial Exercise Date”) and, in accordance with FINRA
Rule 5110(g)(8)(A), prior to at 5:00 p.m. (New York time) on the date that is five (5) years following the Commencement Date (the “Termination
Date”) but not thereafter, to subscribe for and purchase from BioVie Inc., a Nevada corporation (the “Company”),
up to [*] shares of Class A Common Stock, par value $0.0001 per share, of the Company (the “Warrant Shares”), as subject
to adjustment hereunder. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b).
Section 1. Definitions.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:
“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.
“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.
“Commencement
Date” means [*], 2025, the date on which sales of the securities issued in the Offering commenced.
“Commission”
means the United States Securities and Exchange Commission.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Offering”
shall have the meaning ascribed to such term in the Placement Agent Agreement.
“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
“Placement
Agent Agreement” means the placement agent agreement, dated October 28, 2024, by and between the Company and the Holder as placement
agent set forth therein.
“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
“Trading
Day” means a day on which the Nasdaq Capital Market is open for trading.
“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).
“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock then listed or quoted
on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the
Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of a share of Common Stock for such date (or the nearest preceding date) on the OTCQB or OTCQX as applicable, (c) if Common Stock is not
then listed or quoted for trading on the OTCQB or OTCQX and if prices for Common Stock are then reported in the “Pink Sheets”
published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent
bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of the Common Stock as determined by
an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which
shall be paid by the Company.
Section 2. Exercise.
a) Exercise
of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise
Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate
by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile
copy (or e-mail attachment) of the Notice of Exercise Form annexed hereto. Within one (1) Trading Day following the date of exercise as
aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire
transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below
is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company
for cancellation within five (5) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises
of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of
lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares
purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases.
The Company shall deliver any objection to any Notice of Exercise Form within one (1) Business Day of receipt of such notice. The Holder
and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given
time may be less than the amount stated on the face hereof.
b) Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $[*], subject to adjustment hereunder (the
“Exercise Price”).
c) Cashless
Exercise. In lieu of exercising this Warrant by delivering the aggregate Exercise Price by wire transfer or cashier’s check,
at the election of the Holder this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise”
in which the Holder shall be entitled to receive the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by
(A), where:
| |
(A) = |
the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless exercise,” as set forth in the applicable Notice of Exercise; |
| |
|
|
| |
(B) = |
the Exercise Price of this Warrant, as adjusted hereunder; and |
| |
|
|
| |
(X) = |
the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. |
If Warrant Shares
are issued in such a “cashless exercise,” the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of this Warrant being exercised, and the holding period
of this Warrant being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position
contrary to this Section 2(c).
Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).
d) Mechanics
of Exercise.
i. Delivery
of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by its transfer
agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner- of- sale limitations pursuant
to Rule 144 and, in either case, the Warrant Shares have been sold by the Holder prior to the Warrant Share Delivery Date (as defined
below), and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder
or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by
the Holder in the Notice of Exercise by the date that is one (1) Trading Day after the delivery to the Company of the Notice of Exercise
(such date, the “Warrant Share Delivery Date”) provided that the Company shall not be obligated to deliver the Warrant
Shares hereunder unless the Company has received the aggregate Exercise Price on or before the Warrant Share Delivery Date. If the Warrant
Shares can be delivered via DWAC, the transfer agent shall have received from the Company, at the expense of the Company, any legal opinions
or other documentation required by it to deliver such Warrant Shares without legend (subject to receipt by the Company of reasonable back
up documentation from the Holder, including with respect to affiliate status) and, if applicable and requested by the Company prior to
the Warrant Share Delivery Date, the transfer agent shall have received from the Holder a confirmation of sale of the Warrant Shares (provided
the requirement of the Holder to provide a confirmation as to the sale of Warrant Shares shall not be applicable to the issuance of unlegended
Warrant Shares upon a cashless exercise of this Warrant if the Warrant Shares are then eligible for resale pursuant to Rule 144(b)(1)).
The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed
to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the
Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant
to Section 2(d)(vi) prior to the issuance of such shares, having been paid. If the Company fails for any reason to deliver to the Holder
the Warrant Shares subject to a proper Notice of Exercise by the second Trading Day following the Warrant Share Delivery Date, provided
that payment of the aggregate Exercise Price (other than in the instance of a cashless exercise) is received by the Company by such date,
the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to
such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing
to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after the second Trading
Day following such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
ii. Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.
iii. Rescission
Rights. If the Company fails to cause its transfer agent to deliver to the Holder the Warrant Shares pursuant to Section 2(d)(i) by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise; provided, however, that the
Holder shall be required to return any Warrant Shares or Common Stock subject to any such rescinded exercise notice concurrently with
the return to Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and the restoration of Holder’s
right to acquire such Warrant Shares pursuant to this Warrant (including, issuance of a replacement warrant certificate evidencing such
restored right).
iv. Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if
the Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares pursuant to an exercise on or before the Warrant
Share Delivery Date (other than any such failure that is solely due to any action or inaction by the Holder with respect to such exercise),
and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which
the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder
the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver
to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation
was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of
shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of
the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to
timely deliver Warrant Shares upon exercise of the Warrant as required pursuant to the terms hereof.
v. No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.
vi. Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all transfer agent
fees required for same- day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established
clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.
vii. Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.
viii. Signature.
This Section 2 and the exercise form attached hereto set forth the totality of the procedures required of the Holder in order to exercise
this Purchase Warrant. Without limiting the preceding sentences, no ink-original exercise form shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any exercise form be required in order to exercise this Purchase Warrant. No
additional legal opinion, other information or instructions shall be required of the Holder to exercise this Purchase Warrant. The Company
shall honor exercises of this Purchase Warrant and shall deliver Warrant Shares underlying this Purchase Warrant in accordance with the
terms, conditions and time periods set forth herein.
e) Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership
Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the
Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which
such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of
the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole
discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether
this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of
this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to
verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Company’s
transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company
shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any
case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of
Common Stock was reported. The “Beneficial Ownership Limitation” shall be 9.99% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The
Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this
Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st
day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.
Section 3. Certain Adjustments.
a) Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification. For the purposes of clarification, the Exercise Price of this Warrant
will not be adjusted in the event that the Company or any subsidiary of the Company , as applicable, sells or grants any option to purchase,
or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase
or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less than the Exercise Price then
in effect.
b) [RESERVED]
c) Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right
to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall
not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result
of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).
d) Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other than
cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of shares or other securities, property or options by
way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "Distribution"),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided,
however, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the
Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be
held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such
Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised
this Warrant.
e) Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or
(v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin- off or scheme of arrangement) with another
Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including
any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons
making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable by holders of Common Stock as a result of such Fundamental Transaction for each share of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of
this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to
such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all
of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall
refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.
f) Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.
g) Notice
to Holder.
i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
to the Holder a notice by mail or e-mail setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.
ii. Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock (a reverse stock split shall not be deemed a reclassification), any consolidation or merger to which the Company is
a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common
Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed a notice to the Holder
at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
provide such notice or any defect therein shall not affect the validity of the corporate action required to be specified in such notice.
To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any
of the subsidiaries of the Company, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the
effective date of the event triggering such notice except as may otherwise be expressly set forth herein.
Section 4. Transfer of Warrant.
a) Transferability.
Pursuant to FINRA Rule 5110(e)(1), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred,
assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result
in the effective economic disposition of the securities by any person for a period of 180 days immediately following the Commencement
Date, except the transfer of any security:
1. by
operation of law or by reason of reorganization of the Company;
2. to
any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject
to the lock-up restriction in this Section 4(a) for the remainder of the time period;
3. if
the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the securities being offered;
4. that
is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or
otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund;
or
5. the
exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section 4(a) for
the remainder of the time period.
Subject to the foregoing
restriction, any applicable securities laws and the conditions set forth in Section 4(d), this Warrant and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date the Holder delivers an assignment form to the Company assigning this Warrant full. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.
b) New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.
c) Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.
d) Representation
by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.
Section 5. Registration Rights.
a) Grant
of Right. The Company, upon written demand (a “Demand Notice”) of the Holder(s) of at least 51% of the Warrants
and/or the underlying Warrant Shares (“Majority Holders”), agrees to register, on one occasion, all or any portion
of the Warrant Shares underlying the Warrants (collectively, the “Registrable Securities”). On such occasion, the Company
will file a registration statement with the Commission covering the Registrable Securities within sixty (60) days after receipt of a Demand
Notice and use its reasonable best efforts to have the registration statement declared effective promptly thereafter, subject to compliance
with review by the Commission; provided, however, that the Company shall not be required to comply with a Demand Notice if the Company
has filed a registration statement with respect to which the Holder is entitled to piggyback registration rights pursuant to Section 5.2
hereof and either: (i) the Holder has elected to participate in the offering covered by such registration statement or (ii) if such registration
statement relates to an underwritten primary offering of securities of the Company, until the offering covered by such registration statement
has been withdrawn or until thirty (30) days after such offering is consummated. The demand for registration may be made at any time beginning
on the Initial Exercise Date and expiring on the fifth anniversary of the Commencement Date in accordance with FINRA Rule 5110(g)(8)(C).
The Company covenants and agrees to give written notice of its receipt of any Demand Notice by any Holder(s) to all other registered Holders
of the Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of any such Demand Notice.
b) Terms.
The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 5.1.1, but
the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent
them in connection with the sale of the Registrable Securities. The Company agrees to use its reasonable best efforts to cause the filing
required herein to become effective promptly and to qualify or register the Registrable Securities in such States as are reasonably requested
by the Holder(s); provided, however, that in no event shall the Company be required to register the Registrable Securities in a State
in which such registration would cause: (i) the Company to be obligated to register or license to do business in such State or submit
to general service of process in such State, or (ii) the principal stockholders of the Company to be obligated to escrow their shares
of capital stock of the Company. The Company shall cause any registration statement filed pursuant to the demand right granted under Section
5.1.1 to remain effective for a period of at least twelve (12) consecutive months after the date that the Holders of the Registrable Securities
covered by such registration statement are first given the opportunity to sell all of such securities. The Holders shall only use the
prospectuses provided by the Company to sell the Warrant Shares covered by such registration statement, and will immediately cease to
use any prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer be used due to a material
misstatement or omission. Notwithstanding the provisions of this Section 5.1.2, the Holder shall be entitled to a demand registration
under this Section 5.1.2 on only one (1) occasion and such demand registration right shall terminate on the fifth anniversary of the Commencement
Date in accordance with FINRA Rules 5110(g)(8)(B) and 5110(g)(8)(C).
| 5.2 | “Piggy-Back” Registration. |
a) Grant
of Right. In addition to the demand right of registration described in Section 5.1 hereof, the Holder shall have the right, for a
period of no more than five (5) years from the Initial Exercise Date in accordance with FINRA Rule 5110(g)(8)(D), to include the Registrable
Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction contemplated
by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form); provided, however, that if, solely
in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall,
in its reasonable discretion, impose a limitation on the number of Shares which may be included in the Registration Statement because,
in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution,
then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities
with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable
Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable
Securities sought to be included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities unless
the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such
Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.
b) Terms.
The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 5.2.1 hereof, but
the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent
them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company shall furnish
the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice prior to the proposed date of
filing of such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed by
the Company during the five (5) year period following the Initial Exercise Date until such time as all of the Registrable Securities have
been sold by the Holder. The holders of the Registrable Securities shall exercise the “piggy-back” rights provided for herein
by giving written notice within ten (10) days of the receipt of the Company’s notice of its intention to file a registration statement.
Except as otherwise provided in this Warrant, there shall be no limit on the number of times the Holder may request registration under
this Section 5.2.2; provided, however, that such registration rights shall terminate on the second anniversary of the Initial Exercise
Date.
a) Indemnification.
The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder and
each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20 (a) of the Exchange
Act against all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other expenses reasonably
incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the Securities
Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and with the same effect as the
provisions pursuant to which the Company has agreed to indemnify the Placement Agent contained in Section 5.1 of the Placement Agent Agreement.
The Holder(s) of the Registrable Securities to be sold pursuant to such registration statement, and their successors and assigns, shall
severally, and not jointly, indemnify the Company, against all loss, claim, damage, expense or liability (including all reasonable attorneys’
fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which they may become
subject under the Securities Act, the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or
their successors or assigns, in writing, for specific inclusion in such registration statement to the same extent and with the same effect
as the provisions contained in Section 5.2 of the Placement Agent Agreement pursuant to which the Placement Agent has agreed to indemnify
the Company.
b) Exercise
of Warrants. Nothing contained in this Warrant shall be construed as requiring the Holder to exercise its Warrants prior to or after
the initial filing of any registration statement or the effectiveness thereof.
c) Documents
Delivered to Holders. The Company shall furnish to each Holder participating in any of the foregoing offerings and to each underwriter
of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel to the Company,
dated the effective date of such registration statement (and, if such registration includes an underwritten public offering, an opinion
dated the date of the closing under any underwriting agreement related thereto), and (ii) a “cold comfort” letter dated the
effective date of such registration statement (and, if such registration includes an underwritten public offering, a letter dated the
date of the closing under the underwriting agreement) signed by the independent registered public accounting firm which has issued a report
on the Company’s financial statements included in such registration statement, in each case covering substantially the same matters
with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants’ letter,
with respect to events subsequent to the date of such financial statements, as are customarily covered in opinions of issuer’s counsel
and in accountants’ letters delivered to underwriters in underwritten public offerings of securities. The Company shall also deliver
promptly to each Holder participating in the offering requesting the correspondence and memoranda described below and to the managing
underwriter, if any, copies of all correspondence between the Commission and the Company, its counsel or auditors and all memoranda relating
to discussions with the Commission or its staff with respect to the registration statement and permit each Holder and underwriter to do
such investigation, upon reasonable advance notice, with respect to information contained in or omitted from the registration statement
as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access
to books, records and properties and opportunities to discuss the business of the Company with its officers and independent auditors,
all to such reasonable extent and at such reasonable times as any such Holder shall reasonably request.
d) Placement
Agent Agreement. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected by any
Holders whose Registrable Securities are being registered pursuant to this Section 5, which managing underwriter shall be reasonably satisfactory
to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each Holder and such managing underwriters,
and shall contain such representations, warranties and covenants by the Company and such other terms as are customarily contained in agreements
of that type used by the managing underwriter. The Holders shall be parties to any underwriting agreement relating to an underwritten
sale of their Registrable Securities and may, at their option, require that any or all the representations, warranties and covenants of
the Company to or for the benefit of such underwriters shall also be made to and for the benefit of such Holders. Such Holders shall not
be required to make any representations or warranties to or agreements with the Company or the underwriters except as they may relate
to such Holders, their Warrant Shares and their intended methods of distribution.
e) Documents
to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company a
completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.
f) Damages.
Should the registration or the effectiveness thereof required by Sections 5.1 and 5.2 hereof be delayed by the Company or the Company
otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to the Holder(s),
be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions
or the continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other
security.
Section 6.
Miscellaneous.
a) No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).
b) Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any certificate relating to the Warrant Shares, and in case of
loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.
c) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.
d) Authorized
Shares.
The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).
Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.
Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.
e) Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Placement Agent Agreement.
f) Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.
g) Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this
Warrant or the Placement Agent Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which
results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.
h) Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Placement Agent Agreement.
i) Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.
j) Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.
k) Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.
l) Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.
m) Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.
n) Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.
********************
IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.
| |
BIOVIE INC. |
| |
|
|
| |
By: |
|
| |
|
Name: |
| |
|
Title: |
NOTICE OF EXERCISE
(1) The
undersigned hereby elects to purchase
Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment
of the exercise price in full, together with all applicable transfer taxes, if any.
(2) Payment
shall take the form of (check applicable box):
[ ] in lawful money of the
United States; or
[ ] if permitted the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).
(3) Please
register and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:
The Warrant Shares shall be delivered to the following
DWAC Account Number or by physical delivery of a certificate to:
(4) Accredited
Investor. If the Warrant is being exercised via cash exercise, the undersigned is an “accredited investor” as defined
in Regulation D promulgated under the Securities Act of 1933, as amended
[SIGNATURE OF HOLDER]
| Name of Investing Entity: |
|
| Signature of Authorized Signatory of Investing Entity: |
|
| Name of Authorized Signatory: |
|
| Title of Authorized Signatory: |
|
ASSIGNMENT FORM
(To assign the foregoing warrant, execute
this form and supply required information. Do
not use this form to exercise the warrant.)
FOR VALUE RECEIVED, [____]
all of or [________] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to
| |
|
Dated: _____________, _______ |
|
| |
|
|
|
| |
Holder’s Signature: |
|
|
| |
|
|
|
| |
Holder’s Address: |
|
|
| |
|
|
|
| |
|
|
|
NOTE: The signature to this Assignment Form must
correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever. Officers
of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the
foregoing Warrant.
PRE-FUNDED COMMON STOCK PURCHASE WARRANT
BIOVIE INC.
| Warrant Shares: |
|
| |
Issue Date: , 2025 |
THIS PRE-FUNDED COMMON STOCK
PURCHASE WARRANT (the “Warrant”) certifies that, for value received,
or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the Issue Date and until this Warrant is exercised in full (the “Termination Date”)
but not thereafter, to subscribe for and purchase from BioVie, Inc., a Nevada corporation (the “Company”), up to
shares of Common Stock (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share
of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Section 1. Definitions.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:
“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.
“Commission”
means the United States Securities and Exchange Commission.
“Common Stock”
means the Class A common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed.
“Common Stock Equivalents”
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.
“Exchange Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Liens”
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.
“Offering Circular”
means the Company’s offering statement on Form 1-A (File No. 024-__________).
“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.
“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
“Securities Act”
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
“Trading Day”
means a day on which the Common Stock is traded on a Trading Market.
“Trading Market”
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
OTCQB, OTCQX or Pink Open Market operated by OTC Markets Group, the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market,
the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).
“Transfer Agent”
means West Coast Stock Transfer, Inc., 721 N. Vulcan Ave. 1st FL, Encinitas, CA 92024 , and any successor transfer agent of the Company.
“Warrants”
means this Warrant and other Pre-Funded Common Stock Purchase Warrants issued by the Company pursuant to the Offering Statement.
Section 2. Exercise.
a) Exercise of the
purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Issue Date and on or
before the Termination Date by delivery to the Company of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise
in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) one (1) Trading Day and (ii) the number
of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid,
the Holder shall deliver to the Company the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise
by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c)
below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to
the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all
of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased in connection with such partial exercise. The Holder and the Company shall maintain records showing the number
of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one
(1) Trading Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that,
by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant
Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.
b) Exercise Price.
The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded to the
Company on or prior to the Issue Date and, consequently, no additional consideration (other than the nominal exercise price of $0.001
per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not
be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any
reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining unpaid
exercise price per share of Common Stock under this Warrant shall be $0.0001, subject to adjustment hereunder (the “Exercise
Price”).
c) Cashless Exercise.
This Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder
shall be entitled to receive a number of Warrant Shares for the deemed surrender of the Warrant in whole or in part equal to the quotient
obtained by dividing [(A-B) (X)] by (A), where:
| |
(A) = |
as applicable: (i) the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (x) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (y) the Bid Price of the Common Stock as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter pursuant to Section 2(a) hereof (including until two (2) hours after the close of “regular trading hours” on a Trading Day), or (iii) the Closing Sale Price of the Common Stock on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day; |
| |
(B) = |
the Exercise Price of this Warrant, as adjusted hereunder; and |
| |
(X) = |
the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. |
The
issue price for each such Warrant Share to be issued pursuant to the cashless exercise of a Warrant will be equal to (B), as defined above,
and the total issue price for the aggregate number of Warrant Shares issued pursuant to the cashless exercise of a Warrant will be deemed
paid and satisfied in full by the deemed surrender to the Company of the portion of such Warrant being exercised in accordance with this
Section 1(c). Notwithstanding anything herein to the contrary, the Company shall not be required to make any cash payments or net cash
settlement to the Holder in lieu of delivery of the Warrant Shares. If Warrant Shares are issued in such a cashless exercise, the parties
acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics
of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c).
“Bid Price”
means, for any security as of the particular time of determination, the bid price for such security on the Trading Market as reported
by Bloomberg as of such time of determination, or, if the Trading Market is not the principal securities exchange or trading market for
such security, the bid price of such security on the principal securities exchange or trading market where such security is listed or
traded as reported by Bloomberg as of such time of determination, or if the foregoing does not apply, the bid price of such security in
the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg as of such time of determination,
or, if no bid price is reported for such security by Bloomberg as of such time of determination, the average of the bid prices of any
market makers for such security as reported on the Pink Open Market as of such time of determination. If the Bid Price cannot be calculated
for a security as of the particular time of determination on any of the foregoing bases, the Bid Price of such security as of such time
of determination shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are
unable to agree upon the fair market value of such security, then such fair market value shall be determined pursuant to the provisions
set forth in clause (d) of the definition of VWAP. All such determinations to be appropriately adjusted for any stock dividend, share
split, share consolidation, reclassification or other similar transaction during the applicable calculation period.
“Closing
Sale Price” means, for any security as of any date, the last closing trade price for such security on the Trading Market, as
reported by Bloomberg, or, if the Trading Market begins to operate on an extended hours basis and does not designate the closing trade
price, then the last trade price of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Trading Market
is not the principal securities exchange or trading market for such security, the last trade price of such security on the principal securities
exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last
trade price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg,
or, if no last trade price is reported for such security by Bloomberg, the average of the ask prices of any market makers for such security
as reported on the in the OTC Link or on the Pink Open Market. If the Closing Sale Price cannot be calculated for a security on a particular
date on any of the foregoing bases, Closing Sale Price of such security on such date shall be the fair market value as mutually determined
by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such
fair market value shall be determined pursuant to the provisions set forth in clause (d) of the definition of VWAP. All such determinations
to be appropriately adjusted for any stock dividend, share split, share consolidation, reclassification or other similar transaction during
the applicable calculation period.
“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted for trading on a Trading Market other than the OTCQB, OTCQX or Pink Open Market operated by OTC Markets Group, the daily volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock
is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York
City time)), (b) if the Common Stock is then quoted for trading on the OTCQB or OTCQX operated by OTC Markets Group, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, or (c) in all other cases,
the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a
majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company.
d) Mechanics
of Exercise.
i. Delivery of
Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent
to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (the “DWAC”) if the Company is then a participant in such system
and either (A) there is an effective registration statement or offering statement permitting the issuance of the Warrant Shares to or
resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery
of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the
date that is the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period after
the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery
of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the Holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment
of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading
Days after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement
Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject
to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not
as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery
Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered to said Holder or the Holder
rescinds such exercise. The Company agrees to maintain a Transfer Agent that is a participant in the Fast Automated Securities Transfer
or FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period”
means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any
Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Issue Date, which may be delivered at any time after
the time of execution of the Placement Agent Agreement, dated [__], 2025 between the Company and ThinkEquity LLC, the Company agrees to
deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Issue Date.
ii. Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.
iii. Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.
iv. Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue by (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which
case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued
had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall
be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder
in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise
of the Warrant as required pursuant to the terms hereof.
v. No Fractional
Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As
to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.
vi. Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.
vii. Closing
of Books. The Company shall not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.
e) Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would
beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number
of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares
of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number
of shares of Common Stock which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially
owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or non-converted
portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation
on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution
Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder
that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the
Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained
in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation
to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent
setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within
two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares
of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior
to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance
of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial
Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the
number of shares of Common Stock outstanding immediately after giving effect to the issuance of Common Stock upon exercise of this Warrant
held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.
Section 3. Certain
Adjustments.
a) Stock Dividends
and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which,
for avoidance of doubt, shall not include any Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding
shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split or consolidation) outstanding
Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of the Company,
then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common
Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of
shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall
be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.
b) Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of shares
of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to
such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without
limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale
of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in
any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled
to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase
Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).
c) Pro Rata Distributions.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the
Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares
of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).
d) Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or amalgamation or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of 50% or more of the outstanding shares of Common Stock or 50% or more
of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of shares of Common Stock or any compulsory share exchange pursuant to
which shares of Common Stock are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly
or indirectly, in one or more related transactions consummates a share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such
other Person or group acquires more than 50% of the outstanding shares of Common Stock or more of the outstanding Common Stock or 50%
or more of the voting power of the common equity of the Company (each a “Fundamental Transaction”), then, upon any
subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to
any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation or is otherwise the continuing corporation, and any additional consideration (the
“Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of
shares of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor
Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of
this Section 3(d) pursuant to written agreements prior to such Fundamental Transaction and shall, at the option of the Holder, deliver
to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to this Warrant which is exercisable for a corresponding number of shares or other securities of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of or other securities (but taking into account the relative value of the shares of Common
Stock pursuant to such Fundamental Transaction and the value of such shares or securities, such number of shares or securities and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction). Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall
refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.
e) Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.
f) Notice to
Holder.
i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.
ii. Notice to
Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock,
(B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize
the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any shares of the Company or
of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common
Stock, any consolidation or merger, amalgamation or arrangement to which the Company is a party, any sale or transfer of all or substantially
all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or
property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the
Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number
or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, amalgamation, arrangement, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, amalgamation, arrangement
sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall
not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this
Warrant constitutes, or contains, material, non-public information regarding the Company or any of its subsidiaries (the “Subsidiaries”),
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain
entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.
Section 4. Transfer
of Warrant.
a) Transferability.
This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of
the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. This Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.
b) New Warrants.
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent
or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date of this Warrant and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.
c) Warrant Register.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.
Section 5. Miscellaneous.
a) No Rights
as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder
of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without
limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) or to receive
cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event, including if the Company is for any reason unable
to issue and deliver Warrant Shares upon exercise of this Warrant as required pursuant to the terms thereof, shall the Company be required
to net cash settle an exercise of this Warrant.
b) Loss, Theft,
Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to
it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which shall in no event include the posting of
any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company shall make and deliver
a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.
c) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.
d) Authorized
Shares.
The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing
the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company shall take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed or quoted for trading. The Company covenants that
all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the
purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued,
fully paid and non-assessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other
than taxes in respect of any transfer occurring contemporaneously with such issue).
Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, amalgamation, arrangement dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may
be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality
of the foregoing, the Company shall (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.
Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.
e) Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict of
laws thereof. Each party agrees that all legal Proceedings concerning the interpretation, enforcement and defense of this Warrant shall
be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the “New York Courts”).
Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement
of any provision hereunder), and hereby irrevocably waives, and agrees not to assert in any suit, action or Proceeding, any claim that
it is not personally subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for
such Proceeding. If any party shall commence an action or Proceeding to enforce any provisions of this Warrant, then the prevailing party
in such action or Proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred
in the investigation, preparation and prosecution of such action or Proceeding.
f) Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.
g) Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys’ fees, including those of appellate Proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.
h) Notices.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by facsimile or by e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company, at 680 W Nye Lane Suite 204, Carson City, NV 89703, Attention: Wendy Kim, email address: wkim@bioviepharma.com
or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other
communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile, email
or sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number, email address or address
of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given
and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via facsimile at the facsimile
number or e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading
Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number or e-mail at the
e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading
Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv)
upon actual receipt by the party to whom such notice is required to be given.
i) Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.
j) Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.
k) Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.
l) Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder on the other hand.
m) Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.
n) No Expense
Reimbursement. The Holder shall in no way be required the pay, or to reimburse the Company for, any fees or expenses of the Company’s
transfer agent in connection with the issuance or holding or sale of the Common Stock, Warrant and/or Warrant Shares. The Company shall
solely be responsible for any and all such fees and expenses.
o) Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.
********************
(Signature Page Follows)
IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.
| |
BIOVIE, INC. |
| |
|
|
| |
By: |
|
| |
Name: |
|
| |
Title: |
|
NOTICE OF EXERCISE
(1) The undersigned hereby elects
to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.
(2) Payment shall take the form
of (check applicable box):
☐
in lawful money of the United States; or
☐
the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).
(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:
The Warrant Shares shall be delivered to the following
DWAC Account Number:
[SIGNATURE
OF HOLDER]
| Name of Investing Entity: |
|
| Signature of Authorized Signatory of Investing Entity: |
|
| Name of Authorized Signatory: |
|
| Title of Authorized Signatory: |
|
ASSIGNMENT FORM
(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)
FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to
| Name: |
|
|
|
| |
|
(Please Print) |
|
| |
|
|
|
| Address: |
|
|
|
| |
|
(Please Print) |
|
| |
|
|
|
| Phone Number: |
|
|
|
| |
|
|
|
| Email Address: |
|
|
|
| |
|
|
|
| Dated: _____________________ __, ______ |
|
|
|
| |
|
|
|
| Holder’s Signature: |
|
|
|
|
| |
|
|
|
|
| Holder’s Address: |
|
|
|
|
EXHIBIT 11.1
CONSENT OF INDEPENDENT REGISTERED
PUBLIC
ACCOUNTING FIRM
We consent to the incorporation by reference in this
Registration Statement of BioVie Inc. on Form 1-A to be filed on or about December 31, 2024, of our report dated September 30, 2024, on
our audits of the financial statements as of June 30, 2024 and 2023 and for each of the years then ended, which report was included in
the Annual Report on Form 10-K filed September 30, 2024. Our report includes an explanatory paragraph about the existence of substantial
doubt concerning the Company’s ability to continue as a going concern. We also consent to the reference to our firm under the caption
“Experts” in the Registration Statement on Form 1-A.
/s/ EISNERAMPER LLP
Iselin, New Jersey
December 31, 2024
Exhibit 12.1
 |
9275 W. Russell Road, Suite 240
Las Vegas, Nevada 89148
PH
(702) 692-8026 | FX (702) 692-8075
fennemorelaw.com
|
December 31, 2024
BioVie Inc.
680 West Nye Lane, Suite
201
Carson City, Nevada 89703
| Re: | BioVie Inc./Regulation A Offering Statement on Form 1-A |
Ladies and Gentlemen:
We have acted as special Nevada
counsel to BioVie Inc., a Nevada corporation (the “Company”), in connection with the filing with the Securities and Exchange
Commission (the “Commission”) of a Regulation A Offering Statement on Form 1-A (the “Offering Statement”) pursuant
to the Securities Act of 1933, as amended (the “Securities Act”), for qualification for exemption from registration of (a)
up to 15,000,000 shares (the “Offered Shares”) of the Company’s Class A Common Stock, $0.0001 par value per share (the
“Common Stock”) and (b) up to 15,000,000 pre-funded warrants (the “Pre-Funded Warrants”) exercisable for one share
of Common Stock (the “Pre-Funded Warrant Shares”). The Offered Shares, the Pre-Funded Warrants, and the Pre-Funded Warrant
Shares are referred to herein collectively as the “Securities.” The Securities are being offered, sold, and issued under the
terms of a Placement Agency Agreement (the “Placement Agreement”) by and between the Company and ThinkEquity LLC, acting as
the exclusive placement agent.
For purposes of these opinions,
we have examined originals or copies, certified or otherwise identified to our satisfaction, of:
| (a) | the Offering Statement; |
| (b) | a form of the Placement Agreement; |
| (c) | a form of Pre-Funded Warrant; and |
| (d) | certain resolutions and actions of the Board of Directors of the Company relating to the issuance and
the qualification for exemption from registration of the Securities under the Securities Act. |
BioVie Inc.
December 31, 2024
Page 2
We have obtained from officers
and agents of the Company, and have relied upon, such certificates, representations, and assurances as we have deemed necessary and appropriate
for purposes of rendering this opinion letter. We have also examined such other corporate documents, records, certificates, and instruments
(collectively with the documents identified in (a) through (d) above, the “Documents”) as we deem necessary or advisable to
render the opinions set forth herein.
In our examination, we have
assumed:
(a) the
legal capacity of all natural persons executing the Documents;
(b) the
genuineness of all signatures on the Documents;
(c) the
authenticity of all Documents submitted to us as originals, and the conformity to original documents of all Documents submitted to us
as copies;
(d) that
the parties to such Documents, other than the Company, had the power, corporate or other, to enter into and perform all obligations thereunder;
(e) other
than with respect to the Company, the due authorization by all requisite action, corporate or other, of the Documents;
(f) the
execution, delivery, and performance by all parties of the Documents; and
(g) that
all Documents are valid, binding, and enforceable against the parties thereto.
We have relied upon the accuracy
and completeness of the information, factual matters, representations, and warranties contained in such Documents. We have been advised
that prior to the issuances of the Offered Shares and Pre-Funded Warrant Shares the Company’s Pricing Committee will adopt resolutions
(the “Pricing Committee Resolutions”) setting the price, number of Shares to be issued and reserving sufficient authorized
but unissued shares of Common Stock for issuance of the Offered Shares and Pre-Funded Warrant Shares.
The opinions expressed below
are limited to the matters specifically set forth herein and no other opinion shall be inferred beyond the matters expressly stated. We
disclaim any undertaking to advise you of any subsequent changes in the facts stated or assumed for purposes of delivering these opinions
expressed herein or any changes in applicable law that may come to our attention after the date the Offering Statement is qualified.
BioVie Inc.
December 31, 2024
Page 3
On the basis of the foregoing
and in reliance thereon, and subject to the assumptions, limitations, and qualifications set forth herein, we are of the opinion that:
| (a) | the Offered Shares have been duly authorized, and when issued in accordance with the terms of the Placement
Agreement, will be validly issued, fully paid, and nonassessable; and |
| (b) | the Pre-Funded Warrant Shares have been duly authorized, and when issued upon exercise of the Pre-Funded
Warrants in accordance with the terms thereof, will be validly issued, fully paid, and non-assessable. |
While certain members of this
firm are admitted to practice in certain jurisdictions other than Nevada, in rendering the foregoing opinions we have not examined the
laws of any jurisdiction other than Nevada. Accordingly, we express no opinion regarding the effect of the laws of any other jurisdiction
or state, including any federal laws. The opinions we express herein are limited solely to the laws of the State of Nevada, other than
the securities laws and regulations of the State of Nevada as to which we express no opinion.
We hereby consent to the filing
of this opinion as an exhibit to the Offering Statement. In giving the foregoing consent, we do not hereby admit that we are in the category
of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.
| |
Very truly yours,
/s/ Fennemore Craig, P.C.
Fennemore Craig, P.C. |
tmor/cdol
BioVie (NASDAQ:BIVI)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
BioVie (NASDAQ:BIVI)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
